CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2003



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2003

HYMAN, PHELPS
& MCNAMARA, P.C.
WASHINGTON, DC

DEMCO

1.0 I
1.1
1.2
1.3
1.4
1.5
1.6
1.7

DRUG P

PATEN

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23RD EDITION

Cumulative Supplement 11

November 2003

CONTENTS

		PAGE
1.0	INTRODUCTION	iii
1.1	How to Use the Cumulative Supplement	iii
1.2	Applicant Name Changes	iv
1.3	Nitroglycerin, Film, Extended Release; Transdermal 23rd Annual Edition	v
1.4	NDA Patent 30-month Rule	vi
1.5	Availability of the Edition	vi
1.6	Report of Counts for the Prescription Drug Product List	vii
1.7	Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
	A. Patent and Exclusivity Lists	A-1
	B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

CUMULATIVE SUPPLEMENT 11
November 2003

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 23rd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AAIPHARMA INC (AAIPHARMA)	AAIPHARMA LLC (AAIPHARMA LLC)
BAYER CORP (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
BAYER CORP CONSUMER CARE DIV (BAYER CORP CONSUMER)	BAYER CORP CONSUMER CARE LLC (BAYER)
BAYER CORP PHARMACEUTICALS DIV (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
ESI LEDERLE INC (ESI LEDERLE)	CLONMEL HEALTHCARE INC (CLONMEL HEALTHCARE)
FAULDING PHARMACEUTICAL CO (FAULDING)	MAYNE PHARMA USA INC (MAYNE PHARMA USA)
FAULDING PHARMACEUTICALS INC (FAULDING PHARMS)	ALPHARMA PHARMACEUTICALS INC (ALPHARMA USPD)
FH FAULDING AND CO LTD (FAULDING)	MAYNE PHARMA USA INC (MAYNE PHARMA USA)
LEK SERVICES INC (LEK SVCS)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO (LEK LJUBLJANA)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK PHARMACEUTICAL AND CHEMICAL DD (LEK PHARM)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
NEOSAN PHARMACEUTICALS (NEOSAN PHARMS)	AAIPHARMA LLC (AAIPHARMA LLC)
ORGANON INC (ORGANON INC)	ORGANON USA INC (ORGANON USA INC)
ORGANON INC SUB AKZO INC (ORGANON)	ORGANON USA INC (ORGANON USA INC)
ORGANON INC SUB AKZO NOBEL INC (ORGANON INC)	ORGANON USA INC (ORGANON USA INC)
SIDMAK LABORATORIES INC (SIDMAK LABS)	PLIVA INC (PLIVA)
SYNTEX (USA) INC LLC (SYNTEX USA INC)	ROCHE PALO ALTO LLC (ROCHE PALO)
WALLACE LABORATORIES DIV CARTER WALLACE INC (WALLACE LABS)	MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC (MEDPOINTE PHARM HLC)
WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC (WALLACE PHARMS)	MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC (MEDPOINTE PHARM HLC)

1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL 23RD ANNUAL EDITION

The *Approved Drug Products with Therapeutic Equivalence Evaluations 23rd annual edition*, page 3-265 omitted the 3 character Therapeutic Equivalence (TE) Codes for Nitroglycerin, Film, Extended Release; Transdermal products. The correct codes are listed below by product name, applicant holder, TE code, strength, NDA number, and product number.

PRODUCT NAME	APPLICANT	TE CODE	STRENGTH	NDA	PRODUCT
MINITRAN	3M	AB1	0.1MG/HR	N89771	001
MINITRAN	3M	AB1	0.2MG/HR	N89772	001
MINITRAN	3M	AB1	0.4MG/HR	N89773	001
MINITRAN	3M	AB1	0.6MG/HR	N89774	001
NITRO-DUR	KEY PHARMS	AB1	0.1MG/HR	N20145	001
NITRO-DUR	KEY PHARMS	AB1	0.2MG/HR	N20145	002

NITRO-DUR	KEY PHARMS	AB1	0.4MG/HR	N20145	004
NITRO-DUR	KEY PHARMS	AB1	0.6MG/HR	N20145	005
NITROGLYCERIN	HERCON LABS	AB2	0.2MG/HR	N89884	001
NITROGLYCERIN	HERCON LABS	AB2	0.4MG/HR	N89885	001
NITROGLYCERIN	HERCON LABS	AB2	0.6MG/HR	N89886	001
NITROGLYCERIN	MYLAN	AB2	0.1MG/HR	N75033	001
NITROGLYCERIN	MYLAN	AB2	0.2MG/HR	N74609	001
NITROGLYCERIN	MYLAN	AB2	0.4MG/HR	N74607	001

1.4 NDA PATENT 30-MONTH RULE

The Food and Drug Administration has amended its patent submission and listing requirements for new drug applications (NDAs). This final rule became effective on August 18, 2003. The final rule, among other things, limits to one per ANDA or 505(b)(2) application the maximum number of statutory 30-month stays of approval to which an innovator will be entitled when multiple patents are submitted for the same NDA.

Patents listed prior to August 18, 2003 will be designated by a "#" sign and are considered listed under the previous regulations that permitted multiple 30-month stays for an NDA. Patents listed after the effective date of the final rule will not have the # designation displayed and are considered listed under the new rule.

1.5 AVAILABILITY OF THE EDITION

The 23rd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is $108.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm

The Internet version of the monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 23rd annual edition of the 2002 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder.orange/23bookpub.pdf

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.htm

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2002) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2002	JUN 2003	SEP 2003	DEC 2003
DRUG PRODUCTS LISTED	10465	10514	10624	
SINGLE SOURCE	2420 (23.1%)	2417 (23.0%)	2406	
MULTISOURCE	7939 (75.9%)	7989 (76.0%)	8110	
THERAPEUTICALLY EQUIVALENT	7659 (73.2%)	7708 (73.3%)	7830(73.7%)	
NOT THERAPEUTICALLY EQUIVALENT	280 (2.7%)	281 (2.7%)	280(2.6%)	
EXCEPTIONS	106 (1.0%)	108 (1.0%)	108(1.0%)	
NEW MOLECULAR ENTITIES APPROVED	6	6	6	
NUMBER OF APPLICANTS	598	604	602	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

>A>		ABARELIX						
>A>		INJECTABLE; INTRAMUSCULAR						
>A>		PLENAXIS						
>A>	+	PRAECIS	100MG/VIAL	N21320 001	NOV 25, 2003	NOV	NEWA	
		ACETAMINOPHEN; BUTALBITAL; CAFFEINE						
		SOLUTION; ORAL						
		ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE						
	+	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	N40387 001	JAN 31, 2003	JAN	NEWA	
		TABLET; ORAL						
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
AB		VINTAGE PHARMS	325MG;50MG;40MG	N40511 001	AUG 27, 2003	AUG	NEWA	
AB			500MG;50MG;40MG	N40513 001	AUG 25, 2003	AUG	NEWA	
		BUTALBITAL, APAP, AND CAFFEINE						
AB		AXIOM PHARM	325MG;50MG;40MG	N89536 001	FEB 16, 1988	MAY	CAHN	
		ESGIC-PLUS						
AB	+	MIKART	500MG;50MG;40MG	N89451 001	MAY 23, 1988	AUG	CTNA	
		FIORICET						
AB	+	WATSON PHARMS	325MG;50MG;40MG	N88616 001	NOV 09, 1984	APR	CAHN	
		ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE						
		CAPSULE; ORAL						
		BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE						
AB		ABLE	325MG;50MG;40MG;30MG	N76528 001	AUG 21, 2003	AUG	NEWA	
		FIORICET W/ CODEINE						
AB	+	WATSON PHARMS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CAHN	
		ACETAMINOPHEN; CODEINE PHOSPHATE						
		CAPSULE; ORAL						
		PHENAPHEN W/ CODEINE NO. 3						
		@ ROBINS AH	325MG;30MG	N84445 001		JUN	DISC	
		PHENAPHEN W/ CODEINE NO. 4						
		@ ROBINS AH	325MG;60MG	N84446 001		JUN	DISC	
		TABLET; ORAL						
		ACETAMINOPHEN AND CODEINE PHOSPAHTE						
AA		ANDRX PHARMS	300MG;15MG	N40443 001	JAN 22, 2003	JAN	NEWA	
AA			300MG;30MG	N40443 002	JAN 22, 2003	JAN	NEWA	
AA			300MG;60MG	N40443 003	JAN 22, 2003	JAN	NEWA	
		ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	+	DURAMED PHARMS BARR	300MG;15MG	N40223 001	NOV 18, 1997	AUG	CRLD	
AA		RANBAXY	300MG;60MG	N87083 001		JAN	CAHN	
		ACETAMINOPHEN W/ CODEINE PHOSPHATE #3						
AA		RANBAXY	300MG;30MG	N85868 001		JAN	CAHN	
		CODRIX						
	+	ANDRX PHARMS	500MG;30MG	N40441 001	MAR 27, 2003	MAR	NEWA	
	+		500MG;15MG	N40447 001	FEB 26, 2003	FEB	NEWA	
	+		500MG;60MG	N40488 001	MAR 28, 2003	MAR	NEWA	
		TYLENOL W/ CODEINE NO. 1						
		@ ORTHO MCNEIL PHARM	300MG;7.5MG	N85055 001		AUG	DISC	
		TYLENOL W/ CODEINE NO. 2						
		@ ORTHO MCNEIL PHARM	300MG;15MG	N85055 002		AUG	DISC	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

		TYLENOL W/ CODEINE NO. 4					
	@	ORTHO MCNEIL PHARM	300MG;60MG	N85055 004		AUG	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
AA	+	MALLINCKRODT	500MG/15ML;10MG/15ML	N40508 001	AUG 29, 2003	AUG	NEWA
	+	MIKART	325MG/15ML;7.5MG/15ML	N40482 001	SEP 25, 2003	SEP	NEWA
AA			500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	AUG	CTEC
AA	+		500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	AUG	CTEC
AA		VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	N40520 001	OCT 30, 2003	OCT	NEWA

TABLET; ORAL

		ANEXSIA					
AA		MALLINCKRODT	750MG;10MG	N40468 001	OCT 31, 2002	OCT	CTNA
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
AA		ABLE	500MG;7.5MG	N40490 001	MAY 21, 2003	MAY	NEWA
AA			650MG;7.5MG	N40474 001	JAN 02, 2003	JAN	NEWA
AA		ANDRX PHARMS	500MG;5MG	N40493 001	MAY 28, 2003	MAY	NEWA
AA			660MG;10MG	N40495 001	MAY 28, 2003	MAY	NEWA
AA			750MG;7.5MG	N40494 001	MAY 28, 2003	MAY	NEWA
AA		AXIOM PHARM	500MG;5MG	N40236 001	SEP 25, 1997	MAY	CAHN
AA			650MG;10MG	N40240 001	NOV 26, 1997	MAY	CAHN
AA			650MG;7.5MG	N40240 002	NOV 26, 1997	MAY	CAHN
AA			750MG;7.5MG	N40236 002	SEP 25, 1997	MAY	CAHN
AA		MIKART	325MG;7.5MG	N40432 001	JAN 22, 2003	JAN	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

		OXYCODONE AND ACETAMINOPHEN					
AA		AXIOM PHARM	500MG;5MG	N40219 001	JAN 22, 1998	MAY	CAHN

TABLET; ORAL

AA		WATSON LABS	325MG;7.5MG	N40535 001	SEP 05, 2003	SEP	NEWA
AA			325MG;10MG	N40535 002	SEP 05, 2003	SEP	NEWA
		PERCOCET					
AA	+	ENDO PHARMS	325MG;7.5MG	N40434 001	NOV 23, 2001	SEP	CFTG
AA	+		325MG;10MG	N40434 002	NOV 23, 2001	SEP	CFTG

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

		PROPOXYPHENE HCL AND ACETAMINOPHEN						
AA		VINTAGE PHARMS	650MG;65MG	N40507 001	JUL 30, 2003	JUL	NEWA	>A>

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

		PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN					
	+	AAIPHARMA	500MG;100MG	N76429 001	SEP 10, 2003	SEP	NEWA

		ACETAZOLAMIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		DIAMOX						
		@ DURAMED PHARMS BARR	500MG	N12945 001		JUN	CAHN	
	+		500MG	N12945 003	APR 25, 1995	JUN	CAHN	
		TABLET; ORAL						
	AB	DURAMED PHARMS BARR	125MG	N08943 001		JUN	CAHN	
	AB	+	250MG	N08943 002		JUN	CAHN	
		ACETAZOLAMIDE SODIUM						
		INJECTABLE; INJECTION						
	AP	+ DURAMED PHARMS BARR	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990	JUN	CAHN	
		ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE						
		SUSPENSION/DROPS; OTIC						
		NEO-CORT-DOME						
		@ BAYER PHARMS	2%;1%;EQ 0.35% BASE	N50238 001		JUN	DISC	
		ACYCLOVIR						
		CAPSULE; ORAL						
		ACYCLOVIR						
	AB	AAIPHARMA	200MG	N74833 001	APR 22, 1997	APR	CAHN	
		TABLET; ORAL						
		@ CLONMEL HLTHCARE	400MG	N74834 001	APR 24, 1997	JUL	DISC	
		@	800MG	N74834 002	APR 24, 1997	JUL	DISC	
		ACYCLOVIR SODIUM						
		INJECTABLE; INJECTION						
		ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE						
	+	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N74885 001	DEC 19, 1997	AUG	CAHN	
			EQ 1GM BASE/VIAL	N74885 002	DEC 19, 1997	AUG	CAHN	
		ACYCLOVIR SODIUM						
	AP	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N74913 001	OCT 15, 1997	AUG	CAHN	
	AP		EQ 1GM BASE/VIAL	N74913 002	OCT 15, 1997	AUG	CAHN	
		ALBUMIN HUMAN						
		INJECTABLE; INJECTION						
		OPTISON						
	+	AMERSHAM HLTH	10MG/ML	N20899 001	DEC 31, 1997	JUN	CAHN	
		ALBUTEROL SULFATE						
		SOLUTION; INHALATION						
		ALBUTEROL SULFATE						
>A>	AN	BREATH LTD	EQ 0.083% BASE	N76370 001	NOV 24, 2003	NOV	NEWA	
	AN	NOVEX	EQ 0.5% BASE	N76391 001	APR 01, 2003	APR	NEWA	
		SYRUP; ORAL						
		PROVENTIL						
		@ SCHERING	EQ 2MG BASE/5ML	N18062 001	JAN 19, 1983	AUG	DISC	
		TABLET; ORAL						
		ALBUTEROL SULFATE						
		@ CLONMEL HLTHCARE	EQ 2MG BASE	N72859 001	DEC 20, 1989	JUN	DISC	
		@	EQ 4MG BASE	N72860 001	DEC 20, 1989	JUN	DISC	

AB +	MYLAN	EQ 2MG BASE	N72893 001	JAN 17, 1991	AUG	CRLD
AB +		EQ 4MG BASE	N72894 001	JAN 17, 1991	AUG	CRLD
	PROVENTIL					
	@ SCHERING	EQ 2MG BASE	N17853 001	MAY 07, 1982	AUG	DISC
	@	EQ 4MG BASE	N17853 002	MAY 07, 1982	AUG	DISC
	TABLET, EXTENDED RELEASE; ORAL					
	@ SCHERING	EQ 4MG BASE	N19383 001	JUL 13, 1987	OCT	DISC
ALENDRONATE SODIUM						
	SOLUTION; ORAL					
	FOSAMAX					
	+ MERCK	EQ 70MG ACID/75ML	N21575 001	SEP 17, 2003	SEP	NEWA
ALFENTANIL HYDROCHLORIDE						
	INJECTABLE; INJECTION					
	ALFENTA					
AP +	AKORN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986	MAR	CAHN
ALFUZOSIN HYDROCHLORIDE						
	TABLET, EXTENDED RELEASE; ORAL					
	UROXATRAL					
	+ SANOFI SYN RES	10MG	N21287 001	JUN 12, 2003	JUN	NEWA
ALLOPURINOL						
	TABLET; ORAL					
	ALLOPURINOL					
AB	VINTAGE PHARMS	100MG	N75798 001	JUN 27, 2003	JUN	NEWA
AB		300MG	N75798 002	JUN 27, 2003	JUN	NEWA
ALMOTRIPTAN MALATE						
	TABLET; ORAL					
	AXERT					
	JANSSEN ORTHO	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	APR	CAHN
	+	EQ 12.5MG BASE	N21001 002	MAY 07, 2001	APR	CAHN
ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K						
	INJECTABLE; INJECTION					
	INFUVITE ADULT					
	+ SABEX 2002	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N21163 001	MAY 18, 2000	JUN	CPOT
	INJECTABLE; IV (INFUSION)					
	+ SABEX 2002	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30UGM/ML	N21559 001	JUN 16, 2003	JUN	NEWA

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

CERNEVIT-12

@ BAXTER HLTHCARE — 11.2 IU/VIAL;125MG/VIAL;60UGM/VIAL;200 IU/VIAL;5.5MG/VIAL;414UGM/VIAL;46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14 MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL — N20924 001 APR 06, 1999 MAR DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ CLONMEL HLTHCARE — 0.25MG — N74174 001 OCT 19, 1993 JUN DISC
@ — 0.5MG — N74174 002 OCT 19, 1993 JUN DISC
@ — 1MG — N74174 003 OCT 19, 1993 JUN DISC
@ — 2MG — N74174 004 OCT 19, 1993 JUN DISC

TABLET, EXTENDED RELEASE; ORAL

XANAX XR

PHARMACIA AND UPJOHN — 0.5MG — N21434 001 JAN 17, 2003 JAN NEWA
1MG — N21434 002 JAN 17, 2003 JAN NEWA
2MG — N21434 003 JAN 17, 2003 JAN NEWA
\+ 3MG — N21434 004 JAN 17, 2003 JAN NEWA

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

@ PHARMACIA AND UPJOHN — 0.01MG/ML — N20755 002 OCT 01, 1997 OCT DISC
AP \+ 0.02MG/VIAL — N20379 002 JUL 06, 1995 OCT CRLD
@ — 0.02MG/ML — N20755 003 OCT 01, 1997 OCT DISC

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HCL

AB GENEVA PHARMS — 100MG — N71293 001 FEB 18, 1987 APR CAHN

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB ALTANA — 0.1% — N76065 001 MAY 15, 2003 MAY NEWA
AB TARO PHARM INDS — 0.1% — N76229 001 MAY 31, 2002 MAY CTEC
AT — 0.1% — N76229 001 MAY 31, 2002 APR NEWA

CYCLOCORT

AT \+ FUJISAWA HLTHCARE — 0.1% — N18116 002 APR CFTG
AB \+ — 0.1% — N18116 002 MAY CTEC

OINTMENT; TOPICAL

AMCINONIDE

AB TARO PHARM INDS — 0.1% — N76367 001 MAR 19, 2003 MAR NEWA

AMINO ACIDS

INJECTABLE; INJECTION

PREMASOL 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	10% (10GM/100ML)	N75880 002	JUN 19, 2003	JUN	NEWA

PREMASOL 6% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	6% (6GM/100ML)	N75880 001	JUN 19, 2003	JUN	NEWA

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

@	BAXTER HLTHCARE	250MG/ML	N18590 001	OCT 29, 1982	AUG	CAHN
@	ELKINS SINN	250MG/ML	N18590 001	OCT 29, 1982	JUN	DISC

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP +	ABBOTT	25MG/ML	N87601 001	JUL 23, 1982	JUN	CRLD
@	ELKINS SINN	25MG/ML	N87239 001		JUN	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP	APOTEX	50MG/ML	N76394 001	APR 25, 2003	APR	NEWA
AP	SICOR PHARMS	50MG/ML	N76163 001	SEP 05, 2003	SEP	NEWA

CORDARONE

AP +	WYETH PHARMS INC	50MG/ML	N20377 001	AUG 03, 1995	MAR	CAHN

TABLET; ORAL

AMIODARONE HCL

AB	EON	400MG	N75315 002	JUN 30, 2000	SEP	CRLD
	TARO	100MG	N75424 002	DEC 18, 2002	SEP	CRLD
AB +		400MG	N76362 001	NOV 29, 2002	SEP	CRLD

CORDARONE

AB	WYETH PHARMS INC	200MG	N18972 001	DEC 24, 1985	MAR	CAHN

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

@	ROCHE	40MG/ML	N85749 001		JUN	DISC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

@	SCHERING	10MG;2MG	N14713 007		MAR	DISC

ETRAFON 2-25

@	SCHERING	25MG;2MG	N14713 004		MAR	DISC

ETRAFON-FORTE

@	SCHERING	25MG;4MG	N14713 006		MAR	DISC

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+	ACCESS PHARMS	5%	N20511 001	DEC 17, 1996	JUL	CAHN

AMLODIPINE MALEATE
TABLET; ORAL
AMVAZ

	DR REDDYS LABS INC	2.5MG	N21435	001	OCT 31, 2003	OCT	NEWA
		5MG	N21435	002	OCT 31, 2003	OCT	NEWA
+		10MG	N21435	003	OCT 31, 2003	OCT	NEWA

AMMONIUM LACTATE
CREAM; TOPICAL
AMMONIUM LACTATE

AB	TARO	EQ 12% BASE	N75883	001	APR 10, 2003	APR	NEWA

AMOXICILLIN
FOR SUSPENSION; ORAL
AMOXIL

AB	GLAXOSMITHKLINE	50MG/ML	N62226	005		JUL	CRLD

WYMOX

	@ WYETH AYERST	125MG/5ML	N62131	001		JUN	DISC
	@	250MG/5ML	N62131	002		JUN	DISC

TABLET, FOR SUSPENSION; ORAL
DISPERMOX

	RANBAXY	200MG	N65080	002	AUG 11, 2003	AUG	NEWA
+		400MG	N65080	001	AUG 11, 2003	AUG	NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL
PREVPAC

+	TAP PHARM	500MG;500MG;30MG	N50757	001	DEC 02, 1997	MAY	CDFR

AMOXICILLIN; CLAVULANATE POTASSIUM
FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	RANBAXY	200MG/5ML;EQ 28.5MG BASE/5ML	N65132	001	MAR 19, 2003	MAR	NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	N65132	002	MAR 19, 2003	MAR	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL
ADDERALL XR 10

	SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303	001	OCT 11, 2001	JAN	CAHN

ADDERALL XR 15

	SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N21303	006	MAY 22, 2002	JAN	CAHN

ADDERALL XR 20

	SHIRE LABS	5MG;5MG;5MG;5MG	N21303	002	OCT 11, 2001	JAN	CAHN

ADDERALL XR 25

	SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303	004	MAY 22, 2002	JAN	CAHN

ADDERALL XR 30

+	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303	003	OCT 11, 2001	JAN	CAHN

ADDERALL XR 5

	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N21303	005	MAY 22, 2002	JAN	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	ADDERALL 12.5					
AB	SHIRE LABS	3.125MG;3.125MG;3.125MG;3.125MG	N11522 012	AUG 31, 2000	MAR	CFTG
	ADDERALL 15					
AB	SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N11522 013	AUG 31, 2000	MAR	CFTG
	ADDERALL 7.5					
AB	SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	MAR	CFTG
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB	ABRIKA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	N40472 001	SEP 30, 2003	SEP	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40472 002	SEP 30, 2003	SEP	NEWA
AB		5MG;5MG;5MG;5MG	N40472 003	SEP 30, 2003	SEP	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40472 004	SEP 30, 2003	SEP	NEWA
AB	BARR	1.875MG;1.875MG;1.875MG;1.875MG	N40422 005	MAR 19, 2003	MAR	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	N40422 006	MAR 19, 2003	MAR	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	N40422 007	MAR 19, 2003	MAR	NEWA
AB	MALLINCKRODT	1.25MG;1.25MG;1.25MG;1.25MG	N40440 001	OCT 07, 2003	OCT	NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	N40440 002	OCT 07, 2003	OCT	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40440 003	OCT 07, 2003	OCT	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	N40440 004	OCT 07, 2003	OCT	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	N40440 005	OCT 07, 2003	OCT	NEWA
AB		5MG;5MG;5MG;5MG	N40440 006	OCT 07, 2003	OCT	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40440 007	OCT 07, 2003	OCT	NEWA
AB	MUTUAL PHARM	1.25MG;1.25MG;1.25MG;1.25MG	N40480 001	SEP 09, 2003	SEP	NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	N40480 002	SEP 09, 2003	SEP	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40480 003	SEP 09, 2003	SEP	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	N40480 004	SEP 09, 2003	SEP	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	N40480 005	SEP 09, 2003	SEP	NEWA
AB		5MG;5MG;5MG;5MG	N40480 006	SEP 09, 2003	SEP	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40480 007	SEP 09, 2003	SEP	NEWA
AB	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	N40456 001	MAY 06, 2003	MAY	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40456 002	MAY 06, 2003	MAY	NEWA
AB		5MG;5MG;5MG;5MG	N40456 003	MAY 06, 2003	MAY	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40456 004	MAY 06, 2003	MAY	NEWA

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM					
	@ APOTHECON	EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988	OCT	WDAG
	@	EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988	OCT	WDAG
	@	EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988	OCT	WDAG
	@	EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988	OCT	WDAG
	@	EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988	OCT	WDAG
	@ BAXTER HLTHCARE	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	AUG	CAHN
	@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	AUG	CAHN
	@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	AUG	CAHN
	@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	AUG	CAHN
	@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	AUG	CAHN
	@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	AUG	CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

OMNIPEN-N

	@ WYETH AYERST	EQ 125MG BASE/VIAL	N60626 001		JUN	DISC
	@	EQ 250MG BASE/VIAL	N60626 002		JUN	DISC
	@	EQ 500MG BASE/VIAL	N60626 003		JUN	DISC
	@	EQ 1GM BASE/VIAL	N60626 004		JUN	DISC
	@	EQ 2GM BASE/VIAL	N60626 005		JUN	DISC

TOTACILLIN-N

AP	+ GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	N60677 001		JUN	CRLD
AP	+	EQ 250MG BASE/VIAL	N60677 002		JUN	CRLD
AP	+	EQ 500MG BASE/VIAL	N60677 003		JUN	CRLD
AP	+	EQ 1GM BASE/VIAL	N60677 004		JUN	CRLD
AP	+	EQ 2GM BASE/VIAL	N60677 005		JUN	CRLD

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

OMNIPEN (AMPICILLIN)

	@ WYETH AYERST	250MG	N60624 001		JUN	DISC
	@	500MG	N60624 002		JUN	DISC

FOR SUSPENSION; ORAL

	@ WYETH AYERST	100MG/ML	N60625 001		JUN	DISC
	@	125MG/5ML	N60625 002		JUN	DISC
	@	250MG/5ML	N60625 003		JUN	DISC

PRINCIPEN

	APOTHECON	EQ 100MG BASE/ML	N61394 001		JUN	CTEC

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

	GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999	MAR	CMFD
+		150MG	N21007 002	APR 15, 1999	MAR	CMFD

SOLUTION; ORAL

+	GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999	MAR	CMFD

APREPITANT

CAPSULE; ORAL

EMEND

	MERCK	80MG	N21549 001	MAR 26, 2003	MAR	NEWA
+		125MG	N21549 002	MAR 26, 2003	MAR	NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

+	ENCYSIVE	100MG/ML	N20883 001	JUN 30, 2000	JUN	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

\+ AAIPHARMA — 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML — N08809 004 AUG 08, 1985 JUN CTEC

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AB + WATSON PHARMS — 325MG;50MG;40MG — N17534 005 APR 16, 1986 MAR CAHN

TABLET; ORAL

AB + WATSON PHARMS — 325MG;50MG;40MG — N17534 003 APR 16, 1986 MAR CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE NO 3

AB + WATSON PHARMS — 325MG;50MG;40MG;30MG — N19429 003 OCT 26, 1990 MAR CAHN

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

\+ WOMEN FIRST HLTHCARE — 325MG;200MG — N11702 003 DEC 29, 1983 JUN CTEC

MICRAININ

@ MEDPOINTE PHARM HLC — 325MG;200MG — N84978 001 JUN DISC

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

AB + IVAX PHARMS — 325MG;400MG — N87211 001 DEC 22, 1982 JUN CRLD

ROBAXISAL

@ ROBINS AH — 325MG;400MG — N12281 001 JUN DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA AXIOM PHARM — 325MG;4.5MG;0.38MG — N40260 001 JUL 17, 1998 MAY CAHN

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB

81MG;20MG	N21387 001	JUN 24, 2003	JUN	NEWA
81MG;40MG	N21387 002	JUN 24, 2003	JUN	NEWA
81MG;80MG	N21387 003	JUN 24, 2003	JUN	NEWA
325MG;20MG	N21387 004	JUN 24, 2003	JUN	NEWA
325MG;40MG	N21387 005	JUN 24, 2003	JUN	NEWA
325MG;80MG	N21387 006	JUN 24, 2003	JUN	NEWA

\+

	ASPIRIN; PROPOXYPHENE HYDROCHLORIDE						
	CAPSULE; ORAL						
	DARVON W/ ASA						
	@ AAIPHARMA LLC	325MG;65MG	N10996 005			JUL	DISC
	ATAZANAVIR SULFATE						
	CAPSULE; ORAL						
	REYATAZ						
	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N21567 001	JUN 20, 2003		JUN	NEWA
		EQ 150MG BASE	N21567 002	JUN 20, 2003		JUN	NEWA
	+	EQ 200MG BASE	N21567 003	JUN 20, 2003		JUN	NEWA
	ATOMOXETINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	STRATTERA						
	@ LILLY	5MG	N21411 001	NOV 26, 2002		MAY	DISC
	ATROPINE						
	INJECTABLE; INJECTION						
	ATROPEN						
	+ MERIDIAN MEDCL TECHN	EQ 0.5MG SULFATE/0.7ML	N17106 003	JUN 19, 2003		JUL	NEWA
	+	EQ 1MG SULFATE/0.7ML	N17106 002	JUN 19, 2003		JUL	NEWA
	ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	ATROPINE AND DEMEROL						
	@ ABBOTT	0.4MG/ML;75MG/ML	N87847 001	NOV 26, 1982		OCT	WDAG
	@	0.4MG/ML;100MG/ML	N87848 001	NOV 26, 1982		OCT	WDAG
	@	0.4MG/ML;50MG/ML	N87853 001	NOV 26, 1982		OCT	WDAG
	AZATHIOPRINE						
	TABLET; ORAL						
	AZASAN						
	AAIPHARMA LLC	25MG	N75252 002	FEB 03, 2003		FEB	NEWA
AB		50MG	N75252 001	JUN 07, 1999		FEB	NEWA
		75MG	N75252 003	FEB 03, 2003		FEB	NEWA
		100MG	N75252 004	FEB 03, 2003		FEB	NEWA
	AZELASTINE HYDROCHLORIDE						
	SOLUTION/DROPS; OPHTHALMIC						
	OPTIVAR						
	+ MEDPOINTE	0.05%	N21127 001	MAY 22, 2000		APR	CAHN
	AZITHROMYCIN						
	TABLET; ORAL						
	ZITHROMAX						
	PFIZER	EQ 500MG BASE	N50784 001	MAY 24, 2002		AUG	CRLD
	BACLOFEN						
	TABLET, ORALLY DISINTEGRATING; ORAL						
>D>	BACLOFEN						
>D>	SCHWARZ PHARMA	10MG	N21589 001	OCT 30, 2003		NOV	CTNA
>D>	+	20MG	N21589 002	OCT 30, 2003		NOV	CTNA

			10MG	N21589 001	OCT 30, 2003	OCT	NEWA
			20MG	N21589 002	OCT 30, 2003	OCT	NEWA
	+						
>A>		KEMSTRO					
>A>		SCHWARZ PHARMA	10MG	N21589 001	OCT 30, 2003	NOV	CTNA
>A>			20MG	N21589 002	OCT 30, 2003	NOV	CTNA
>A>	+						
		BECLOMETHASONE DIPROPIONATE					
		AEROSOL, METERED; INHALATION					
		BECLOVENT					
		@ GLAXOSMITHKLINE	0.042MG/INH	N18153 001		MAR	DISC
		AEROSOL, METERED; NASAL					
		BECONASE					
		@ GLAXOSMITHKLINE	0.042MG/INH	N18584 001		MAR	DISC
		VANCENASE					
		@ SCHERING	0.042MG/INH	N18521 001		MAR	DISC
		BENZYL PENICILLOYL-POLYLYSINE					
		INJECTABLE; INJECTION					
		PRE-PEN					
	+	HOLLISTER STIER LABS	60UMOLAR	N50114 001		JUL	CAHN
		BEPRIDIL HYDROCHLORIDE					
		TABLET; ORAL					
		VASCOR					
>D>		ORTHO MCNEIL PHARM	200MG	N19002 001	DEC 28, 1990	NOV	CRLD
>A>	+		200MG	N19002 001	DEC 28, 1990	NOV	CRLD
>D>	+		300MG	N19002 002	DEC 28, 1990	NOV	DISC
>A>		@	300MG	N19002 002	DEC 28, 1990	NOV	DISC
		BETAMETHASONE					
		TABLET; ORAL					
		CELESTONE					
		@ SCHERING	0.6MG	N12657 003		FEB	DISC
		BETAMETHASONE DIPROPIONATE					
		CREAM; TOPICAL					
		ALPHATREX					
AB	+	SAVAGE LABS	EQ 0.05% BASE	N19138 001	JUN 26, 1984	MAY	CRLD
		DIPROSONE					
		@ SCHERING	EQ 0.05% BASE	N17536 001		MAY	DISC
		GEL, AUGMENTED; TOPICAL					
		BETAMETHASONE DIPROPIONATE					
AB		ALTANA	EQ 0.05% BASE	N75276 001	MAY 13, 2003	MAY	NEWA
		DIPROLENE					
AB	+	SCHERING	EQ 0.05% BASE	N19408 002	NOV 22, 1991	MAY	CFTG
		BETHANECHOL CHLORIDE					
		TABLET; ORAL					
		BETHANECHOL CHLORIDE					
AA		WOCKHARDT	5MG	N40532 001	SEP 29, 2003	SEP	NEWA
AA			10MG	N40533 001	SEP 29, 2003	SEP	NEWA
AA			25MG	N40534 001	SEP 29, 2003	SEP	NEWA

AA		50MG	N40518 001	SEP 29, 2003	SEP	NEWA
	URECHOLINE					
AA	+ ODYSSEY PHARMS	5MG	N89095 001	DEC 19, 1985	SEP	CFTG
AA	+	10MG	N88440 001	MAY 29, 1984	SEP	CFTG
AA	+	25MG	N88441 001	MAY 29, 1984	SEP	CFTG
AA	+	50MG	N89096 001	DEC 19, 1985	SEP	CFTG
	BISOPROLOL FUMARATE					
	TABLET; ORAL					
	ZEBETA					
AB	DURAMED PHARMS BARR	5MG	N19982 002	JUL 31, 1992	JUN	CAHN
AB	+	10MG	N19982 001	JUL 31, 1992	JUN	CAHN
AB	WYETH PHARMS INC	5MG	N19982 002	JUL 31, 1992	MAR	CAHN
AB	+	10MG	N19982 001	JUL 31, 1992	MAR	CAHN
	BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE					
	TABLET; ORAL					
	ZIAC					
AB	DURAMED PHARMS BARR	2.5MG;6.25MG	N20186 003	MAR 26, 1993	JUN	CAHN
AB		5MG;6.25MG	N20186 001	MAR 26, 1993	JUN	CAHN
AB	+	10MG;6.25MG	N20186 002	MAR 26, 1993	JUN	CAHN
AB	WYETH PHARMS INC	2.5MG;6.25MG	N20186 003	MAR 26, 1993	MAR	CAHN
AB		5MG;6.25MG	N20186 001	MAR 26, 1993	MAR	CAHN
AB	+	10MG;6.25MG	N20186 002	MAR 26, 1993	MAR	CAHN
	BIVALIRUDIN					
	INJECTABLE; INTRAVENOUS					
	ANGIOMAX					
	+ MEDICINES CO	250MG/VIAL	N20873 001	DEC 15, 2000	OCT	CAHN
	BLEOMYCIN SULFATE					
	INJECTABLE; INJECTION					
	BLEOMYCIN SULFATE					
AP	GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N64084 001	JUN 01, 1996	AUG	CAHN
AP		EQ 30 UNITS BASE/VIAL	N64084 002	JUN 01, 1996	AUG	CAHN
	BORTEZOMIB					
	INJECTABLE; INTRAVENOUS					
	VELCADE					
	+ MILLENNIUM PHARMS	3.5MG/VIAL	N21602 001	MAY 13, 2003	MAY	NEWA
	BRETYLIUM TOSYLATE					
	INJECTABLE; INJECTION					
	BRETYLIUM TOSYLATE					
	@ BAXTER HLTHCARE	50MG/ML	N70545 001	MAY 14, 1986	AUG	CAHN
	@	50MG/ML	N70546 001	MAY 14, 1986	AUG	CAHN
	@ ELKINS SINN	50MG/ML	N70545 001	MAY 14, 1986	JUN	DISC
	@	50MG/ML	N70546 001	MAY 14, 1986	JUN	DISC
	BRIMONIDINE TARTRATE					
	SOLUTION/DROPS; OPHTHALMIC					
	BRIMONIDINE TARTRATE					
AT	ALCON	0.2%	N76254 001	SEP 16, 2003	SEP	NEWA

AT	+	BAUSCH AND LOMB	0.2%	N76260 001	MAY 28, 2003	SEP	CFTG
	+		0.2%	N76260 001	MAY 28, 2003	MAY	NEWA

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

>D>		SYRUP; ORAL							
>D>		BROMANATE DC							
>D>	AA	ALPHARMA	2MG/5ML;10MG/5ML;12.5MG/5ML	N88723 001	FEB 25, 1985	NOV	DISC
>A>		@	2MG/5ML;10MG/5ML;12.5MG/5ML	N88723 001	FEB 25, 1985	NOV	DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

		SYRUP; ORAL							
		DIMETANE-DX							
		@ ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML	N19279 001	AUG 24, 1984	MAR	DISC
		MYPHETANE DX							
	AA	+ MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	N88811 001	JUN 07, 1985	MAR	CTEC

BUDESONIDE

		AEROSOL, METERED; NASAL							
		RHINOCORT							
		@ ASTRAZENECA	0.032MG/INH	N20233 001	FEB 14, 1994	SEP	DISC

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		DUOCAINE							
	+	AMPHASTAR	0.375% (37.5MG/10ML);1% (100MG/10ML)	N21496 001	MAY 23, 2003	MAY	NEWA

BUPROPION HYDROCHLORIDE

		TABLET, EXTENDED RELEASE; ORAL							
>A>		BUPROPRION HCL							
>A>	AB	EON	100MG	N75932 001	NOV 25, 2003	NOV	NEWA
		WELLBUTRIN SR							
		GLAXOSMITHKLINE	100MG	N20358 002	OCT 04, 1996	NOV	CFTG
>D>			100MG	N20358 002	OCT 04, 1996	NOV	CFTG
>A>	AB		150MG	N20358 003	OCT 04, 1996	OCT	CRLD
	+		200MG	N20358 004	JUN 14, 2002	OCT	CRLD
		WELLBUTRIN XL							
		SMITHKLINE BEECHAM	150MG	N21515 001	AUG 28, 2003	AUG	NEWA
			300MG	N21515 002	AUG 28, 2003	AUG	NEWA
	+						

BUSPIRONE HYDROCHLORIDE

		TABLET; ORAL							
		BUSPIRONE HCL							
	AB	EGIS	15MG	N75119 003	JAN 23, 2003	JAN	NEWA

BUSULFAN

		INJECTABLE; INJECTION							
		BUSULFEX							
	+	ESP PHARMA	6MG/ML	N20954 001	FEB 04, 1999	JUN	CAHN

CAFFEINE CITRATE
SOLUTION; INTRAVENOUS, ORAL
CAFCIT

+	MEAD JOHNSON	EQ 10MG BASE/ML	N20793 001	SEP 21, 1999	JUN	CAHN

CALCITRIOL
INJECTABLE; INJECTION
CALCITRIOL

AP	AAIPHARMA	0.001MG/ML	N75766 001	FEB 20, 2003	FEB	NEWA
AP		0.002MG/ML	N75766 002	FEB 20, 2003	FEB	NEWA
AP	GENSIA SICOR PHARMS	0.001MG/ML	N75823 001	MAR 31, 2003	MAR	NEWA
AP		0.002MG/ML	N75823 002	MAR 31, 2003	MAR	NEWA
AP	LUITPOLD	0.001MG/ML	N75746 001	SEP 26, 2003	SEP	NEWA
AP		0.002MG/ML	N75746 002	SEP 26, 2003	SEP	NEWA
AP	LYNE	0.001MG/ML	N76206 001	SEP 17, 2003	SEP	NEWA

SOLUTION; ORAL

AA	ROXANE	1UGM/ML	N76242 001	JUL 18, 2003	JUL	NEWA

ROCALTROL

AA	+ ROCHE	1UGM/ML	N21068 001	NOV 20, 1998	JUL	CFTG

CALCIUM ACETATE
CAPSULE; ORAL
PHOSLO

	Ⓐ NABI	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	AUG	CAHN
	Ⓐ	EQ 169MG CALCIUM	N21160 002	APR 02, 2001	AUG	CAHN

PHOSLO GELCAPS

+	NABI	EQ 169MG CALCIUM	N21160 003	APR 02, 2001	AUG	CAHN

TABLET; ORAL
PHOSLO

+	NABI	EQ 169MG CALCIUM	N19976 001	DEC 10, 1990	AUG	CAHN

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
INJECTABLE; INTRATHECAL
ELLIOTTS B SOLUTION

+	QOL MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML ;1.9MG/ML;7.3MG/ML;0.2MG/ML	N20577 001	SEP 27, 1996	MAY	CAHN

CARBAMAZEPINE
TABLET; ORAL
TERIL

AB	TARO	200MG	N76525 001	SEP 26, 2003	SEP	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA
TABLET; ORAL
STALEVO 100

	ORION PHARMA INC	25MG;200MG;100MG	N21485 002	JUN 11, 2003	JUN	NEWA

STALEVO 150

+	ORION PHARMA INC	37.5MG;200MG;150MG	N21485 003	JUN 11, 2003	JUN	NEWA

STALEVO 50

	ORION PHARMA INC	12.5MG;200MG;50MG	N21485 001	JUN 11, 2003	JUN	NEWA

CARBINOXAMINE MALEATE
SOLUTION; ORAL
CARBINOXAMINE MALEATE

+	MIKART	4MG/5ML	N40458 001	APR 25, 2003	APR	NEWA

TABLET; ORAL

+	MIKART	4MG	N40442 001	MAR 19, 2003	MAR	NEWA

CARBOPLATIN
INJECTABLE; IV (INFUSION)
PARAPLATIN

+	BRISTOL MYERS SQUIBB	EQ 50MG /5ML(10MG/ML)	N20452 001	JUL 14, 2003	JUL	NEWA
+		EQ 150MG /15ML(10MG/ML)	N20452 002	JUL 14, 2003	JUL	NEWA
+		EQ 450MG /45ML(10MG/ML)	N20452 003	JUL 14, 2003	JUL	NEWA

CARVEDILOL
TABLET; ORAL
COREG

+	GLAXOSMITHKLINE	12.5MG	N20297 002	SEP 14, 1995	APR	CRLD
		25MG	N20297 001	SEP 14, 1995	APR	CRLD

CEFACLOR
CAPSULE; ORAL
CEFACLOR

AB	CEPH INTL	EQ 250MG BASE	N62205 001		OCT	CTNA
AB		EQ 500MG BASE	N62205 002		OCT	CTNA

CEFADROXIL/CEFADROXIL HEMIHYDRATE
CAPSULE; ORAL
CEFADROXIL

AB	RANBAXY	EQ 500MG BASE	N65015 001	JUN 22, 1999	OCT	CAHN

FOR SUSPENSION; ORAL

AB	RANBAXY	EQ 125MG BASE/5ML	N65115 001	MAR 26, 2003	MAR	NEWA
AB		EQ 250MG BASE/5ML	N65115 002	MAR 26, 2003	MAR	NEWA
AB		EQ 500MG BASE/5ML	N65115 003	MAR 26, 2003	MAR	NEWA

DURICEF

AB	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527 002		MAR	CFTG
AB		EQ 250MG BASE/5ML	N50527 003		MAR	CFTG
AB	+	EQ 500MG BASE/5ML	N50527 001		MAR	CFTG

CEFAZOLIN SODIUM
INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	N65047 001	SEP 18, 2001	OCT	CAHN
AP		EQ 1GM BASE/VIAL	N65047 002	SEP 18, 2001	OCT	CAHN

CEFDITOREN PIVOXIL
TABLET; ORAL
SPECTRACEF

+	PURDUE PHARMA LP	200MG	N21222 001	AUG 29, 2001	MAY	CAHN

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

@ LEDERLE 100MG/5ML N50622 001 APR 28, 1989 APR DISC

TABLET; ORAL

@ LEDERLE 200MG N50621 001 APR 28, 1989 APR DISC

@ 400MG N50621 002 APR 28, 1989 APR DISC

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP LUPIN EQ 500MG BASE/VIAL N65124 001 SEP 24, 2003 SEP NEWA

AP EQ 1GM BASE/VIAL N65124 002 SEP 24, 2003 SEP NEWA

AP EQ 2GM BASE/VIAL N65124 003 SEP 24, 2003 SEP NEWA

CLAFORAN

AP AVENTIS PHARMS EQ 1GM BASE/VIAL N62659 001 JAN 13, 1987 SEP CTEC

AP EQ 2GM BASE/VIAL N62659 002 JAN 13, 1987 SEP CTEC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP BAXTER HLTHCARE EQ 10GM BASE/VIAL N65050 001 SEP 11, 2000 AUG CAHN

MEFOXIN IN PLASTIC CONTAINER

\+ MERCK EQ 20MG BASE/ML N63182 001 JAN 25, 1993 MAR CRLD

\+ EQ 40MG BASE/ML N63182 002 JAN 25, 1993 MAR CRLD

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB RANBAXY EQ 100MG BASE N65083 001 AUG 20, 2003 AUG NEWA

AB EQ 200MG BASE N65083 002 AUG 20, 2003 AUG NEWA

VANTIN

AB PHARMACIA AND UPJOHN EQ 100MG BASE N50674 001 AUG 07, 1992 AUG CFTG

AB + EQ 200MG BASE N50674 002 AUG 07, 1992 AUG CFTG

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

FUJISAWA HLTHCARE EQ 1GM BASE/VIAL N63294 002 MAR 31, 1994 AUG CAHN

EQ 2GM BASE/VIAL N63294 003 MAR 31, 1994 AUG CAHN

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP LUPIN EQ 250MG BASE/VIAL N65125 001 SEP 30, 2003 SEP NEWA

AP EQ 500MG BASE/VIAL N65125 002 SEP 30, 2003 SEP NEWA

AP EQ 1GM BASE/VIAL N65125 003 SEP 30, 2003 SEP NEWA

AP EQ 2GM BASE/VIAL N65125 004 SEP 30, 2003 SEP NEWA

ROCEPHIN

AP + HLR EQ 250MG BASE/VIAL N50585 001 DEC 21, 1984 SEP CFTG

AP + EQ 500MG BASE/VIAL N50585 002 DEC 21, 1984 SEP CFTG

AP + EQ 1GM BASE/VIAL N50585 003 DEC 21, 1984 SEP CFTG

AP +		EQ 2GM BASE/VIAL	N50585 004	DEC 21, 1984	SEP	CFTG	

CEFUROXIME AXETIL
TABLET; ORAL
CEFUROXIME AXETIL

AB	BIOCHEMIE US	EQ 250MG BASE	N65126 001	OCT 28, 2003	OCT	NEWA	
AB		EQ 500MG BASE	N65126 002	OCT 28, 2003	OCT	NEWA	
AB	LUPIN	EQ 250MG BASE	N65135 001	JUL 25, 2003	JUL	NEWA	
AB		EQ 500MG BASE	N65135 002	JUL 25, 2003	JUL	NEWA	
AB	RANBAXY	EQ 125MG BASE	N65118 001	APR 25, 2003	APR	NEWA	
AB		EQ 250MG BASE	N65118 002	APR 25, 2003	APR	NEWA	
AB		EQ 500MG BASE	N65118 003	APR 25, 2003	APR	NEWA	

CEPHALEXIN
CAPSULE; ORAL
CEPHALEXIN

AB	CEPH INTL	EQ 250MG BASE	N62118 001		OCT	CTNA	
AB		EQ 500MG BASE	N62118 002		OCT	CTNA	
	@ TEVA	EQ 250MG BASE	N62821 001	FEB 05, 1988	OCT	WDAG	

FOR SUSPENSION; ORAL

+	CEPH INTL	EQ 100MG BASE/ML	N62117 001		OCT	CTNA	
AB		EQ 125MG BASE/5ML	N62117 002		OCT	CTNA	
AB		EQ 250MG BASE/5ML	N62117 003		OCT	CTNA	

AB +
TABLET, FOR SUSPENSION; ORAL
PANIXINE DISPERDOSE

	RANBAXY	EQ 125MG BASE	N65100 002	SEP 11, 2003	SEP	NEWA	
+		EQ 250MG BASE	N65100 001	SEP 11, 2003	SEP	NEWA	

CEPHALOTHIN SODIUM
INJECTABLE; INJECTION
CEPHALOTHIN SODIUM

+	BRISTOL	EQ 1GM BASE/VIAL	N62464 001	MAY 07, 1984	MAR	CRLD	
+		EQ 2GM BASE/VIAL	N62464 002	MAY 07, 1984	MAR	CRLD	
+		EQ 4GM BASE/VIAL	N62464 003	MAY 07, 1984	MAR	CRLD	
	KEFLIN						
	@ LILLY	EQ 1GM BASE/VIAL	N50482 001		MAR	DISC	
	@	EQ 2GM BASE/VIAL	N50482 002		MAR	DISC	
	@	EQ 4GM BASE/VIAL	N50482 003		MAR	DISC	

CEPHAPIRIN SODIUM
INJECTABLE; INJECTION
CEPHAPIRIN SODIUM

	@ BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62720 001	JUL 02, 1987	AUG	CAHN	
	@	EQ 1GM BASE/VIAL	N62720 002	JUL 02, 1987	AUG	CAHN	
	@	EQ 2GM BASE/VIAL	N62720 003	JUL 02, 1987	AUG	CAHN	
	@	EQ 20GM BASE/VIAL	N62720 004	JUL 02, 1987	AUG	CAHN	

CHLORAMBUCIL
TABLET; ORAL
LEUKERAN

+	SMITHKLINE BEECHAM	2MG	N10669 002		OCT	CAHN	

CHLORAMPHENICOL
CAPSULE; ORAL
MYCHEL
@ ARMENPHARM 250MG N60851 001 JUL DISC
OINTMENT; OPHTHALMIC
CHLORAMPHENICOL
AT + ALTANA 1% N60133 001 MAY CRLD
CHLOROMYCETIN
@ PARKEDALE 1% N50156 001 MAY DISC
CHLOROPTIC S.O.P.
@ ALLERGAN 1% N61187 001 JUN DISC
SOLUTION/DROPS; OPHTHALMIC
CHLOROPTIC
@ ALLERGAN 0.5% N50091 001 JUN DISC
SOLUTION/DROPS; OTIC
CHLOROMYCETIN
@ PARKEDALE 0.5% N50205 001 MAY DISC

CHLORAMPHENICOL SODIUM SUCCINATE
INJECTABLE; INJECTION
CHLORAMPHENICOL SODIUM SUCCINATE
@ GRUPPO LEPETIT EQ 1GM BASE/VIAL N62278 001 JUL DISC

CHLOROQUINE HYDROCHLORIDE
INJECTABLE; INJECTION
ARALEN HCL
@ SANOFI SYNTHELABO EQ 40MG BASE/ML N06002 002 JUN DISC

CHLOROQUINE PHOSPHATE
TABLET; ORAL
CHLOROQUINE PHOSPHATE
AA IMPAX LABS EQ 300MG BASE N40516 001 AUG 29, 2003 AUG NEWA
@ WATSON LABS EQ 150MG BASE N87979 001 DEC 21, 1982 SEP DISC
@ EQ 300MG BASE N88030 001 DEC 21, 1982 SEP DISC
AA + WEST WARD EQ 150MG BASE N83082 001 SEP CRLD

CHLOROTHIAZIDE; METHYLDOPA
TABLET; ORAL
ALDOCLOR-150
@ MERCK 150MG;250MG N16016 001 MAY DISC
ALDOCLOR-250
@ MERCK 250MG;250MG N16016 002 MAY DISC

CHLORPROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
CHLORPROMAZINE HCL
AP BAXTER HLTHCARE 25MG/ML N83329 001 JUN CAHN
TABLET; ORAL
@ LEDERLE 10MG N84803 001 JUN DISC

CHLORTHALIDONE
TABLET; ORAL
CHLORTHALIDONE
@ CLONMEL HLTHCARE 25MG N87451 001 JUL CAHN
@ 50MG N87450 001 JUL CAHN
AB + MYLAN 50MG N86831 001 OCT CRLD
HYGROTON
@ AVENTIS PHARMS 25MG N12283 004 OCT DISC
@ 50MG N12283 003 OCT DISC
THALITONE
@ MONARCH PHARMS 25MG N19574 002 FEB 12, 1992 MAY DISC

CICLOPIROX
SHAMPOO; TOPICAL
LOPROX
+ MEDICIS 1% N21159 001 FEB 28, 2003 FEB NEWA
>D> LOTION; TOPICAL
>D> + MEDICIS 0.77% N19824 001 DEC 30, 1988 NOV CDFR
>A> SUSPENSION; TOPICAL
>A> + MEDICIS 0.77% N19824 001 DEC 30, 1988 NOV CDFR

CILOSTAZOL
TABLET; ORAL
PLETAL
+ OTSUKA 50MG N20863 001 JAN 15, 1999 OCT CRLD

CIMETIDINE
SOLUTION; ORAL
CIMETIDINE HCL
AA DURAMED PHARM BARR 300MG/5ML N75110 001 JUN 18, 1998 AUG CAIN

CIMETIDINE HYDROCHLORIDE
SOLUTION; ORAL
AA + ALPHARMA EQ 300MG BASE/5ML N74176 001 JUN 01, 1994 AUG CRLD
AA DURAMED PHARMS BARR EQ 300MG BASE/5ML N75110 001 JUN 18, 1998 AUG CAIN
TAGAMET
@ GLAXOSMITHKLINE EQ 300MG BASE/5ML N17924 001 AUG DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE
TABLET; ORAL
CIPRO XR
+ BAYER PHARMS 425.2MG;EQ 574.9MG BASE N21473 002 AUG 28, 2003 AUG NEWA

CIPROFLOXACIN; DEXAMETHASONE
SUSPENSION/DROPS; OTIC
CIPRODEX
+ ALCON 0.3%;0.1% N21537 001 JUL 18, 2003 JUL NEWA

CITRIC ACID; UREA, C-13
FOR SOLUTION; TABLET, FOR SOLUTION; ORAL
IDKIT:HP
@ ORIDION 4GM;75MG N21314 001 DEC 17, 2002 JUL DISC

CLADRIBINE
INJECTABLE; INJECTION
LEUSTATIN

AP	+	ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993	APR	CTEC

CLEMASTINE FUMARATE
SYRUP; ORAL
CLEMASTINE FUMARATE

AA	+	TEVA	EQ 0.5MG BASE/5ML	N73399 001	JUN 30, 1994	JUN	CRLD
		TAVIST					
		@ NOVARTIS	EQ 0.5MG BASE/5ML	N18675 001	JUN 28, 1985	JUN	DISC

CLINDAMYCIN HYDROCHLORIDE
CAPSULE; ORAL
CLINDAMYCIN HCL

AB		WATSON LABS	EQ 300MG BASE	N63083 002	MAR 18, 2003	MAR	NEWA

CLINDAMYCIN PHOSPHATE
INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

		@ BAXTER HLTHCARE	EQ 150MG BASE/ML				
AP			EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	AUG	CAHN
		@	EQ 150MG BASE/ML	N62889 001	APR 25, 1988	AUG	CAHN
				N63068 001	AUG 28, 1989	AUG	CAHN

CLOBETASOL PROPIONATE
LOTION; TOPICAL
CLOBEX

	+	GALDERMA LABS LP	0.05%	N21535 001	JUL 24, 2003	JUL	NEWA

CLOFIBRATE
CAPSULE; ORAL
ATROMID-S

		@ WYETH AYERST	500MG	N16099 002		JUN	DISC

CLONAZEPAM
TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING
ROCHE

			0.125MG				
			0.25MG	N20813 001	DEC 23, 1997	APR	CMFD
			0.5MG	N20813 002	DEC 23, 1997	APR	CMFD
	+		1MG	N20813 003	DEC 23, 1997	APR	CMFD
			2MG	N20813 004	DEC 23, 1997	APR	CMFD
				N20813 005	DEC 23, 1997	APR	CMFD

CLORAZEPATE DIPOTASSIUM
CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

		@ CLONMEL HLTHCARE	3.75MG				
		@	7.5MG	N71742 001	DEC 14, 1987	JUN	DISC
		@	15MG	N71743 001	DEC 14, 1987	JUN	DISC
				N71744 001	DEC 14, 1987	JUN	DISC

CLOZAPINE
TABLET; ORAL
CLOZAPINE
IVAX PHARMS 12.5MG N74949 003 JUL 31, 2003 JUL NEWA
AB + 100MG N74949 002 NOV 26, 1997 SEP CRLD
CLOZARIL
AB NOVARTIS 100MG N19758 002 SEP 26, 1989 SEP CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SYRUP; ORAL
PHENERGAN VC W/ CODEINE
@ WYETH AYERST 10MG/5ML;5MG/5ML;6.25MG/5ML N08306 005 APR 02, 1984 JUN DISC
PROMETH VC W/ CODEINE
AA + ALPHARMA 10MG/5ML;5MG/5ML;6.25MG/5ML N88764 001 OCT 31, 1984 JUN CRLD

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
SYRUP; ORAL
PHENERGAN W/ CODEINE
@ WYETH AYERST 10MG/5ML;6.25MG/5ML N08306 004 APR 02, 1984 JUN DISC
PROMETH W/ CODEINE
AA + ALPHARMA 10MG/5ML;6.25MG/5ML N88763 001 OCT 31, 1984 JUN CRLD

COLESTIPOL HYDROCHLORIDE
TABLET; ORAL
COLESTID
+ PHARMACIA AND UPJOHN 1GM N20222 001 JUL 19, 1994 MAY CRLD

COPPER
INTRAUTERINE DEVICE; INTRAUTERINE
COPPER T MODEL TCU 380A
+ FEI 309MG/COPPER N18680 001 NOV 15, 1984 MAR CAHN

CORTICOTROPIN
INJECTABLE; INJECTION
>D> CORTICOTROPIN
>D> + ORGANICS LAGRANGE 40 UNITS/ML N10831 001 NOV DISC
>A> @ 40 UNITS/ML N10831 001 NOV DISC
>D> BC 80 UNITS/ML N10831 002 NOV DISC
>A> @ 80 UNITS/ML N10831 002 NOV DISC
H.P. ACTHAR GEL
>D> BC + QUESTCOR PHARMS 80 UNITS/ML N08372 008 NOV CTEC
>A> + 80 UNITS/ML N08372 008 NOV CTEC

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE
BP + PHARMACIA AND UPJOHN 25MG N08126 001 APR CRLD
CORTONE
@ MERCK 25MG N07750 003 APR DISC

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

+	AMPHASTAR	0.25MG/VIAL	N16750 001		JUN	CAHN

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

CROMOPTIC

@	KING PHARMS	4%	N75088 001	APR 27, 1999	MAY	DISC

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

+	QUESTCOR PHARMS	0.5MG/INH	N19722 001	NOV 05, 1996	JUN	CAHN

INJECTABLE; INJECTION

CYANOCOBALAMIN

@	BAXTER HLTHCARE	1MG/ML	N80515 002		AUG	CAHN
@	ELKINS SINN	1MG/ML	N80515 002		JUN	DISC
AP	PHARMAFORCE	1MG/ML	N40451 001	SEP 23, 2003	SEP	NEWA
@	WYETH AYERST	0.1MG/ML	N80554 001		JUN	DISC
@		1MG/ML	N80554 002		JUN	DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL

AA	MCNEIL CONS SPECLT	5MG	N17821 001		MAR	CMFD
		5MG	N17821 001		APR	CTEC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

NEOSAR

@	GENSIA SICOR PHARMS	100MG/VIAL	N40015 001	APR 29, 1993	AUG	DISC
AP		100MG/VIAL	N87442 001	FEB 16, 1982	AUG	CAHN
@		200MG/VIAL	N40015 002	APR 29, 1993	AUG	DISC
AP		200MG/VIAL	N87442 002	FEB 16, 1982	AUG	CAHN
@		500MG/VIAL	N40015 003	APR 29, 1993	AUG	DISC
AP		500MG/VIAL	N87442 003	FEB 16, 1982	AUG	CAHN
@		1GM/VIAL	N40015 004	APR 29, 1993	AUG	DISC
AP		1GM/VIAL	N87442 004	JUL 08, 1983	AUG	CAHN
@		2GM/VIAL	N40015 005	APR 29, 1993	AUG	DISC
AP		2GM/VIAL	N87442 005	MAR 30, 1989	AUG	CAHN

CYCLOSPORINE

CAPSULE; ORAL

GENGRAF

AB1	ABBOTT	25MG	N65003 001	MAY 12, 2000	FEB	CTNA
BX		50MG	N65003 002	MAY 12, 2000	FEB	CTNA
AB1		100MG	N65003 003	MAY 12, 2000	FEB	CTNA

EMULSION; OPHTHALMIC

RESTASIS

+	ALLERGAN	0.05%	N50790 001	DEC 23, 2002	MAR	CMS1

		CYCLOSPORINE						
		INJECTABLE; INJECTION						
		CYCLOSPORINE						
	AP	PHARMAFORCE	50MG/ML	N65151 001	OCT 07, 2003	OCT	NEWA	
		CYPROHEPTADINE HYDROCHLORIDE						
		TABLET; ORAL						
		CYPROHEPTADINE HCL						
	AA	COREPHARMA	4MG	N40537 001	SEP 30, 2003	SEP	NEWA	
		CYTARABINE						
		INJECTABLE; INJECTION						
>D>		CYTARABINE						
>D>	AP +	GENSIA SICOR PHARMS	100MG/VIAL	N16793 001		NOV	DISC	
>D>	AP +		500MG/VIAL	N16793 002		NOV	DISC	
>D>	AP +		1GM/VIAL	N16793 003	DEC 21, 1987	NOV	DISC	
>D>	AP +		2GM/VIAL	N16793 004	DEC 21, 1987	NOV	DISC	
>A>		@ SICOR PHARMS	100MG/VIAL	N16793 001		NOV	DISC	
>D>	AP		100MG/VIAL	N75206 001	DEC 30, 1998	NOV	CTNA	
	AP		100MG/VIAL	N75206 001	DEC 30, 1998	JUL	CAHN	
>A>		@	500MG/VIAL	N16793 002		NOV	DISC	
>D>	AP +		500MG/VIAL	N75206 002	DEC 30, 1998	NOV	CTNA	
	AP +		500MG/VIAL	N75206 002	DEC 30, 1998	JUL	CAHN	
>A>		@	1GM/VIAL	N16793 003	DEC 21, 1987	NOV	DISC	
>D>	AP		1GM/VIAL	N75206 004	DEC 30, 1998	NOV	CTNA	
	AP		1GM/VIAL	N75206 004	DEC 30, 1998	JUL	CAHN	
>A>		@	2GM/VIAL	N16793 004	DEC 21, 1987	NOV	DISC	
>D>	AP		2GM/VIAL	N75206 003	DEC 30, 1998	NOV	CTNA	
	AP		2GM/VIAL	N75206 003	DEC 30, 1998	JUL	CAHN	
		CYTOSAR-U						
	AP +	GENSIA SICOR PHARMS	100MG/VIAL	N16793 001		JUN	CAHN	
	AP +		500MG/VIAL	N16793 002		JUN	CAHN	
	AP +		1GM/VIAL	N16793 003	DEC 21, 1987	JUN	CAHN	
	AP +		2GM/VIAL	N16793 004	DEC 21, 1987	JUN	CAHN	
>A>	AP	SICOR PHARMS	100MG/VIAL	N75206 001	DEC 30, 1998	NOV	CTNA	
>A>	AP +		500MG/VIAL	N75206 002	DEC 30, 1998	NOV	CTNA	
>A>	AP +		1GM/VIAL	N75206 004	DEC 30, 1998	NOV	CTNA	
>A>	AP +		2GM/VIAL	N75206 003	DEC 30, 1998	NOV	CTNA	
		DALFOPRISTIN; QUINUPRISTIN						
		INJECTABLE; IV (INFUSION)						
		SYNERCID						
	+	KING PHARMS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	FEB	CAHN	
		@	420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	FEB	CAHN	
		DAPTOMYCIN						
		INJECTABLE; IV (INFUSION)						
		CUBICIN						
		CUBIST	250MG/VIAL	N21572 001	SEP 12, 2003	SEP	NEWA	
	+		500MG/VIAL	N21572 002	SEP 12, 2003	SEP	NEWA	

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@	ESP PHARMA	75MG	N50261 001		OCT	CAHN
		150MG	N50261 002		OCT	CAHN
+		300MG	N50261 003		OCT	CAHN
@	WYETH PHARMS INC	75MG	N50261 001		MAR	CAHN
		150MG	N50261 002		MAR	CAHN
+		300MG	N50261 003		MAR	CAHN

DESIRUDIN

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+	AVENTIS PHARMS	15MG/VIAL	N21271 001	APR 04, 2003	APR	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

DESMOPRESSIN ACETATE

AB +	FERRING	0.01MG/SPRAY	N21333 001	SEP 16, 2002	MAY	CMS1

MINIRIN

AB +	FERRING	0.01MG/SPRAY	N21333 001	SEP 16, 2002	JUN	CTNA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

ORTHO-CEPT

@	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 001	DEC 14, 1992	MAR	DISC

TABLET; ORAL-28

AB +	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 002	DEC 14, 1992	MAR	CRLD

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	CLAY PARK	0.25%	N76510 001	JUL 01, 2003	JUL	NEWA

DEXAMETHASONE

ELIXIR; ORAL

DECADRON

@	MERCK	0.5MG/5ML	N12376 002		APR	DISC

HEXADROL

AA +	ORGANON	0.5MG/5ML	N12674 001		APR	CRLD

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE

AP	BAXTER HLTHCARE	EQ 4MG PHOSPHATE/ML	N84282 001		AUG	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

AP	AM PHARM	EQ 10MG PHOSPHATE/ML	N40491 001	APR 11, 2003	APR	NEWA

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

@	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001		MAY	DISC

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL							
MYLARAMINE							
+ MORTON GROVE	2MG/5ML	N88251 001	MAR 23, 1984	OCT	CRLD		
POLARAMINE							
@ SCHERING	2MG/5ML	N86837 001	JUL 19, 1982	OCT	DISC		
TABLET; ORAL							
DEXCHLORPHENIRAMINE MALEATE							
+ PLIVA	2MG	N88682 001	JAN 17, 1986	OCT	CRLD		
POLARAMINE							
@ SCHERING	2MG	N86835 001		OCT	DISC		

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL							
DEXEDRINE							
AB GLAXOSMITHKLINE	5MG	N17078 001		JUL	CRLD		
AB	10MG	N17078 002		JUL	CRLD		
DEXTROAMPHETAMINE SULFATE							
AB MALLINCKRODT	5MG	N76353 001	MAY 06, 2003	MAY	NEWA		
AB	10MG	N76353 002	MAY 06, 2003	MAY	NEWA		
AB	15MG	N76353 003	MAY 06, 2003	MAY	NEWA		

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL							
PHENERGAN W/ DEXTROMETHORPHAN							
@ WYETH AYERST	15MG/5ML;6.25MG/5ML	N11265 002	APR 02, 1984	JUN	DISC		
PROMETH W/ DEXTROMETHORPHAN							
AA + ALPHARMA	15MG/5ML;6.25MG/5ML	N88762 001	OCT 31, 1984	JUN	CRLD		

DIAZEPAM

GEL; RECTAL							
DIASTAT							
XCEL PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997	OCT	CRLD		
INJECTABLE; INJECTION							
DIAZEPAM							
@ BAXTER HLTHCARE	5MG/ML	N71308 001	JUL 17, 1987	AUG	CAHN		
	5MG/ML	N71309 001	JUL 17, 1987	AUG	CAHN		
AP	5MG/ML	N71310 001	JUL 17, 1987	AUG	CAHN		
AP @ ELKINS SINN	5MG/ML	N70311 001	DEC 16, 1985	JUN	DISC		
@	5MG/ML	N70312 001	DEC 16, 1985	JUN	DISC		
@	5MG/ML	N70313 001	DEC 16, 1985	JUN	DISC		
TABLET; ORAL							
@ CLONMEL HLTHCARE	5MG	N70227 001	SEP 26, 1985	AUG	DISC		
@	10MG	N70228 001	SEP 26, 1985	AUG	DISC		

DICHLORPHENAMIDE

TABLET; ORAL							
DARANIDE							
@ MERCK	50MG	N11366 001		MAY	DISC		

DICLOXACILLIN SODIUM
CAPSULE; ORAL
PATHOCIL

		@ WYETH AYERST	EQ 250MG BASE	N50011 002		JUN	DISC
		@	EQ 500MG BASE	N50011 003	MAR 28, 1983	JUN	DISC

FOR SUSPENSION; ORAL
DICLOXACILLIN SODIUM

	+	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001		JUN	CTEC

PATHOCIL

		@ WYETH AYERST	EQ 62.5MG BASE/5ML	N50092 001		JUN	DISC

DICYCLOMINE HYDROCHLORIDE
INJECTABLE; INJECTION
BENTYL

>D>	AP	+	AVENTIS PHARMS	10MG/ML	N08370 001	OCT 15, 1984	NOV	CAHN
>A>	AP	+	AXCAN SCANDIPHARM	10MG/ML	N08370 001	OCT 15, 1984	NOV	CAHN

BENTYL PRESERVATIVE FREE

>D>	AP	+	AVENTIS PHARMS	10MG/ML	N08370 002	OCT 15, 1984	NOV	CAHN
>A>	AP	+	AXCAN SCANDIPHARM	10MG/ML	N08370 002	OCT 15, 1984	NOV	CAHN

DICYCLOMINE HCL (PRESERVATIVE-FREE)

	AP		BEDFORD	10MG/ML	N40465 001	JUN 30, 2003	JUN	NEWA

SYRUP; ORAL
BENTYL

>D>		+	AVENTIS PHARMS	10MG/5ML	N07961 002	OCT 15, 1984	NOV	CAHN
>A>		+	AXCAN SCANDIPHARM	10MG/5ML	N07961 002	OCT 15, 1984	NOV	CAHN

DIENESTROL
CREAM; VAGINAL
DIENESTROL

		@ ORTHO MCNEIL	0.01%	N06110 005		AUG	DISC

DIGOXIN
INJECTABLE; INJECTION
DIGOXIN

AP		SABEX 2002	0.25MG/ML	N40481 001	AUG 21, 2003	AUG	NEWA
		@ WYETH AYERST	0.25MG/ML	N84386 001		JUN	DISC

TABLET; ORAL

AB		CARACO	0.125MG	N76363 001	JAN 31, 2003	JAN	NEWA
AB			0.25MG	N76363 002	JAN 31, 2003	JAN	NEWA

DIHYDROERGOTAMINE MESYLATE
INJECTABLE; INJECTION
D.H.E. 45

AP	+	XCEL PHARMS	1MG/ML	N05929 001		APR	CFTG

DIHYDROERGOTAMINE MESYLATE

AP		BEDFORD	1MG/ML	N40453 001	JUN 09, 2003	JUN	NEWA
AP		PADDOCK	1MG/ML	N40475 001	APR 28, 2003	APR	NEWA

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD

BC	+	AVENTIS PHARMS	360MG	N20062 005	AUG 24, 1999	OCT	NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TAZTIA XT

AB4	ANDRX PHARMS	120MG	N75401 001	APR 10, 2003	APR	NEWA
AB4		180MG	N75401 002	APR 10, 2003	APR	NEWA
AB4		240MG	N75401 003	APR 10, 2003	APR	NEWA
AB4		300MG	N75401 004	APR 10, 2003	APR	NEWA
AB4		360MG	N75401 005	APR 10, 2003	APR	NEWA

TIAZAC

AB4 +	BIOVAIL	120MG	N20401 001	SEP 11, 1995	APR	CFTG
AB4		120MG	N20401 001	SEP 11, 1995	AUG	CRLD
AB4 +		180MG	N20401 002	SEP 11, 1995	APR	CFTG
AB4		180MG	N20401 002	SEP 11, 1995	AUG	CRLD
AB4 +		240MG	N20401 003	SEP 11, 1995	APR	CFTG
AB4		240MG	N20401 003	SEP 11, 1995	AUG	CRLD
AB4 +		300MG	N20401 004	SEP 11, 1995	APR	CFTG
AB4		300MG	N20401 004	SEP 11, 1995	AUG	CRLD
AB4 +		360MG	N20401 005	SEP 11, 1995	APR	CFTG
AB4		360MG	N20401 005	SEP 11, 1995	AUG	CRLD

INJECTABLE; INJECTION

DILTIAZEM HCL

AP +	BEDFORD	5MG/ML	N74617 001	FEB 28, 1996	AUG	CRLD

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

+	BIOVAIL	120MG	N21392 001	FEB 06, 2003	FEB	NEWA
+		180MG	N21392 002	FEB 06, 2003	FEB	NEWA
+		240MG	N21392 003	FEB 06, 2003	FEB	NEWA
+		300MG	N21392 004	FEB 06, 2003	FEB	NEWA
+		360MG	N21392 005	FEB 06, 2003	FEB	NEWA
+		420MG	N21392 006	FEB 06, 2003	FEB	NEWA

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

@	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996	MAY	DISC
@		EQ 180MG HCL	N20506 002	OCT 04, 1996	MAY	DISC
@		EQ 240MG HCL	N20506 003	OCT 04, 1996	MAY	DISC

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

@	BAXTER HLTHCARE	50MG/ML	N84767 001		AUG	CAHN
+	STERIS	50MG/ML	N80615 001		JUN	CTEC
@	WYETH AYERST	50MG/ML	N84316 001		JUN	DISC

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

RIMSO-50

AT +	EDWARDS LIFESCIENCES	50%	N17788 001		JUL	CAHN

DIMYRISTOYL LECITHIN; PERFLEXANE
INJECTABLE; INTRAVENOUS
IMAGENT
+ IMCOR 0.92MG/VIAL;0.092MG/VIAL N21191 001 MAY 31, 2002 AUG CAHN

DIPHENHYDRAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL
AP BAXTER HLTHCARE 50MG/ML N80817 002 JUN CAHN
@ 50MG/ML N83183 001 AUG CAHN
@ WYETH AYERST 50MG/ML N80577 001 JUN DISC

DIPYRIDAMOLE
TABLET; ORAL
DIPYRIDAMOLE
AB CLONMEL HLTHCARE 25MG N88999 001 FEB 05, 1991 JUL CAHN
@ 25MG N88999 001 FEB 05, 1991 AUG DISC
AB 50MG N89000 001 FEB 05, 1991 JUL CAHN
AB 75MG N89001 001 FEB 05, 1991 JUL CAHN
@ 75MG N89001 001 FEB 05, 1991 AUG DISC

DOBUTAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
DOBUTAMINE HCL
@ BAXTER HLTHCARE EQ 12.5MG BASE/ML N74381 001 SEP 26, 1996 AUG CAHN
@ ELKINS SINN EQ 12.5MG BASE/ML N74381 001 SEP 26, 1996 JUN DISC

DOLASETRON MESYLATE MONOHYDRATE
INJECTABLE; INJECTION
ANZEMET
AVENTIS PHARMS EQ 12.5MG BASE/0.625ML N20624 002 SEP 11, 1997 JUL CPOT
EQ 12.5MG BASE/0.625ML N20624 002 SEP 11, 1997 SEP CPOT
+ EQ 100MG BASE/5ML N20624 001 SEP 11, 1997 SEP CPOT
+ EQ 500MG BASE/25ML N20624 003 DEC 11, 2001 SEP NEWA

DOPAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
DOPAMINE HCL
@ BAXTER HLTHCARE 40MG/ML N18398 001 JUN DISC
@ 80MG/ML N18398 002 MAR 22, 1982 JUN DISC

DOXAPRAM HYDROCHLORIDE
INJECTABLE; INJECTION
DOPRAM
AP + BAXTER HLTHCARE CORP 20MG/ML N14879 001 JAN CAHN
DOXAPRAM HCL
AP BEDFORD 20MG/ML N76266 001 JAN 10, 2003 JAN NEWA

DOXORUBICIN HYDROCHLORIDE
INJECTABLE; INJECTION
ADRIAMYCIN RDF
@ PHARMACIA AND UPJOHN 150MG/VIAL N50467 004 JUL 22, 1987 JUL DISC

DOXYCYCLINE
CAPSULE; ORAL
DOXYCYCLINE

AB	AXIOM PHARM	EQ 50MG BASE	N65041 001	APR 28, 2000	MAY	CAHN
AB		EQ 100MG BASE	N65041 002	APR 28, 2000	MAY	CAHN
+	RANBAXY	EQ 75MG BASE	N65053 003	SEP 10, 2003	OCT	NEWA

DOXYCYCLINE HYCLATE
CAPSULE; ORAL
DOXYCYCLINE HYCLATE

AB	AXIOM PHARM	EQ 50MG BASE	N61717 001		MAY	CAHN
AB		EQ 100MG BASE	N61717 002		MAY	CAHN

CAPSULE, COATED PELLETS; ORAL
DORYX

	FAULDING	EQ 75MG BASE	N50582 002	AUG 13, 2001	FEB	NEWA

INJECTABLE; INJECTION
DOXY 100

+	AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001	DEC 09, 1983	MAR	CRLD

DOXY 200

+	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002	DEC 09, 1983	MAR	CRLD

DOXYCYCLINE

	@ BAXTER HLTHCARE	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	AUG	CAHN
	@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	AUG	CAHN

DOXYCYCLINE HYCLATE

	@ BAXTER HLTHCARE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	AUG	CAHN
	@	EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	AUG	CAHN

VIBRAMYCIN

	@ PFIZER	EQ 100MG BASE/VIAL	N50442 002		MAR	DISC
	@	EQ 200MG BASE/VIAL	N50442 001		MAR	DISC

TABLET; ORAL
DOXYCYCLINE HYCLATE

AB	AXIOM PHARM	EQ 100MG BASE	N62269 002	NOV 08, 1982	MAY	CAHN
AB	WEST WARD	EQ 100MG BASE	N65095 001	JUL 02, 2003	JUL	NEWA

DOXYCYCLINE HYLATE

	@ AXIOM PHARM	EQ 50MG BASE	N62269 003		MAY	CAHN

EDROPHONIUM CHLORIDE
INJECTABLE; INJECTION
REVERSOL

	@ ORGANON	10MG/ML	N89624 001	MAY 13, 1988	MAY	DISC

ELETRIPTAN HYDROBROMIDE
TABLET; ORAL
RELPAX

	PFIZER IRELAND	EQ 20MG BASE	N21016 001	DEC 26, 2002	MAR	CAHN
+		EQ 40MG BASE	N21016 002	DEC 26, 2002	MAR	CAHN

EMTRICITABINE
CAPSULE; ORAL
EMTRIVA

+	GILEAD	200MG	N21500 001	JUL 02, 2003	JUL	NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	IVAX PHARMS	5MG;12.5MG	N75736 001	MAR 25, 2003	MAR	NEWA
AB		10MG;25MG	N75736 002	MAR 25, 2003	MAR	NEWA

ENFUVIRTIDE
INJECTABLE; SUBCUTANEOUS
FUZEON

+	ROCHE	90MG/VIAL	N21481 001	MAR 13, 2003	MAR	NEWA

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX

+	AVENTIS	300MG/3ML	N20164 009	JAN 23, 2003	JAN	NEWA

EPINASTINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
ELESTAT

+	ALLERGAN	0.05%	N21565 001	OCT 16, 2003	OCT	NEWA

EPINEPHRINE
INJECTABLE; IM-SC
TWINJECT

+	HOLLISTER STIER LABS	0.3MG /DELIVERY	N20800 001	MAY 30, 2003	MAY	NEWA

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

@	ASTRAZENECA	0.005MG/ML;1%	N17751 006		OCT	WDAG
@	DENTSPLY PHARM	0.005MG/ML;1.5%	N21384 001		MAR	DISC

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE

@	ELKINS SINN	0.01MG/ML;1%	N80406 001		JUN	DISC
@		0.01MG/ML;2%	N80406 002		JUN	DISC

EPIRUBICIN HYDROCHLORIDE
INJECTABLE; INJECTION
ELLENCE

>D>	BX	+	PHARMACIA AND UPJOHN	2MG/ML	N50778 001	SEP 15, 1999	NOV	CTEC
>A>		+		2MG/ML	N50778 001	SEP 15, 1999	NOV	CTEC

EPROSARTAN MESYLATE
TABLET; ORAL
TEVETEN
BIOVAIL

		EQ 300MG BASE	N20738 004	DEC 22, 1997	JUL	CAHN
		EQ 400MG BASE	N20738 005	DEC 22, 1997	JUL	CAHN
+		EQ 600MG BASE	N20738 006	MAY 27, 1999	JUL	CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

	BIOVAIL	600MG;12.5MG	N21268 001	NOV 01, 2001	JUL	CAHN
+		600MG;25MG	N21268 002	NOV 01, 2001	JUL	CAHN

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+	HARVEST PHARMS	2MG	N87693 001	FEB 24, 1983	MAR	CAHN

ERYTHROMYCIN

SOLUTION; TOPICAL

STATICIN

+	WESTWOOD SQUIBB	1.5%	N50526 001		APR	CTEC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN

	@ ELKINS SINN	EQ 500MG BASE/VIAL	N62563 001	MAR 28, 1985	JUN	DISC
	@	EQ 1GM BASE/VIAL	N62563 002	MAR 28, 1985	JUN	DISC

ERYTHROMYCIN LACTOBIONATE

AP	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62993 001	MAY 09, 1989	AUG	CAHN
AP		EQ 1GM BASE/VIAL	N62993 002	MAY 09, 1989	AUG	CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

LEXAPRO

>D>	FOREST LABS	5MG	N21323 001	AUG 14, 2002	NOV	DISC
>A>	@	5MG	N21323 001	AUG 14, 2002	NOV	DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

+	BAXTER HLTHCARE CORP	10MG/ML	N19386 006	FEB 25, 2003	JUN	NEWA
+		20MG/ML	N19386 007	MAY 28, 2003	JUN	NEWA

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	2GM/100ML	N19386 005	JAN 27, 2003	MAR	NEWA

BREVIBLOC IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	1GM/100ML	N19386 004	FEB 16, 2001	MAR	NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

BX	+ BERLEX LABS	0.0375MG/24HR	N20375 005	MAY 27, 2003	JUN	NEWA
	+	0.06MG/24HR	N20375 006	MAY 27, 2003	JUN	NEWA

TABLET; ORAL

ESTRADIOL

@ CLONMEL HLTHCARE	0.5MG	N40275 001	DEC 29, 1998	AUG	DISC
@	1MG	N40275 002	DEC 29, 1998	AUG	DISC
@	2MG	N40275 003	DEC 29, 1998	AUG	DISC

	ESTRADIOL ACETATE						
	INSERT, EXTENDED RELEASE; VAGINAL						
	FEMRING						
	GALEN LTD	0.05MG/24HR	N21367 001	MAR 20, 2003	MAR	NEWA
+		0.1MG/24HR	N21367 002	MAR 20, 2003	MAR	NEWA
	ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE						
	INJECTABLE; INTRAMUSCULAR						
	LUNELLE						
	@ PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N20874 001	OCT 05, 2000	AUG	DISC
	ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE						
	INJECTABLE; INJECTION						
	DEPO-TESTADIOL						
	@ PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N17968 001		MAY	WDAG
	ESTRADIOL HEMIHYDRATE						
	EMULSION; TOPICAL						
	ESTRASORB						
+	NOVAVAX	0.25%	N21371 001	OCT 09, 2003	OCT	NEWA
>A>	ESTRADIOL; LEVONORGESTREL						
>A>	FILM, EXTENDED RELEASE; TRANSDERMAL						
>A>	CLIMARA PRO						
>A> +	BERLEX LABS	0.045MG/24HR;0.015MG/24HR	N21258 001	NOV 21, 2003	NOV	NEWA
	ESTRADIOL; NORGESTIMATE						
	TABLET; ORAL						
	PREFEST						
+	KING PHARMS	1MG;1MG;0.09MG	N21040 001	OCT 22, 1999	MAY	CTNA
	ESTROGENS, CONJUGATED						
	CREAM; TOPICAL, VAGINAL						
	PREMARIN						
+	WYETH PHARMS INC	0.625MG/GM	N20216 001		MAR	CAHN
	INJECTABLE; INJECTION						
+	WYETH PHARMS INC	25MG/VIAL	N10402 001		MAR	CAHN
	TABLET; ORAL						
	WYETH PHARMS INC	0.3MG	N04782 003		MAR	CAHN
		0.45MG	N04782 006	JUL 16, 2003	JUL	NEWA
+		0.625MG	N04782 004		MAR	CAHN
		0.9MG	N04782 005	JAN 26, 1984	MAR	CAHN
+		1.25MG	N04782 001		MAR	CAHN
		2.5MG	N04782 002		MAR	CAHN
	ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE						
	TABLET; ORAL-28						
	PREMPHASE (PREMARIN;CYCRIN 14/14)						
	@ WYETH PHARMS INC	0.625MG;0.625MG;5MG	N20303 002	DEC 30, 1994	MAR	CAHN
	PREMPHASE 14/14						
+	WYETH PHARMS INC	0.625MG;0.625MG;5MG	N20527 002	NOV 17, 1995	MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPRO

+	WYETH PHARMS INC	0.3MG;1.5MG	N20527 005	JUN 04, 2003	JUN	NEWA
+		0.45MG;1.5MG	N20527 004	MAR 12, 2003	MAR	NEWA
+		0.625MG;0.625MG;2.5MG;2.5MG	N20527 001	NOV 17, 1995	MAR	CAHN
+		0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	MAR	CAHN

PREMPRO (PREMARIN;CYCRIN)

@	WYETH PHARMS INC	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	MAR	CAHN

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

	MONARCH PHARMS	0.3MG	N84951 001		JAN	CRLD

ETHACRYNIC ACID

TABLET; ORAL

EDECRIN

+	MERCK	25MG	N16092 001		MAY	CRLD
@		50MG	N16092 002		MAY	DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HCL

AB	+	WEST WARD	400MG	N75095 002	NOV 30, 1999	JUN	CRLD

MYAMBUTOL

@	LEDERLE	100MG	N16320 001		JUN	DISC
@		400MG	N16320 003		JUN	DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

DEMULEN 1/35-28

AB	+	GD SEARLE LLC	0.035MG;1MG	N18160 001		JUL	CRLD

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

	+	ORGANON USA INC	0.015MG;0.12MG	N21187 001	OCT 03, 2001	JUN	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

SEASONALE

	+	BARR	0.03MG;0.15MG	N21544 001	SEP 05, 2003	SEP	NEWA

TABLET; ORAL-21

ALESSE

AB1	+	WYETH PHARMS INC	0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAR	CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		BARR	0.02MG;0.1MG	N75862 001	APR 29, 2003	APR	NEWA

NORDETTE-21

AB	+	WYETH PHARMS INC	0.03MG;0.15MG	N18668 001	MAY 10, 1982	MAR	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

TRIPHASIL-21

AB	+	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG;0.075MG	N19192 001	NOV 01, 1984	MAR	CAHN

TABLET; ORAL-28

ALESSE

AB1		WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	MAR 27, 1997	MAR	CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		BARR	0.02MG;0.1MG	N75862 002	APR 29, 2003	APR	NEWA

NORDETTE-28

AB		WYETH PHARMS INC	0.03MG;0.15MG	N18782 001	JUL 21, 1982	MAR	CAHN

TRIPHASIL-28

AB		WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG;0.075MG	N19190 001	NOV 01, 1984	MAR	CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

>D>	+	ORTHO MCNEIL PHARM	0.02MG/24HR;0.015MG/24HR	N21180 001	NOV 20, 2001	NOV	CPOT
>A>	+		0.02MG/24HR;0.15MG/24HR	N21180 001	NOV 20, 2001	NOV	CPOT

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BREVICON 21-DAY

AB	+	WATSON LABS	0.035MG;0.5MG	N17566 001		AUG	CRLD

MODICON 21

	@	ORTHO MCNEIL PHARM	0.035MG;0.5MG	N17488 001		AUG	DISC

ORTHO-NOVUM 1/35-21

	@	ORTHO MCNEIL PHARM	0.035MG;1MG	N17489 002		AUG	DISC

ORTHO-NOVUM 10/11-21

	@	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354 001	JAN 11, 1982	AUG	DISC

ORTHO-NOVUM 7/7/7-21

	@	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N18985 001	APR 04, 1984	AUG	DISC

TRI-NORINYL 21-DAY

	@	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N18977 001	APR 13, 1984	MAR	CPOT
	@		0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984	FEB	DISC

TABLET; ORAL-28

ORTHO-NOVUM 7/7/7-28

AB	+	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N18985 002	APR 04, 1984	FEB	CRLD

OVCON-35

	+	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001		JAN	CRLD

OVCON-50

	+	WARNER CHILCOTT	0.05MG;1MG	N17576 001		JAN	CRLD

TRI-NORINYL 28-DAY

	+	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N18977 002	APR 13, 1984	MAR	CPOT
	+		0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984	JAN	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

>A> TABLET, CHEWABLE; ORAL-28

>A> OVCON-35

>A> + WARNER CHILCOTT 0.035MG;0.4MG N21490 001 NOV 14, 2003 NOV NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

\+ GALEN CHEM 0.005MG;1MG N21065 002 OCT 15, 1999 MAY CAHN

TABLET; ORAL-21

ESTROSTEP 21

@ GALEN CHEM 0.02MG;0.03MG;0.035MG;1MG;1MG;1MG N20130 001 OCT 09, 1996 APR CAHN

JUNEL 1.5/30

AB BARR 0.03MG;1.5MG N76381 001 MAY 30, 2003 MAY NEWA

JUNEL 1/20

AB BARR 0.02MG;1MG N76380 001 MAY 30, 2003 MAY NEWA

LOESTRIN 21 1.5/30

\+ GALEN CHEM 0.03MG;1.5MG N17875 001 APR CAHN

AB + 0.03MG;1.5MG N17875 001 MAY CFTG

LOESTRIN 21 1/20

\+ GALEN CHEM 0.02MG;1MG N17876 001 APR CAHN

AB + 0.02MG;1MG N17876 001 MAY CFTG

TABLET; ORAL-28

ESTROSTEP FE

\+ GALEN CHEM 0.02MG;0.03MG;0.035MG;1MG;1MG;1MG N20130 002 OCT 09, 1996 APR CAHN

JUNEL FE 1.5/30

AB BARR 0.03MG;1.5MG N76064 001 SEP 18, 2003 SEP NEWA

JUNEL FE 1/20

AB BARR 0.02MG;1MG N76081 001 SEP 18, 2003 SEP NEWA

LOESTRIN FE 1.5/30

AB + GALEN CHEM 0.03MG;1.5MG N17355 001 APR CAHN

LOESTRIN FE 1/20

AB + GALEN CHEM 0.02MG;1MG N17354 001 APR CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

AB + WYETH PHARMS INC 0.03MG;0.3MG N17612 001 MAR CAHN

OGESTREL 0.5/50-21

AB WATSON LABS 0.05MG;0.5MG N75406 001 DEC 15, 1999 FEB CAHN

OVRAL

AB + WYETH PHARMS INC 0.05MG;0.5MG N16672 001 MAR CAHN

TABLET; ORAL-28

LO/OVRAL-28

AB WYETH PHARMS INC 0.03MG;0.3MG N17802 001 MAR CAHN

OGESTREL 0.5/50-28

AB WATSON LABS 0.05MG;0.5MG N75406 002 DEC 15, 1999 FEB CAHN

OVRAL-28

AB WYETH PHARMS INC 0.05MG;0.5MG N16806 001 MAR CAHN

ETHIONAMIDE
TABLET; ORAL
TRECATOR-SC

+	WYETH PHARMS INC	250MG	N13026 002		MAR	CAHN

ETHOTOIN
TABLET; ORAL
PEGANONE

+	OVATION PHARMS	250MG	N10841 001		MAR	CAHN
@		500MG	N10841 003		MAR	CAHN

ETIDRONATE DISODIUM
TABLET; ORAL
DIDRONEL

AB	PROCTER AND GAMBLE	200MG	N17831 001		JUL	CTEC
AB +		400MG	N17831 002		JUL	CTEC

ETIDRONATE DISODIUM

AB	GENPHARM	200MG	N75800 001	JAN 24, 2003	JAN	NEWA
AB		400MG	N75800 002	JAN 24, 2003	JAN	NEWA

ETODOLAC
CAPSULE; ORAL
LODINE

AB	WYETH PHARMS INC	200MG	N18922 002	JAN 31, 1991	MAR	CAHN
AB +		300MG	N18922 003	JAN 31, 1991	MAR	CAHN

TABLET; ORAL

AB	WYETH PHARMS INC	400MG	N18922 004	JUL 29, 1993	MAR	CAHN
AB +		500MG	N18922 005	JUN 28, 1996	MAR	CAHN

TABLET, EXTENDED RELEASE; ORAL
ETODOLAC

AB	TARO	400MG	N76174 001	MAR 13, 2003	MAR	NEWA
AB		500MG	N76174 002	MAR 13, 2003	MAR	NEWA
AB		600MG	N76174 003	MAR 13, 2003	MAR	NEWA

LODINE XL

AB +	WYETH PHARMS INC	400MG	N20584 001	OCT 25, 1996	MAR	CAHN
AB +		500MG	N20584 003	JAN 20, 1998	MAR	CAHN
AB +		600MG	N20584 002	OCT 25, 1996	MAR	CAHN

ETOPOSIDE
INJECTABLE; INJECTION
ETOPOSIDE

AP	SICOR PHARMS	20MG/ML	N74284 001	FEB 10, 1994	JUL	CAHN
AP		20MG/ML	N74529 001	JUL 24, 1996	JUL	CAHN

TOPOSAR

AP	GENSIA SICOR PHARMS	20MG/ML	N74166 001	FEB 27, 1995	JUL	CAHN

FAMOTIDINE
INJECTABLE; INJECTION
FAMOTIDINE

AP	BAXTER HLTHCARE	10MG/ML	N75488 001	APR 16, 2001	AUG	CAHN

FAMOTIDINE PRESERVATIVE FREE

AP	BAXTER HLTHCARE	10MG/ML	N75486 001	APR 16, 2001	JUN	CAHN

FELBAMATE
SUSPENSION; ORAL
FELBATOL
+ MEDPOINTE 600MG/5ML N20189 003 JUL 29, 1993 MAR CAHN
TABLET; ORAL
MEDPOINTE 400MG N20189 001 JUL 29, 1993 MAR CAHN
+ 600MG N20189 002 JUL 29, 1993 MAR CAHN

FENOFIBRATE
CAPSULE; ORAL
FENOFIBRATE (MICRONIZED)
AB IMPAX LABS 67MG N75868 001 OCT 27, 2003 OCT NEWA
AB 134MG N75868 002 OCT 27, 2003 OCT NEWA
AB 200MG N75868 003 OCT 27, 2003 OCT NEWA
AB TEVA 67MG N75753 001 SEP 03, 2002 OCT CFTG
67MG N75753 001 SEP 03, 2002 MAR CTEC
AB 134MG N75753 002 APR 09, 2002 OCT CFTG
134MG N75753 002 APR 09, 2002 MAR CTEC
AB + 200MG N75753 003 APR 09, 2002 OCT CFTG
+ 200MG N75753 003 APR 09, 2002 MAR CRLD
TRICOR (MICRONIZED)
@ ABBOTT 67MG N19304 002 FEB 09, 1998 MAR DISC
@ 134MG N19304 003 JUN 30, 1999 MAR DISC
@ 200MG N19304 004 JUN 30, 1999 MAR DISC

FENTANYL
FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC
>D> + ALZA 0.6MG/24HR N19813 004 AUG 07, 1990 NOV CFTG
>A> AB + 0.6MG/24HR N19813 004 AUG 07, 1990 NOV CFTG
>D> 1.2MG/24HR N19813 003 AUG 07, 1990 NOV CFTG
>A> AB 1.2MG/24HR N19813 003 AUG 07, 1990 NOV CFTG
>D> 1.8MG/24HR N19813 002 AUG 07, 1990 NOV CFTG
>A> AB 1.8MG/24HR N19813 002 AUG 07, 1990 NOV CFTG
>D> 2.4MG/24HR N19813 001 AUG 07, 1990 NOV CFTG
>A> AB 2.4MG/24HR N19813 001 AUG 07, 1990 NOV CFTG
>A> FENTANYL
>A> AB MYLAN TECHNOLOGIES 0.6MG/24HR N76258 001 NOV 21, 2003 NOV NEWA
>A> AB 1.2MG/24HR N76258 002 NOV 21, 2003 NOV NEWA
>A> AB 1.8MG/24HR N76258 003 NOV 21, 2003 NOV NEWA
>A> AB 2.4MG/24HR N76258 004 NOV 21, 2003 NOV NEWA

FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE PRESERVATIVE FREE
AP + BAXTER HLTHCARE EQ 0.05MG BASE/ML N19101 001 JUL 11, 1984 AUG CAHN

FERRIC AMMONIUM CITRATE
FOR SOLUTION; ORAL
FERRISELTZ
@ OTSUKA 600MG/PACKET N20292 001 OCT 14, 1997 AUG CAHN

FERRIC HEXACYANOFERRATE(II)
CAPSULE; ORAL
RADIOGARDASE (PRUSSIAN BLUE)

>D>	+	HEYDT	500MG	N21626 001	OCT 02, 2003	NOV	CAHN
	+		500MG	N21626 001	OCT 02, 2003	OCT	NEWA
>A>	+	HEYL CHEMISCH	500MG	N21626 001	OCT 02, 2003	NOV	CAHN

FLAVOXATE HYDROCHLORIDE
TABLET; ORAL
FLAVOXATE HCL

AB		IMPAX PHARMS	100MG	N76234 001	AUG 28, 2003	AUG	NEWA

URISPAS

	+	ORTHO MCNEIL PHARM	100MG	N16769 001		MAR	CAHN
AB	+		100MG	N16769 001		AUG	CFTG

FLECAINIDE ACETATE
TABLET; ORAL
FLECAINIDE ACETATE

AB		GENEVA PHARMS	50MG	N76030 001	OCT 28, 2002	JUN	CAHN
AB			100MG	N76030 002	OCT 28, 2002	JUN	CAHN
AB			150MG	N76030 003	OCT 28, 2002	JUN	CAHN
AB		RANBAXY	50MG	N76421 001	MAR 28, 2003	MAR	NEWA
AB			100MG	N76421 002	MAR 28, 2003	MAR	NEWA
AB			150MG	N76421 003	MAR 28, 2003	MAR	NEWA
AB		ROXANE	50MG	N76278 001	JAN 14, 2003	JAN	NEWA
AB			100MG	N76278 002	JAN 14, 2003	JAN	NEWA
AB			150MG	N76278 003	JAN 14, 2003	JAN	NEWA

FLUDARABINE PHOSPHATE
INJECTABLE; INJECTION
FLUDARA

AP	+	BERLEX	50MG/VIAL	N20038 001	APR 18, 1991	AUG	CFTG

FLUDARABINE PHOSPHATE

AP		GENSIA SICOR PHARMS	50MG/VIAL	N76349 001	AUG 28, 2003	AUG	NEWA

FLUDROCORTISONE ACETATE
TABLET; ORAL
FLUDROCORTISONE ACETATE

AB		BARR	0.1MG	N40425 001	JAN 21, 2003	JAN	NEWA

FLUNISOLIDE
SPRAY, METERED; NASAL
NASAREL

	+	IVAX RES	0.029MG/SPRAY	N20409 001	MAR 08, 1995	JUL	CPOT

FLUOCINONIDE
CREAM; TOPICAL
FLUOCINONIDE

AB1		ALPHARMA US PHARM	0.05%	N73085 001	FEB 14, 1992	MAY	CTEC
AB1		FOUGERA	0.05%	N73030 001	OCT 17, 1994	MAY	CTEC
AB1		TARO	0.05%	N19117 001	JUN 26, 1984	MAY	CTEC
AB1			0.05%	N71500 001	JUN 10, 1987	MAY	CTEC

AB1	TEVA	0.05%	N72488 001	FEB 06, 1989	MAY	CTEC
	FLUOCINONIDE EMULSIFIED BASE					
AB2	ALPHARMA US PHARM	0.05%	N74204 001	JUN 13, 1995	MAY	CTEC
AB2	DRAXIS HLTH	0.05%	N72494 001	JAN 19, 1989	MAY	CTEC
AB2	TARO	0.05%	N72494 001	JAN 19, 1989	JUN	CAHN
AB2	TEVA	0.05%	N72490 001	FEB 07, 1989	MAY	CTEC
	LIDEX					
AB1 +	MEDICIS	0.05%	N16908 002		MAY	CTEC
	LIDEX-E					
AB2 +	MEDICIS	0.05%	N16908 003		MAY	CRLD
	FLUORESCEIN SODIUM					
	INJECTABLE; INJECTION					
	FUNDUSCEIN-25					
	@ NOVARTIS	25%	N17869 001		JAN	DISC
	FLUOROURACIL					
	INJECTABLE; INJECTION					
	ADRUCIL					
AP	GENSIA SICOR PHARMS	50MG/ML	N40023 001	OCT 18, 1991	JUL	CAHN
AP +		50MG/ML	N81225 001	AUG 28, 1991	JUL	CAHN
	FLUOROURACIL					
AP	SICOR PHARMS	50MG/ML	N40333 001	JAN 27, 2000	JUL	CAHN
AP		50MG/ML	N40334 001	FEB 25, 2000	JUL	CAHN
	SOLUTION; TOPICAL					
	EFUDEX					
>D> +	ICN	2%	N16831 001		NOV	CFTG
>A> AT +		2%	N16831 001		NOV	CFTG
>D> +		5%	N16831 002		NOV	CFTG
>A> AT +		5%	N16831 002		NOV	CFTG
	FLUOROPLEX					
	@ ALLERGAN HERBERT	1%	N16765 001		JUN	DISC
>A>	FLUOROURACIL					
>A> AT	TARO	2%	N76526 001	NOV 05, 2003	NOV	NEWA
>A> AT		5%	N76526 002	NOV 05, 2003	NOV	NEWA
	FLUPHENAZINE DECANOATE					
	INJECTABLE; INJECTION					
	FLUPHENAZINE DECANOATE					
	@ KING PHARMS	25MG/ML	N74966 001	APR 16, 1998	MAY	DISC
	FLURANDRENOLIDE					
	LOTION; TOPICAL					
	CORDRAN					
+	OCLASSEN	0.05%	N13790 001		MAY	CTEC
+	WATSON LABS	0.05%	N13790 001		OCT	CAHN
	FLUTAMIDE					
	CAPSULE; ORAL					
	FLUTAMIDE					
AB	GENPHARM	125MG	N76224 001	MAY 09, 2003	MAY	NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

	AB	GENEVA PHARMS	25MG	N75887 001	JAN 05, 2001	APR	CAHN
	AB		50MG	N75887 002	JAN 05, 2001	APR	CAHN
	AB		100MG	N75887 003	JAN 05, 2001	APR	CAHN

FOLIC ACID
INJECTABLE; INJECTION
FOLIC ACID

	AP +	AM PHARM PARTNERS	5MG/ML	N89202 001	FEB 18, 1986	JUN	CRLD

FOLVITE

	AP +	WYETH PHARMS INC	5MG/ML	N05897 008		MAR	CAHN
		@	5MG/ML	N05897 008		JUN	DISC

TABLET; ORAL

		@ WYETH PHARMS INC	1MG	N05897 004		MAR	CAHN

FOSAMPRENAVIR CALCIUM
TABLET; ORAL
LEXIVA

	+	GLAXOSMITHKLINE	EQ 700MG BASE	N21548 001	OCT 20, 2003	OCT	NEWA

FOSINOPRIL SODIUM
TABLET; ORAL
FOSINOPRIL SODIUM

>A>		TEVA	10MG	N76139 001	NOV 25, 2003	NOV	NEWA
>A>	AB		20MG	N76139 002	NOV 25, 2003	NOV	NEWA
>A>	AB		40MG	N76139 003	NOV 25, 2003	NOV	NEWA

MONOPRIL

>D>		BRISTOL MYERS SQUIBB	10MG	N19915 002	MAY 16, 1991	NOV	CFTG
>A>	AB		10MG	N19915 002	MAY 16, 1991	NOV	CFTG
>D>			20MG	N19915 003	MAY 16, 1991	NOV	CFTG
>A>	AB		20MG	N19915 003	MAY 16, 1991	NOV	CFTG
>D>	+		40MG	N19915 004	MAR 28, 1995	NOV	CFTG
>A>	AB +		40MG	N19915 004	MAR 28, 1995	NOV	CFTG

FUROSEMIDE
INJECTABLE; INJECTION
FUROSEMIDE

		@ BAXTER HLTHCARE	10MG/ML	N18267 001		JUN	DISC
	AP		10MG/ML	N71439 001	SEP 14, 1990	AUG	CAHN

TABLET; ORAL

	AB	CLONMEL HLTHCARE	20MG	N18415 001	JUL 27, 1982	JUL	CAHN
		@	20MG	N18415 001	JUL 27, 1982	AUG	DISC
	AB		40MG	N18415 002	JUL 27, 1982	JUL	CAHN
		@	40MG	N18415 002	JUL 27, 1982	AUG	DISC
	AB		80MG	N18415 003	NOV 26, 1984	JUL	CAHN
		@	80MG	N18415 003	NOV 26, 1984	AUG	DISC

GABAPENTIN
CAPSULE; ORAL
GABAPENTIN

AB	PUREPAC PHARM	100MG	N75350 001	SEP 12, 2003	SEP	NEWA
AB		300MG	N75350 002	SEP 12, 2003	SEP	NEWA
AB		400MG	N75350 003	SEP 12, 2003	SEP	NEWA

NEURONTIN

AB	PFIZER PHARMS	100MG	N20235 001	DEC 30, 1993	SEP	CFTG
AB		300MG	N20235 002	DEC 30, 1993	SEP	CFTG
AB +		400MG	N20235 003	DEC 30, 1993	SEP	CFTG

GADOTERIDOL
INJECTABLE; INJECTION
PROHANCE MULTIPACK

+	BRACCO	279.3MG/ML	N21489 001	OCT 09, 2003	OCT	NEWA

GALANTAMINE HYDROBROMIDE
TABLET; ORAL
REMINYL

+	JANSSEN PHARMA	EQ 4MG BASE	N21169 001	FEB 28, 2001	APR	CRLD
		EQ 12MG BASE	N21169 003	FEB 28, 2001	APR	CRLD

GANCICLOVIR
CAPSULE; ORAL
CYTOVENE

AB	ROCHE PALO	250MG	N20460 001	DEC 22, 1994	JUN	CFTG
AB +		500MG	N20460 002	DEC 12, 1997	JUN	CFTG

GANCICLOVIR

AB	RANBAXY	250MG	N76457 001	JUN 27, 2003	JUN	NEWA
AB		500MG	N76457 002	JUN 27, 2003	JUN	NEWA

GANCICLOVIR SODIUM
INJECTABLE; INJECTION
CYTOVENE IV

AP +	ROCHE PALO	EQ 500MG BASE/VIAL	N19661 001	JUN 23, 1989	JUL	CFTG

GANCICLOVIR SODIUM

AP	BEDFORD	EQ 500MG BASE/VIAL	N76222 001	JUL 16, 2003	JUL	NEWA

GATIFLOXACIN
INJECTABLE; INJECTION
TEQUIN

+	BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)	N21062 001	DEC 17, 1999	APR	CRLD
+		EQ 2MG /ML(400MG/200ML)	N21062 002	DEC 17, 1999	APR	CRLD
+		EQ 10MG /ML(200MG)	N21062 003	DEC 17, 1999	APR	CRLD

SOLUTION/DROPS; OPHTHALMIC
ZYMAR

+	ALLERGAN	0.3%	N21493 001	MAR 28, 2003	MAR	NEWA

GEFITINIB
TABLET; ORAL
IRESSA

+	ASTRAZENECA	250MG	N21399 001	MAY 05, 2003	MAY	NEWA

GEMFIBROZIL
TABLET; ORAL
GEMFIBROZIL
@ CLONMEL HLTHCARE 600MG N74270 001 SEP 27, 1993 AUG DISC

GEMIFLOXACIN MESYLATE
TABLET; ORAL
FACTIVE
+ GENESOFT PHARMS EQ 320MG BASE N21158 001 APR 04, 2003 MAY CAHN
+ LG LIFE EQ 320MG BASE N21158 001 APR 04, 2003 APR NEWA

GEMTUZUMAB OZOGAMICIN
INJECTABLE; INJECTION
MYLOTARG
+ WYETH PHARMS INC 5MG/VIAL N21174 001 MAY 17, 2000 MAR CAHN

GENTAMICIN SULFATE
CREAM; TOPICAL
GARAMYCIN
@ SCHERING EQ 0.1% BASE N60462 001 FEB DISC
GENTAMICIN SULFATE
AT + FOUGERA EQ 0.1% BASE N62531 001 JUL 05, 1984 FEB CRLD
INJECTABLE; INJECTION
AP + AM PHARM PARTNERS EQ 10MG BASE/ML N62356 001 MAR 04, 1982 JUN CRLD
@ BAXTER HLTHCARE EQ 10MG BASE/ML N62251 002 JUN DISC
@ EQ 40MG BASE/ML N62251 001 JUN DISC
OINTMENT; OPHTHALMIC
GARAMYCIN
@ SCHERING EQ 0.3% BASE N50425 001 APR DISC
GENTAMICIN SULFATE
+ AKORN EQ 0.3% BASE N64093 001 AUG 31, 1995 APR CRLD

GLIMEPIRIDE
TABLET; ORAL
AMARYL
+ AVENTIS PHARMS 1MG N20496 001 NOV 30, 1995 JAN CRLD
4MG N20496 003 NOV 30, 1995 JAN CRLD

GLIPIZIDE
TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE
AB WATSON LABS 5MG N76467 001 SEP 08, 2003 SEP NEWA
>A> AB 10MG N76467 002 NOV 07, 2003 NOV NEWA
GLUCOTROL XL
AB PFIZER 5MG N20329 001 APR 26, 1994 SEP CFTG

GLYBURIDE
TABLET; ORAL
GLYBURIDE (MICRONIZED)
@ AVENTIS PHARMS 1.5MG N20055 001 APR 17, 1992 OCT DISC
@ 3MG N20055 002 APR 17, 1992 OCT DISC
@ 6MG N20055 003 MAR 08, 2000 OCT DISC

AB	HIKMA	1.5MG	N75890 001	JUL 31, 2003	JUL	NEWA
AB		3MG	N75890 002	JUL 31, 2003	JUL	NEWA
AB		6MG	N75890 003	JUL 31, 2003	JUL	NEWA

GLYCOPYRROLATE
INJECTABLE; INJECTION
ROBINUL

AP	+ BAXTER HLTHCARE CORP	0.2MG/ML	N17558 001		AUG	CAHN

GONADORELIN HYDROCHLORIDE
INJECTABLE; INJECTION
FACTREL

	+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001	SEP 30, 1982	MAY	CAHN
	@	EQ 0.2MG BASE/VIAL	N18123 002	SEP 30, 1982	MAY	CAHN
	@	EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	MAY	CAHN

GONADOTROPIN, CHORIONIC
INJECTABLE; INJECTION
A.P.L.

	@ FERRING	5,000 UNITS/VIAL	N17055 001		JUL	CAHN
	@	10,000 UNITS/VIAL	N17055 002		JUL	CAHN
	@	20,000 UNITS/VIAL	N17055 003		JUL	CAHN
	@ WYETH AYERST	5,000 UNITS/VIAL	N17055 001		JUN	DISC
	@	10,000 UNITS/VIAL	N17055 002		JUN	DISC

CHORIONIC GONADOTROPIN

	@ STERIS	5,000 UNITS/VIAL	N17016 006		SEP	DISC

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	+ BAUSCH AND LOMB	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N64047 001	JAN 31, 1996	OCT	CRLD

GRANISETRON HYDROCHLORIDE
SOLUTION; ORAL
KYTRIL

	+ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUL	CMFD

GREPAFLOXACIN HYDROCHLORIDE
TABLET; ORAL
RAXAR

	@ OTSUKA	EQ 200MG BASE	N20695 001	NOV 06, 1997	MAY	DISC
	@	EQ 400MG BASE	N20695 002	MAY 14, 1998	MAY	DISC
	@	EQ 600MG BASE	N20695 003	MAY 14, 1998	MAY	DISC

GUANABENZ ACETATE
TABLET; ORAL
GUANABENZ ACETATE

AB	+ WATSON LABS	EQ 8MG BASE	N74025 002	FEB 28, 1994	JUN	CRLD

WYTENSIN

	@ WYETH AYERST	EQ 4MG BASE	N18587 001	SEP 07, 1982	JUN	DISC
	@	EQ 8MG BASE	N18587 002	SEP 07, 1982	JUN	DISC

HALOPERIDOL DECANOATE
INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

	@ KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000	MAY	DISC
	@	EQ 100MG BASE/ML	N75176 002	FEB 09, 2000	MAY	DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEP-LOCK

AP +	BAXTER HLTHCARE	10 UNITS/ML	N17037 007		JUN	CAHN
AP +		100 UNITS/ML	N17037 006		JUN	CAHN
	HEP-LOCK U/P					
AP	BAXTER HLTHCARE	10 UNITS/ML	N17037 010	JUN 10, 1983	JUN	CAHN
AP		100 UNITS/ML	N17037 011	JUN 10, 1983	JUN	CAHN
	HEPARIN LOCK FLUSH					
	@ BAXTER HLTHCARE CORP	10 UNITS/ML	N17007 008		MAY	CAHN
	@	100 UNITS/ML	N17007 009		MAY	CAHN
	HEPARIN SODIUM					
AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17037 001		JUN	CAHN
AP		5,000 UNITS/ML	N17037 002		JUN	CAHN
AP		5,000 UNITS/0.5ML	N17037 013	APR 07, 1986	JUN	CAHN
AP		10,000 UNITS/ML	N17037 003		JUN	CAHN
	@ BAXTER HLTHCARE CORP	1,000 UNITS/ML	N17007 001		MAY	CAHN
	@	2,500 UNITS/ML	N17007 007		MAY	CAHN
	@	5,000 UNITS/ML	N17007 002		MAY	CAHN
	@	5,000 UNITS/0.5ML	N17007 010		MAY	CAHN
	@	7,500 UNITS/ML	N17007 003		MAY	CAHN
	@	10,000 UNITS/ML	N17007 004		MAY	CAHN
	@	15,000 UNITS/ML	N17007 005		MAY	CAHN
	@	20,000 UNITS/ML	N17007 006		MAY	CAHN
	SODIUM HEPARIN					
	@ BAXTER HLTHCARE	1,000 UNITS/ML	N17036 001	MAR 04, 1988	OCT	DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
SYRUP; ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	AXIOM PHARM	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999	MAY	CAHN

HYALURONIDASE
INJECTABLE; INJECTION
WYDASE

@ BAXTER HLTHCARE	150 UNITS/ML	N06343 002		AUG	CAHN
@	150 UNITS/VIAL	N06343 006		AUG	CAHN
@	1,500 UNITS/VIAL	N06343 005		AUG	CAHN

HYDRALAZINE HYDROCHLORIDE
TABLET; ORAL
HYDRALAZINE HCL

	@ CLONMEL HLTHCARE	25MG				
	@	50MG	N86243 001		AUG	DISC
>D> AA	IMPAX LABS	50MG	N86242 002		AUG	DISC
>A>	@	50MG	N84923 001		NOV	DISC
			N84923 001		NOV	DISC

HYDROCHLOROTHIAZIDE
TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB	CLONMEL HLTHCARE	25MG	N87059 001			JUL	CAHN
AB		50MG	N87068 001			JUL	CAHN
	@	100MG	N87060 001			JUL	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA
TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

	@ CLONMEL HLTHCARE	15MG;250MG	N72507 001	JUN 02, 1989		JUL	DISC
	@	25MG;250MG	N72508 001	JUN 02, 1989		JUL	DISC
	@	30MG;500MG	N72509 001	JUN 02, 1989		JUL	DISC
	@	50MG;500MG	N72510 001	JUN 02, 1989		JUL	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
TABLET; ORAL
BENICAR HCT

	SANKYO	12.5MG;20MG	N21532 002	JUN 05, 2003		JUN	NEWA
		12.5MG;40MG	N21532 003	JUN 05, 2003		JUN	NEWA
	+	25MG;40MG	N21532 005	JUN 05, 2003		JUN	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE
TABLET; ORAL
INDERIDE-40/25

AB	WYETH PHARMS INC	25MG;40MG	N18031 001			MAR	CAHN

INDERIDE-80/25

AB	+ WYETH PHARMS INC	25MG;80MG	N18031 002			MAR	CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN
TABLET; ORAL
DIOVAN HCT

	NOVARTIS	25MG;160MG	N20818 003	JAN 17, 2002		JUL	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN
TABLET; ORAL
HYDROCODONE BITARTRATE AND IBUPROFEN

AB	TEVA	7.5MG;200MG	N76023 001	APR 11, 2003		APR	NEWA

VICOPROFEN

AB	+ ABBOTT	7.5MG;200MG	N20716 001	SEP 23, 1997		APR	CFTG

HYDROCORTISONE
LOTION; TOPICAL
HYDROCORTISONE

AT	VINTAGE PHARMS	2.5%	N40417 001	JUL 30, 2003		JUL	NEWA

HYDROCORTISONE CYPIONATE
SUSPENSION; ORAL
CORTEF

	@ PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N09900 001			AUG	DISC

HYDROCORTISONE SODIUM PHOSPHATE
INJECTABLE; INJECTION
HYDROCORTONE
@ MERCK EQ 50MG BASE/ML N12052 001 APR DISC

HYDROCORTISONE SODIUM SUCCINATE
INJECTABLE; INJECTION
HYDROCORTISONE SODIUM SUCCINATE
@ BAXTER HLTHCARE EQ 100MG BASE/VIAL N86619 001 AUG CAHN
@ EQ 250MG BASE/VIAL N87567 001 AUG CAHN
@ EQ 500MG BASE/VIAL N87568 001 AUG CAHN
@ EQ 1GM BASE/VIAL N87569 001 AUG CAHN

HYDROCORTISONE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-CORT-DOME
@ BAYER PHARMS 0.5%;EQ 3.5MG BASE/GM N50237 006 JUN 05, 1984 JUN DISC
@ 1%;EQ 3.5MG BASE/GM N50237 005 JUN 05, 1984 JUN DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
AT ALCON 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N62423 001 AUG 25, 1983 FEB CMFD
SUSPENSION/DROPS; OPHTHALMIC
AT ALCON UNIVERSAL 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N62874 001 MAY 11, 1988 FEB CMFD
SUSPENSION/DROPS; OTIC
AT ALCON UNIVERSAL 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N62488 001 NOV 06, 1985 FEB CMFD

HYDROCORTISONE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OTIC
OTOBIOTIC
@ SCHERING 5MG/ML;EQ 10,000 UNITS BASE/ML N62302 001 OCT WDAG

HYDROFLUMETHIAZIDE
TABLET; ORAL
DIUCARDIN
@ WYETH AYERST 50MG N83383 001 JUN DISC

HYDROFLUMETHIAZIDE; RESERPINE
TABLET; ORAL
SALUTENSIN
@ SHIRE LABS 50MG;0.125MG N12359 003 JUL DISC

HYDROMORPHONE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDROMORPHONE HCL
AP FAULDING 10MG/ML N76444 001 APR 25, 2003 APR NEWA

HYDROXYZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDROXYZINE
@ ELKINS SINN 50MG/ML N85551 002 JUN DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL					
@ ELKINS SINN	25MG/ML	N85551 001		JUN	DISC
TABLET; ORAL					
ATARAX					
@ PFIZER	10MG	N10392 001		FEB	DISC
@	25MG	N10392 004		FEB	DISC
@	50MG	N10392 006		FEB	DISC
@	100MG	N10392 005		FEB	DISC
HYDROXYZINE HCL					
AB + SIDMAK LABS NJ	10MG	N88617 001	JAN 10, 1986	FEB	CRLD
AB +	25MG	N88618 001	JAN 10, 1986	FEB	CRLD
AB +	50MG	N88619 001	JAN 10, 1986	FEB	CRLD
@	100MG	N81054 001	SEP 25, 1995	FEB	DISC

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL					
+ PFIZER	EQ 25MG HCL/5ML	N11795 001		OCT	CRLD

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA					
@ ROCHE	EQ 2.5MG BASE	N21455 001	MAY 16, 2003	JUL	DISC
+	EQ 2.5MG BASE	N21455 001	MAY 16, 2003	MAY	NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE					
+ AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	SEP	CTNA
+	3GM/VIAL	N76078 002	MAY 28, 2002	SEP	CTNA

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC					
@ NOVARTIS	50MG	N21335 001	MAY 10, 2001	JUN	DISC
TABLET; ORAL					
NOVARTIS	100MG	N21588 001	APR 18, 2003	APR	NEWA
+	400MG	N21588 002	APR 18, 2003	APR	NEWA

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE					
@ QUESTCOR PHARMS	100MG/ML	N02282 001		SEP	DISC

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL					
@ BAXTER HLTHCARE	41%	N74629 001	NOV 06, 1996	AUG	CAHN
@	51%	N74629 004	MAR 31, 1998	AUG	CAHN

		@	61%	N74629 002	NOV 06, 1996	AUG	CAHN
		@	76%	N74629 003	NOV 06, 1996	AUG	CAHN
		@ ELKINS SINN PHARM	41%	N74629 001	NOV 06, 1996	JUN	DISC
		@	51%	N74629 004	MAR 31, 1998	JUN	DISC
		@	61%	N74629 002	NOV 06, 1996	JUN	DISC
		@	76%	N74629 003	NOV 06, 1996	JUN	DISC
	IOVERSOL						
	INJECTABLE; INJECTION						
	OPTIRAY 240						
	@ MALLINCKRODT		51%	N20923 001	MAY 28, 1998	JUN	DISC
	OPTIRAY 300						
	+ MALLINCKRODT		64%	N20923 004	MAY 13, 1999	JUN	NEWA
	OPTIRAY 320						
	@ MALLINCKRODT		68%	N20923 002	MAY 29, 1998	JUN	DISC
	IPRATROPIUM BROMIDE						
	SPRAY, METERED; NASAL						
	ATROVENT						
AB	+ BOEHRINGER INGELHEIM		0.021MG/SPRAY	N20393 001	OCT 20, 1995	MAR	CFTG
AB	+		0.042MG/SPRAY	N20394 001	OCT 20, 1995	MAR	CFTG
	IPRATROPIUM BROMIDE						
AB	BAUSCH AND LOMB		0.021MG/SPRAY	N76025 001	MAR 31, 2003	MAR	NEWA
AB			0.042MG/SPRAY	N76103 001	MAR 31, 2003	MAR	NEWA
AB	DEY		0.021MG/SPRAY	N75552 001	MAR 31, 2003	MAR	NEWA
AB			0.042MG/SPRAY	N75553 001	MAR 31, 2003	MAR	NEWA
AB	NOVEX		0.021MG/SPRAY	N76156 001	APR 18, 2003	APR	NEWA
AB			0.042MG/SPRAY	N76155 001	APR 18, 2003	APR	NEWA
>A> AB	ROXANE		0.021MG/SPRAY	N76664 001	NOV 05, 2003	NOV	NEWA
>A> AB			0.042MG/SPRAY	N76598 001	NOV 05, 2003	NOV	NEWA
	ISONIAZID						
	TABLET; ORAL						
	ISONIAZID						
	@ AXIOM PHARM		100MG	N80136 001		MAY	CAHN
AA			300MG	N83633 001		MAY	CAHN
	ISOPROTERENOL HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	ISOPROTERENOL HCL						
	@ BAXTER HLTHCARE		0.2MG/ML	N83486 001		JUN	DISC
	ISOSORBIDE DINITRATE						
	CAPSULE, EXTENDED RELEASE; ORAL						
	DILATRATE-SR						
BC	+ SCHWARZ PHARMA		40MG	N19790 001	SEP 02, 1988	JUN	CRLD
	+		40MG	N19790 001	SEP 02, 1988	JUL	CTEC
	ISORDIL						
	@ WYETH AYERST		40MG	N12882 002	JUL 29, 1988	JUN	DISC
	TABLET; ORAL						
AB	BIOVAIL		5MG	N12093 007	JUL 29, 1988	JUN	CAHN
AB			10MG	N12093 002	JUL 29, 1988	JUN	CAHN
AB			20MG	N12093 006	JUL 29, 1988	JUN	CAHN

AB	+		30MG	N12093 005	JUL 29, 1988	JUN	CAHN
AB			40MG	N12093 001	JUL 29, 1988	JUN	CAHN
	+		40MG	N12093 001	JUL 29, 1988	OCT	CRLD
AB		WYETH PHARMS INC	5MG	N12093 007	JUL 29, 1988	MAR	CAHN
AB			10MG	N12093 002	JUL 29, 1988	MAR	CAHN
AB			20MG	N12093 006	JUL 29, 1988	MAR	CAHN
AB	+		30MG	N12093 005	JUL 29, 1988	MAR	CAHN
AB			40MG	N12093 001	JUL 29, 1988	MAR	CAHN
		SORBITRATE					
		@ ASTRAZENECA	20MG	N86405 002	AUG 21, 1990	OCT	WDAG
		@	40MG	N88125 001	AUG 21, 1990	OCT	WDAG
		TABLET; SUBLINGUAL					
		ISORDIL					
AB		BIOVAIL	2.5MG	N12940 004	JUL 29, 1988	JUN	CAHN
AB			5MG	N12940 003	JUL 29, 1988	JUN	CAHN
	+		10MG	N12940 005	JUL 29, 1988	JUN	CAHN
AB		WYETH PHARMS INC	2.5MG	N12940 004	JUL 29, 1988	MAR	CAHN
AB			5MG	N12940 003	JUL 29, 1988	MAR	CAHN
	+		10MG	N12940 005	JUL 29, 1988	MAR	CAHN
		TABLET, CHEWABLE; ORAL					
		SORBITRATE					
		@ ASTRAZENECA	10MG	N16776 003	APR 01, 1996	OCT	WDAG
		ISOSORBIDE MONONITRATE					
		TABLET, EXTENDED RELEASE; ORAL					
		IMDUR					
AB	+	SCHERING PLOUGH	30MG	N20225 001	AUG 12, 1993	OCT	CAHN
AB	+		60MG	N20225 002	AUG 12, 1993	OCT	CAHN
AB	+		120MG	N20225 003	MAR 30, 1995	OCT	CAHN
		ISOTRETINOIN					
		CAPSULE; ORAL					
		CLARAVIS					
AB		BARR	10MG	N76356 001	APR 11, 2003	APR	NEWA
AB			20MG	N76135 002	APR 11, 2003	APR	NEWA
AB			40MG	N76135 001	APR 11, 2003	APR	NEWA
		SOTRET					
		RANBAXY	30MG	N76503 001	JUN 20, 2003	JUN	NEWA
		ISRADIPINE					
		CAPSULE; ORAL					
		DYNACIRC					
		RELIANT PHARMS	2.5MG	N19546 001	DEC 20, 1990	MAY	CAHN
	+		5MG	N19546 002	DEC 20, 1990	MAY	CAHN
		TABLET, EXTENDED RELEASE; ORAL					
		DYNACIRC CR					
	+	RELIANT PHARMS	5MG	N20336 001	JUN 01, 1994	MAY	CAHN
	+		10MG	N20336 002	JUN 01, 1994	MAY	CAHN
		KANAMYCIN SULFATE					
		INJECTABLE; INJECTION					
		KANAMYCIN					
		@ BAXTER HLTHCARE	EQ 75MG BASE/2ML	N62324 001		AUG	CAHN

	@	EQ 500MG BASE/2ML	N62324 002			AUG	CAHN
	@	EQ 1GM BASE/3ML	N62324 003			AUG	CAHN
	KETOPROFEN						
	CAPSULE; ORAL						
	KETOPROFEN						
AB	CLONMEL HLTHCARE	75MG	N74014 003	JAN 29, 1993		JUN	CAHN
AB +	TEVA	75MG	N73517 001	DEC 22, 1992		JUN	CRLD
	ORUDIS						
	@ WYETH AYERST	25MG	N18754 001	JUL 31, 1987		JUN	DISC
	@	50MG	N18754 002	JAN 09, 1986		JUN	DISC
	@	75MG	N18754 003	JAN 09, 1986		JUN	DISC
	CAPSULE, EXTENDED RELEASE; ORAL						
	ORUVAIL						
AB	WYETH PHARMS INC	100MG	N19816 003	FEB 08, 1995		MAR	CAHN
AB		150MG	N19816 002	FEB 08, 1995		MAR	CAHN
AB +		200MG	N19816 001	SEP 24, 1993		MAR	CAHN
	KETOROLAC TROMETHAMINE						
	INJECTABLE; INJECTION						
	KETOROLAC TROMETHAMINE						
	@ ABBOTT	15MG/ML	N74801 001	JUN 05, 1997		OCT	DISC
	@	30MG/ML	N74801 002	JUN 05, 1997		OCT	DISC
AP +	BEDFORD	30MG/ML	N75228 001	APR 26, 1999		OCT	CRLD
	SOLUTION/DROPS; OPHTHALMIC						
	ACULAR LS						
+	ALLERGAN	0.4%	N21528 001	MAY 30, 2003		MAY	NEWA
	LABETALOL HYDROCHLORIDE						
	TABLET; ORAL						
	LABETALOL HCL						
	@ APOTHECON	100MG	N75223 001	NOV 20, 1998		OCT	WDAG
	@	200MG	N75223 002	NOV 20, 1998		OCT	WDAG
	@	300MG	N75223 003	NOV 20, 1998		OCT	WDAG
	LACTULOSE						
	SOLUTION; ORAL						
	CHRONULAC						
	@ AVENTIS PHARMS	10GM/15ML	N17884 001			AUG	DISC
	CONSTULOSE						
AA +	ALPHARMA	10GM/15ML	N70288 001	AUG 15, 1988		AUG	CRLD
	LACTULOSE						
AA	VISTAPHARM	10GM/15ML	N74138 001	SEP 30, 1992		MAR	CAHN
	SOLUTION; ORAL, RECTAL						
AA	NOVEX	10GM/15ML	N76645 001	JUL 28, 2003		JUL	NEWA
	LAMIVUDINE						
	TABLET; ORAL						
	EPIVIR						
	GLAXOSMITHKLINE	300MG	N20564 003	JUN 24, 2002		SEP	NEWA

LEFLUNOMIDE
TABLET; ORAL
ARAVA
+ AVENTIS PHARMS 20MG N20905 002 SEP 10, 1998 MAR CRLD
@ 100MG N20905 003 SEP 10, 1998 MAR DISC

LEUCOVORIN CALCIUM
FOR SOLUTION; ORAL
LEUCOVORIN CALCIUM
@ FAULDING EQ 60MG BASE/VIAL N08107 003 JAN 30, 1987 OCT CAHN
INJECTABLE; INJECTION
@ ELKINS SINN EQ 50MG BASE/VIAL N70480 001 JAN 02, 1987 JUN DISC
@ EQ 100MG BASE/VIAL N81224 001 JUN 03, 1994 JUN DISC
@ FAULDING EQ 3MG BASE/ML N08107 001 OCT CAHN
AP + EQ 50MG BASE/VIAL N08107 002 OCT CAHN
AP + EQ 100MG BASE/VIAL N08107 004 MAY 23, 1988 OCT CAHN
AP + EQ 350MG BASE/VIAL N08107 005 APR 05, 1989 OCT CAHN

LEUPROLIDE ACETATE
INJECTABLE; SUBCUTANEOUS
ELIGARD
+ ATRIX 30MG/VIAL N21488 001 FEB 13, 2003 FEB NEWA

LEVALBUTEROL HYDROCHLORIDE
SOLUTION; INHALATION
XOPENEX
+ SEPRACOR EQ 0.0103% BASE N20837 003 JAN 30, 2002 JUL CPOT
+ EQ 0.25% BASE N20837 004 JUL 18, 2003 JUL NEWA

>D> LEVAMISOLE HYDROCHLORIDE
>D> TABLET; ORAL
>D> ERGAMISOL
>D> + JANSSEN PHARMA EQ 50MG BASE N20035 001 JUN 18, 1990 NOV DISC
>A> @ EQ 50MG BASE N20035 001 JUN 18, 1990 NOV DISC

LEVETIRACETAM
SOLUTION; ORAL
KEPPRA
+ UCB 100MG/ML N21505 001 JUL 15, 2003 JUL NEWA

LEVOBETAXOLOL HYDROCHLORIDE
SUSPENSION/DROPS; OPHTHALMIC
BETAXON
@ ALCON EQ 0.5% BASE N21114 001 FEB 23, 2000 JUL CAHN
+ MEDPOINTE EQ 0.5% BASE N21114 001 FEB 23, 2000 MAR CAHN

LEVOFLOXACIN
INJECTABLE; INJECTION
LEVAQUIN
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ ORTHO MCNEIL PHARM 500MG /20ML(25MG/ML) N20635 001 DEC 20, 1996 OCT CPOT
+ 750MG /30ML(25MG/ML) N20635 004 DEC 20, 1996 OCT NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	ORTHO MCNEIL PHARM	250MG /50ML(5MG/ML)	N20635 002	DEC 20, 1996	OCT	CPOT
+		500MG 100ML/(5MG/ML)	N20635 003	DEC 20, 1996	OCT	CPOT
+		750MG /150ML(5MG/ML)	N20635 005	DEC 20, 1996	OCT	NEWA

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

BX +	WYETH PHARMS INC	75MG/IMPLANT	N20627 001	AUG 15, 1996	MAR	CAHN
@		75MG/IMPLANT	N20627 001	AUG 15, 1996	JUN	DISC

NORPLANT II

BX +	POPULATION COUNCIL	75MG/IMPLANT	N20544 001	NOV 01, 1996	JUN	CRLD

NORPLANT SYSTEM IN PLASTIC CONTAINER

+	WYETH PHARMS INC	36MG/IMPLANT	N20088 001	DEC 10, 1990	MAR	CAHN
@		36MG/IMPLANT	N20088 001	DEC 10, 1990	JUN	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@	ICN	2MG	N08720 001	DEC 19, 1991	FEB	DISC

LEVORPHANOL TARTRATE

+	ROXANE	2MG	N74278 001	MAR 31, 2000	FEB	CRLD

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

BX	ALARA PHARM	0.025MG	N21342 001	MAR 01, 2002	APR	CAHN
BX		0.05MG	N21342 002	MAR 01, 2002	APR	CAHN
BX		0.075MG	N21342 003	MAR 01, 2002	APR	CAHN
BX		0.088MG	N21342 004	MAR 01, 2002	APR	CAHN
BX		0.1MG	N21342 005	MAR 01, 2002	APR	CAHN
BX		0.112MG	N21342 006	MAR 01, 2002	APR	CAHN
BX		0.125MG	N21342 007	MAR 01, 2002	APR	CAHN
BX		0.15MG	N21342 008	MAR 01, 2002	APR	CAHN
BX		0.175MG	N21342 009	MAR 01, 2002	APR	CAHN
BX		0.2MG	N21342 010	MAR 01, 2002	APR	CAHN
BX +		0.3MG	N21342 011	MAR 01, 2002	APR	CAHN

LEVOLET

BX	VINTAGE PHARMS	0.025MG	N21137 001	JUN 06, 2003	JUN	NEWA
BX		0.05MG	N21137 002	JUN 06, 2003	JUN	NEWA
BX		0.075MG	N21137 003	JUN 06, 2003	JUN	NEWA
BX		0.088MG	N21137 004	JUN 06, 2003	JUN	NEWA
BX		0.1MG	N21137 005	JUN 06, 2003	JUN	NEWA
BX		0.112MG	N21137 006	JUN 06, 2003	JUN	NEWA
BX		0.125MG	N21137 007	JUN 06, 2003	JUN	NEWA
BX		0.137MG	N21137 008	JUN 06, 2003	JUN	NEWA
BX		0.15MG	N21137 009	JUN 06, 2003	JUN	NEWA
BX		0.175MG	N21137 010	JUN 06, 2003	JUN	NEWA
BX		0.2MG	N21137 011	JUN 06, 2003	JUN	NEWA

BX		0.3MG	N21137 012	JUN 06, 2003	JUN	NEWA

LIDOCAINE

SOLUTION; TOPICAL

	XYLOCAINE				
@	ASTRAZENECA	5%	N14127 001		AUG DISC

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL				
@	ELKINS SINN	1%	N80407 001		JUN DISC
@		2%	N80407 002		JUN DISC
@	WYETH AYERST	1%	N83083 001		JUN DISC
@		2%	N83083 002		JUN DISC
	LIDOCAINE HCL PRESERVATIVE FREE				
@	ELKINS SINN	1%	N84625 001		JUN DISC
@		2%	N84625 002		JUN DISC

JELLY; TOPICAL

	LIDOCAINE HCL					
AT	AKORN	2%	N40433 001	FEB 12, 2003	FEB	NEWA

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

	EMLA					
AB +	ASTRAZENECA	2.5%;2.5%	N19941 001	DEC 30, 1992	AUG	CFTG
	LIDOCAINE AND PRILOCAINE					
AB	ALTANA	2.5%;2.5%	N76453 001	AUG 18, 2003	AUG	NEWA
AB	ATRIX	2.5%;2.5%	N76320 001	AUG 27, 2003	AUG	NEWA
AB	HI TECH PHARMA	2.5%;2.5%	N76290 001	SEP 25, 2003	SEP	NEWA

LISINOPRIL

TABLET; ORAL

	LISINOPRIL					
AB	RANBAXY	30MG	N75944 006	FEB 11, 2003	FEB	NEWA
AB	WEST WARD	30MG	N76063 006	JUN 27, 2003	JUN	NEWA
	ZESTRIL					
AB	ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	APR	CRLD

LITHIUM CARBONATE

CAPSULE; ORAL

	LITHIUM CARBONATE					
AB	ROXANE	150MG	N17812 002	JAN 28, 1987	FEB	CTEC
AB	WEST WARD	150MG	N76243 002	FEB 24, 2003	FEB	NEWA

TABLET, EXTENDED RELEASE; ORAL

	ESKALITH CR					
AB +	GLAXOSMITHKLINE	450MG	N18152 001	MAR 29, 1982	JUN	CFTG
	LITHIUM CARBONATE					
AB	ABLE	300MG	N76382 001	APR 21, 2003	APR	NEWA
AB	BARR	450MG	N76366 001	AUG 21, 2003	AUG	NEWA
AB	WEST WARD	450MG	N76490 001	JUN 17, 2003	JUN	NEWA

	LORAZEPAM						
	CONCENTRATE; ORAL						
	LORAZEPAM INTENSOL						
	+ ROXANE	2MG/ML	N72755 001	JUN 28, 1991	MAY	CRLD
	INJECTABLE; INJECTION						
	ATIVAN						
AP	+ BAXTER HLTHCARE CORP	2MG/ML	N18140 001		FEB	CAHN
AP	+	4MG/ML	N18140 002		FEB	CAHN
	TABLET; ORAL						
AB	BIOVAIL	0.5MG	N17794 001		JUN	CAHN
AB		1MG	N17794 002		JUN	CAHN
AB	+	2MG	N17794 003		JUN	CAHN
	MECAMYLAMINE HYDROCHLORIDE						
	TABLET; ORAL						
	INVERSINE						
	+ TARGACEPT	2.5MG	N10251 001		APR	CAHN
	MECLOFENAMATE SODIUM						
	CAPSULE; ORAL						
	MECLOFENAMATE SODIUM						
AB	+ MYLAN	EQ 100MG BASE	N71081 001	SEP 03, 1986	MAY	CRLD
	MECLOMEN						
	@ PARKE DAVIS	EQ 50MG BASE	N18006 001		MAY	DISC
	@	EQ 100MG BASE	N18006 002		MAY	DISC
	MEFLOQUINE HYDROCHLORIDE						
	TABLET; ORAL						
	MEFLOQUINE HCL						
AB	GENEVA PHARMS	250MG	N76175 001	FEB 20, 2002	APR	CAHN
	MEGESTROL ACETATE						
	SUSPENSION; ORAL						
	MEGESTROL ACETATE						
AB	COPLEY PHARM	40MG/ML	N75681 001	MAY 05, 2003	MAY	NEWA
	MEMANTINE HYDROCHLORIDE						
	TABLET; ORAL						
	NAMENDA						
	FOREST LABS	5MG	N21487 001	OCT 16, 2003	OCT	NEWA
	+	10MG	N21487 002	OCT 16, 2003	OCT	NEWA
	@	15MG	N21487 003	OCT 16, 2003	OCT	DISC
	@	20MG	N21487 004	OCT 16, 2003	OCT	DISC
	MENOTROPINS (FSH;LH)						
	INJECTABLE; INJECTION						
	REPRONEX						
BX	+ FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	AUG 27, 1999	MAY	CRLD
	@	150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999	MAY	DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

	@ BAXTER HLTHCARE	25MG/ML	N88279 001	JUN 15, 1984	AUG	CAHN
	@	50MG/ML	N88280 001	JUN 15, 1984	AUG	CAHN
	@	75MG/ML	N88281 001	JUN 15, 1984	AUG	CAHN
	@	100MG/ML	N88282 001	JUN 15, 1984	AUG	CAHN
AP	BAXTER HLTHCARE CORP	25MG/ML	N80455 007		MAY	CAHN
AP		50MG/ML	N80455 008		MAY	CAHN
AP		75MG/ML	N80455 009		MAY	CAHN
AP		100MG/ML	N80455 010		MAY	CAHN

TABLET; ORAL

AA	AXIOM PHARM	50MG	N80448 001	MAY	CAHN
AA		100MG	N80448 002	MAY	CAHN
	@ WYETH AYERST	50MG	N80454 001	JUN	DISC

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

	@ BAXTER HLTHCARE CORP	25MG/ML;25MG/ML	N11730 001	MAY	CAHN

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

	@ BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N08248 002	FEB	CAHN
	@	EQ 30MG BASE/ML	N08248 001	FEB	CAHN

MEPROBAMATE

TABLET; ORAL

EQUANIL

	@ WYETH AYERST	200MG	N10028 005	JUN	DISC
	@	400MG	N10028 004	JUN	DISC

MEPROBAMATE

>D>	AA	MYLAN	400MG	N83618 001	NOV	DISC
>A>		@	400MG	N83618 001	NOV	DISC
		+ ROXANE	600MG	N84332 001	JUN	CRLD
>D>	AA	WEST WARD	200MG	N15417 003	NOV	DISC
>A>		@	200MG	N15417 003	NOV	DISC
>D>	AA		400MG	N15417 002	NOV	DISC
>A>		@	400MG	N15417 002	NOV	DISC

MILTOWN

AA	+ MEDPOINTE	600MG	N83919 001	APR	CAHN
	@ MEDPOINTE PHARM HLC	600MG	N83919 001	JUN	DISC

MERCAPTOPURINE

TABLET; ORAL

PURINETHOL

	+ TEVA	50MG	N09053 002	AUG	CAHN

MESORIDAZINE BESYLATE

TABLET; ORAL

SERENTIL

AUG CAHN		@ NOVARTIS	EQ 10MG BASE	N16774 001		JUN DISC
AUG CAHN		@	EQ 50MG BASE	N16774 003		JUN DISC
AUG CAHN						
AUG CAHN						

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+50 21-DAY

MAY CAHN	AB +	WATSON LABS	0.05MG;1MG	N13625 002		AUG CRLD
MAY CAHN						

ORTHO-NOVUM 1/50 21

		@ ORTHO MCNEIL PHARM	0.05MG;1MG	N12728 004		AUG DISC
MAY CAHN						
MAY CAHN						

METAXALONE

TABLET; ORAL

SKELAXIN

JUN DISC		JONES PHARMA INC	400MG	N13217 001		JUN CAHN
	+		800MG	N13217 003	AUG 30, 2002	JUN CAHN

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

MAY CAHN	+	RANBAXY	500MG/5ML	N21591 001	SEP 11, 2003	SEP NEWA

TABLET; ORAL

METFORMIN HCL

FEB CAHN	AB	PUREPAC PHARM	1GM	N76033 003	JAN 24, 2002	FEB CMS1
FEB CAHN						

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

		BRISTOL MYERS SQUIBB	500MG	N21202 001	OCT 13, 2000	AUG CRLD
JUN DISC	+		750MG	N21202 004	APR 11, 2003	APR NEWA
JUN DISC						

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

NOV DISC		SB PHARMCO	500MG;EQ 1MG BASE	N21410 001	OCT 10, 2002	APR CAHN
NOV DISC			500MG;EQ 2MG BASE	N21410 002	OCT 10, 2002	APR CAHN
JUN CRLD	+		500MG;EQ 4MG BASE	N21410 003	OCT 10, 2002	APR CAHN
NOV DISC			500MG;EQ 4MG BASE	N21410 003	OCT 10, 2002	AUG CRLD
NOV DISC			1GM;EQ 2MG BASE	N21410 004	AUG 25, 2003	AUG NEWA
NOV DISC	+		1GM;EQ 4MG BASE	N21410 005	AUG 25, 2003	AUG NEWA
NOV DISC						

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

APR CAHN	+	METHAPHARM	100MG/VIAL	N19193 001	OCT 31, 1986	OCT CRLD
JUN DISC						

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

DOLOPHINE HCL

AUG CAHN	+	AAIPHARMA	10MG/ML	N21624 001		APR CAHN
	+	ROXANE	10MG/ML	N21624 001		FEB CMS1

		METHAZOLAMIDE					
		TABLET; ORAL					
		METHAZOLAMIDE					
AB	+	MIKART	50MG	N40062 002	JAN 27, 1994	JUN	CRLD
		NEPTAZANE					
		@ LEDERLE	25MG	N11721 002	NOV 25, 1991	JUN	DISC
		@	50MG	N11721 001		JUN	DISC
		METHENAMINE HIPPURATE					
		TABLET; ORAL					
		METHENAMINE HIPPURATE					
AB		COREPHARMA	1GM	N76411 001	JUN 20, 2003	JUN	NEWA
		METHIMAZOLE					
		TABLET; ORAL					
		TAPAZOLE					
AB		LILLY	10MG	N07517 004		JUN	CRLD
		METHOCARBAMOL					
		INJECTABLE; INJECTION					
		ROBAXIN					
AP	+	BAXTER HLTHCARE CORP	100MG/ML	N11790 001		AUG	CAHN
		TABLET; ORAL					
		METHOCARBAMOL					
AA		ABLE	500MG	N40413 001	MAR 17, 2003	MAR	NEWA
AA			750MG	N40413 002	MAR 17, 2003	MAR	NEWA
		@ CLONMEL HLTHCARE	500MG	N85961 001		JUN	DISC
		@	750MG	N85963 001		JUN	DISC
AA		LANNETT	500MG	N84756 002	MAR 31, 2003	MAR	NEWA
>D> AA		NYLOS	750MG	N85033 001		NOV	DISC
>A>		@	750MG	N85033 001		NOV	DISC
AA		VINTAGE PHARMS	500MG	N40489 001	JAN 29, 2003	JAN	NEWA
AA			750MG	N40489 002	JAN 29, 2003	JAN	NEWA
		METHOTREXATE SODIUM					
		INJECTABLE; INJECTION					
		METHOTREXATE LPF					
AP	+	FAULDING	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982	OCT	CAHN
AP	+	WYETH PHARMS INC	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982	MAR	CAHN
		METHOTREXATE SODIUM					
		@ FAULDING	EQ 2.5MG BASE/ML	N11719 004		OCT	CAHN
		+	EQ 20MG BASE/VIAL	N11719 001		OCT	CAHN
AP	+		EQ 25MG BASE/ML	N11719 005		OCT	CAHN
		@	EQ 50MG BASE/VIAL	N11719 003		OCT	CAHN
		@	EQ 100MG BASE/VIAL	N11719 006		OCT	CAHN
		@ WYETH PHARMS INC	EQ 2.5MG BASE/ML	N11719 004		MAR	CAHN
		+	EQ 20MG BASE/VIAL	N11719 001		MAR	CAHN
AP	+		EQ 25MG BASE/ML	N11719 005		MAR	CAHN
		@	EQ 50MG BASE/VIAL	N11719 003		MAR	CAHN
		@	EQ 100MG BASE/VIAL	N11719 006		MAR	CAHN
		METHOTREXATE SODIUM PRESERVATIVE FREE					
AP	+	FAULDING	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	OCT	CAHN

AP +	WYETH PHARMS INC	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	MAR	CAHN

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
PAMINE FORTE

+	BRADLEY PHARMS	5MG	N08848 002	MAR 25, 2003	MAR	NEWA

METHYCLOTHIAZIDE
TABLET; ORAL
AQUATENSEN

@	MEDPOINTE PHARM HLC	5MG	N17364 001		JUN	DISC

METHYLDOPA
TABLET; ORAL
ALDOMET

@	MERCK	125MG	N13400 003		MAY	DISC
@		250MG	N13400 001		MAY	DISC

METHYLDOPA

@	CLONMEL HLTHCARE	125MG	N70070 003	OCT 15, 1985	JUN	DISC

METHYLDOPATE HYDROCHLORIDE
INJECTABLE; INJECTION
METHYLDOPATE HCL

@	BAXTER HLTHCARE	50MG/ML	N70291 001	JUL 01, 1986	AUG	CAHN
@	ELKINS SINN	50MG/ML	N70291 001	JUL 01, 1986	JUN	DISC

METHYLPHENIDATE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

	CELLTECH PHARMS	10MG	N21259 003	MAY 27, 2003	JUL	NEWA
BX		20MG	N21259 001	APR 03, 2001	JUL	CRLD
BX +		30MG	N21259 002	JUN 19, 2003	JUL	CTEC
+		30MG	N21259 002	JUN 19, 2003	JUN	NEWA

RITALIN LA

BX	NOVARTIS	30MG	N21284 002	JUN 05, 2002	JUL	CTEC

TABLET, CHEWABLE; ORAL
METHYLIN

	MALLINCKRODT	2.5MG	N21475 001	APR 15, 2003	APR	NEWA
		5MG	N21475 002	APR 15, 2003	APR	NEWA
+		10MG	N21475 003	APR 15, 2003	APR	NEWA

TABLET, EXTENDED RELEASE; ORAL
CONCERTA

+	MCNEIL CONS SPECLT	18MG	N21121 001	AUG 01, 2000	MAY	CAHN
		18MG	N21121 001	AUG 01, 2000	OCT	CRLD
+		27MG	N21121 004	APR 01, 2002	MAY	CAHN
		27MG	N21121 004	APR 01, 2002	OCT	CRLD
+		36MG	N21121 002	AUG 01, 2000	MAY	CAHN
		36MG	N21121 002	AUG 01, 2000	OCT	CRLD
+		54MG	N21121 003	DEC 08, 2000	MAY	CAHN

		METHYLPREDNISOLONE						
		TABLET; ORAL						
		MEDROL						
		@ PHARMACIA AND UPJOHN	2MG	N11153 002		JUL	DISC
		METHYLPREDNISOLONE ACETATE						
		INJECTABLE; INJECTION						
		DEPO-MEDROL						
>D>	BP	PHARMACIA AND UPJOHN	20MG/ML	N11757 002		NOV	CRLD
>A>	+		20MG/ML	N11757 002		NOV	CRLD
>D>			40MG/ML	N11757 001		NOV	CRLD
>A>	+		40MG/ML	N11757 001		NOV	CRLD
		OINTMENT; TOPICAL						
		MEDROL ACETATE						
		@ PHARMACIA AND UPJOHN	0.25%	N12421 001		JUN	DISC
		METHYSERGIDE MALEATE						
		TABLET; ORAL						
		SANSERT						
		@ NOVARTIS	2MG	N12516 001		JUN	DISC
		METOCLOPRAMIDE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		REGLAN						
	AP +	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	N17862 001		AUG	CAHN
		@	EQ 10MG BASE/ML	N17862 004	MAY 28, 1987	AUG	CAHN
		SOLUTION; ORAL						
		METOCLOPRAMIDE						
	AA	VISTAPHARM	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	APR	CAHN
		TABLET; ORAL						
		METOCLOPRAMIDE HCL						
		@ CLONMEL HLTHCARE	EQ 10MG BASE	N72639 001	MAY 09, 1991	JUN	DISC
		METOLAZONE						
		TABLET; ORAL						
		ZAROXOLYN						
		CELLTECH PHARMS	2.5MG	N17386 001		JUL	CRLD
	+		5MG	N17386 002		JUL	CRLD
		METOPROLOL TARTRATE						
		INJECTABLE; INJECTION						
		METOPROLOL TARTRATE						
	AP	BEDFORD LABS	1MG/ML	N76495 001	JUL 07, 2003	JUL	NEWA
		METRONIDAZOLE						
		CAPSULE; ORAL						
		FLAGYL						
>D>	+	GD SEARLE LLC	375MG	N20334 001	MAY 03, 1995	NOV	CFTG
>A>	AB +		375MG	N20334 001	MAY 03, 1995	NOV	CFTG
>A>		METRONIDAZOLE						
>A>	AB	ABLE	375MG	N76505 001	NOV 13, 2003	NOV	NEWA

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

JUL DISC	AB	ABLE	250MG	N76519 001	JUN 27, 2003	JUN	NEWA
	AB		500MG	N76519 002	JUN 27, 2003	JUN	NEWA

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

NOV CRLD	AB +	GD SEARLE LLC	750MG	N20868 001	NOV 26, 1997	JUN	CFTG

METRONIDAZOLE

NOV CRLD	AB	ABLE	750MG	N76462 001	JUN 25, 2003	JUN	NEWA

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

JUN DISC	@	BAYER PHARMS	EQ 1GM BASE/VIAL	N50549 001		JUN	DISC
	@		EQ 2GM BASE/VIAL	N50549 002		JUN	DISC
	@		EQ 3GM BASE/VIAL	N50549 003		JUN	DISC
	@		EQ 4GM BASE/VIAL	N50549 004		JUN	DISC
JUN DISC	@		EQ 20GM BASE/VIAL	N50549 005	MAR 02, 1988	JUN	DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

AUG CAHN	AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	N75243 001	JUN 20, 2000	JUN	CAHN
AUG CAHN	AP		EQ 5MG BASE/ML	N75243 002	JUN 20, 2000	JUN	CAHN

SYRUP; ORAL

APR CAHN	AA	HI TECH PHARMA	EQ 2MG BASE/ML	N75958 001	SEP 04, 2003	SEP	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HCL

JUN DISC	AB	EON	2.5MG	N76514 001	SEP 11, 2003	SEP	NEWA
	AB		5MG	N76514 002	SEP 11, 2003	SEP	NEWA
	AB	MYLAN	2.5MG	N76577 001	SEP 10, 2003	SEP	NEWA
	AB		5MG	N76577 002	SEP 10, 2003	SEP	NEWA
JUL CRLD	AB		10MG	N76577 003	SEP 10, 2003	SEP	NEWA
JUL CRLD							

PROAMATINE

	AB	SHIRE PHARM	2.5MG	N19815 001	SEP 06, 1996	SEP	CFTG
	AB +		5MG	N19815 002	SEP 06, 1996	SEP	CFTG
	AB		10MG	N19815 003	MAR 20, 2002	SEP	CFTG

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

JUL NEWA	+	ACTELION PHARMS	100MG	N21348 001	JUL 31, 2003	JUL	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

NOV CFTG	AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	JUN	CAHN
NOV CFTG	AP	BIONICHE (CANADA)	EQ 1MG BASE/ML	N76428 001	JUN 16, 2003	JUN	NEWA

NOV NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	AUG	CAHN

MILRINONE LACTOSE IN 5% DEXTROSE

AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	CAHN

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

AP +	SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	WYETH PHARMS INC	EQ 50MG BASE	N50649 001	MAY 31, 1990	MAR	CAHN
AB		EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	CAHN
AB +		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CAHN

MINOCYCLINE HCL

AB	TEVA	EQ 75MG BASE	N63009 002	AUG 12, 2003	AUG	NEWA

VECTRIN

AB	MEDICIS	EQ 75MG BASE	N63067 002	SEP 15, 1999	OCT	CMFD
AB		EQ 100MG BASE	N63067 001	JUL 31, 1990	OCT	CMFD

INJECTABLE; INJECTION

MINOCIN

+	WYETH PHARMS INC	EQ 100MG BASE/VIAL	N50444 001		MAR	CAHN

TABLET; ORAL

MINOCYCLINE HCL

	MEDICIS	EQ 50MG BASE	N65131 001	APR 16, 2003	AUG	CAHN
		EQ 75MG BASE	N65131 002	APR 16, 2003	AUG	CAHN
		EQ 100MG BASE	N65131 003	APR 16, 2003	AUG	CAHN
+						
	PAR PHARM	EQ 50MG BASE	N65131 001	APR 16, 2003	APR	NEWA
		EQ 75MG BASE	N65131 002	APR 16, 2003	APR	NEWA
+		EQ 100MG BASE	N65131 003	APR 16, 2003	APR	NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB	ALPHAPHARM	15MG	N76176 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76176 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76176 003	JUN 19, 2003	JUN	NEWA
AB	AMIDE PHARM	15MG	N76241 001	JUN 25, 2003	JUN	NEWA
AB		30MG	N76241 002	JUN 25, 2003	JUN	NEWA
AB		45MG	N76241 003	JUN 25, 2003	JUN	NEWA
AB	ANDRX PHARMS	15MG	N76336 001	JUN 20, 2003	JUN	NEWA
AB		30MG	N76336 002	JUN 20, 2003	JUN	NEWA
AB		45MG	N76336 003	JUN 20, 2003	JUN	NEWA
AB	EON	15MG	N76219 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76219 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76219 003	JUN 19, 2003	JUN	NEWA
AB	GENEVA PHARMS	15MG	N76189 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76189 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76189 003	JUN 19, 2003	JUN	NEWA
AB	MYLAN	15MG	N76122 001	JUN 19, 2003	JUN	NEWA

AB			30MG	N76122 002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76122 003	JUN 19, 2003	JUN	NEWA
AB		PUREPAC PHARM	15MG	N76308 001	JUN 20, 2003	JUN	NEWA
AB			30MG	N76308 002	JUN 20, 2003	JUN	NEWA
AB			45MG	N76308 003	JUN 20, 2003	JUN	NEWA
AB		ROXANE	15MG	N76270 001	JUN 19, 2003	JUN	NEWA
AB			30MG	N76270 002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76270 003	JUN 19, 2003	JUN	NEWA
AB		TEVA	15MG	N76119 001	JAN 24, 2003	JAN	NEWA
AB			30MG	N76119 002	JAN 24, 2003	JAN	NEWA
AB			45MG	N76119 003	JUN 19, 2003	JUN	NEWA
AB		WATSON LABS	15MG	N76312 001	JUN 19, 2003	JUN	NEWA
AB			30MG	N76312 002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76312 003	JUN 19, 2003	JUN	NEWA
		REMERON					
AB	+	ORGANON	15MG	N20415 001	JUN 14, 1996	JAN	CFTG
AB			30MG	N20415 002	JUN 14, 1996	JAN	CFTG
		MITOMYCIN					
		INJECTABLE; INJECTION					
		MITOMYCIN					
AP		BAXTER HLTHCARE	5MG/VIAL	N64180 001	DEC 23, 1999	AUG	CAHN
AP			20MG/VIAL	N64180 002	DEC 23, 1999	AUG	CAHN
		MOEXIPRIL HYDROCHLORIDE					
		TABLET; ORAL					
		MOEXIPRIL HCL					
AB		TEVA	7.5MG	N76204 001	MAY 08, 2003	MAY	NEWA
AB			15MG	N76204 002	MAY 08, 2003	MAY	NEWA
		UNIVASC					
AB		SCHWARZ PHARMA	7.5MG	N20312 001	APR 19, 1995	MAY	CFTG
AB	+		15MG	N20312 002	APR 19, 1995	MAY	CFTG
		MOMETASONE FUROATE					
		OINTMENT; TOPICAL					
		MOMETASONE FUROATE					
>A> AB		ATRIX	0.1%	N76481 001	NOV 14, 2003	NOV	NEWA
		MORPHINE SULFATE					
		CAPSULE, EXTENDED RELEASE; ORAL					
		AVINZA					
BX	+	LIGAND	30MG	N21260 001	MAR 20, 2002	JUN	CAHN
BX	+		60MG	N21260 002	MAR 20, 2002	JUN	CAHN
	+		90MG	N21260 003	MAR 20, 2002	JUN	CAHN
	+		120MG	N21260 004	MAR 20, 2002	JUN	CAHN
		INJECTABLE; INJECTION					
		DURAMORPH PF					
AP	+	BAXTER HLTHCARE	1MG/ML	N18565 002	SEP 18, 1984	AUG	CAHN
		INFUMORPH					
	+	BAXTER HLTHCARE	10MG/ML	N18565 003	JUL 19, 1991	AUG	CAHN
	+		25MG/ML	N18565 004	JUL 19, 1991	AUG	CAHN

MORPHINE SULFATE
TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

@ CLONMEL HLTHCARE	15MG	N75407 001	JAN 28, 2000	JUL	DISC
AB	MALLINCKRODT	15MG	N76412 001	JUL 31, 2003	JUL	NEWA
AB		30MG	N76412 002	JUL 31, 2003	JUL	NEWA
AB		60MG	N76412 003	JUL 31, 2003	JUL	NEWA
AB		100MG	N76438 001	JUL 03, 2003	JUL	NEWA
AB		200MG	N76438 002	JUL 03, 2003	JUL	NEWA

MOXIFLOXACIN HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
VIGAMOX

+ ALCON	0.5%	N21598 001	APR 15, 2003	APR	NEWA

MUPIROCIN
OINTMENT; TOPICAL
BACTROBAN

>D>	BX +	GLAXOSMITHKLINE	2%	N50591 001	DEC 31, 1987	NOV	CTEC
>A>	AB +		2%	N50591 001	DEC 31, 1987	NOV	CTEC

MUPIROCIN

>A>	AB	CLAY PARK	2%	N65123 001	NOV 07, 2003	NOV	NEWA
	BX	CLAY PARK LABS	2%	N50788 001	DEC 04, 2002	JAN	CTEC
	BX	JOHNSON AND JOHNSON	2%	N50788 001	DEC 04, 2002	APR	CAHN
>A>	AB	TEVA	2%	N65085 001	NOV 07, 2003	NOV	NEWA

MYCOPHENOLATE MOFETIL
CAPSULE; ORAL
CELLCEPT

+ ROCHE PALO	250MG	N50722 001	MAY 03, 1995	FEB	CAHN

SUSPENSION; ORAL

+ ROCHE PALO	200MG/ML	N50759 001	OCT 01, 1998	FEB	CAHN

TABLET; ORAL

+ ROCHE PALO	500MG	N50723 001	JUN 19, 1997	FEB	CAHN

MYCOPHENOLATE MOFETIL HYDROCHLORIDE
INJECTABLE; INJECTION

+ ROCHE PALO	500MG/VIAL	N50758 001	AUG 12, 1998	FEB	CAHN

NABUMETONE
TABLET; ORAL
NABUMETONE

AB	IVAX PHARMS	500MG	N76009 001	JAN 24, 2003	JAN	NEWA
AB		750MG	N76009 002	JAN 24, 2003	JAN	NEWA

NAFTIFINE HYDROCHLORIDE
CREAM; TOPICAL
NAFTIN

ALLERGAN HERBERT	1%	N19599 001	FEB 29, 1988	OCT	CMFD
@	1%	N19599 001	FEB 29, 1988	JUN	DISC

NAFTIFINE HYDROCHLORIDE

GEL; TOPICAL

NAFTIN

+	ALLERGAN HERBERT	1%	N19356 001	JUN 18, 1990	OCT	CMFD
@		1%	N19356 001	JUN 18, 1990	JUN	DISC

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

@	KING PHARMS	10MG/ML	N74471 001	MAR 19, 1998	MAY	DISC
@		20MG/ML	N74471 002	MAR 19, 1998	MAY	DISC

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@	BAXTER HLTHCARE	0.4MG/ML	N70496 001	SEP 24, 1986	AUG	CAHN
@	ELKINS SINN	0.4MG/ML	N70299 001	SEP 24, 1986	JUN	DISC
@	ELKINS SINN PHARM	0.4MG/ML	N70298 001	SEP 24, 1986	JUN	DISC

NALOXONE HCL

@	BAXTER HLTHCARE	0.02MG/ML	N71272 001	MAY 24, 1988	AUG	CAHN
@		1MG/ML	N71273 001	MAY 24, 1988	AUG	CAHN
@		1MG/ML	N71274 001	MAY 24, 1988	AUG	CAHN
@		1MG/ML	N71287 001	MAY 24, 1988	AUG	CAHN
@	ELKINS SINN	0.02MG/ML	N71272 001	MAY 24, 1988	JUN	DISC
@		1MG/ML	N71273 001	MAY 24, 1988	JUN	DISC
@		1MG/ML	N71274 001	MAY 24, 1988	JUN	DISC
@		1MG/ML	N71287 001	MAY 24, 1988	JUN	DISC

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

@	ORGANON USA INC	50MG/ML	N13132 001	JUN 12, 1986	MAY	DISC
@		100MG/ML	N13132 002	JUN 12, 1986	MAY	DISC
@		200MG/ML	N13132 003	JUN 12, 1986	MAY	DISC

NANDROLONE DECANOATE

+	STERIS	50MG/ML	N86385 001	JAN 13, 1984	MAY	CRLD
+		100MG/ML	N86598 001	JAN 13, 1984	MAY	CRLD
+		200MG/ML	N88128 001	DEC 05, 1983	MAY	CRLD

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB		ABLE	EQ 250MG BASE	N76544 001	AUG 22, 2003	AUG	NEWA
AB			EQ 500MG BASE	N76544 002	AUG 22, 2003	AUG	NEWA
AB		HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998	OCT	CAHN
AB			EQ 500MG BASE	N74480 001	MAY 14, 1996	OCT	CAHN

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

AB	+	ELAN PHARM	EQ 375MG BASE	N20353 001	JAN 05, 1996	APR	CFTG
AB	+		EQ 500MG BASE	N20353 002	JAN 05, 1996	MAR	CFTG
AB	+	ELAN PHARMA	EQ 375MG BASE	N20353 001	JAN 05, 1996	JUN	CAHN

AB +		EQ 500MG BASE	N20353 002	JAN 05, 1996	JUN	CAHN
@		EQ 750MG BASE	N20353 003	JAN 05, 1996	JUN	CAHN
NAPROXEN SODIUM						
AB	ANDRX PHARMS	EQ 375MG BASE	N75416 002	APR 23, 2003	APR	NEWA
AB		EQ 500MG BASE	N75416 001	AUG 27, 2002	MAR	NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL

AB	DR REDDYS LABS INC	50MG	N76309 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76309 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76309 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76309 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76309 005	SEP 16, 2003	SEP	NEWA
AB	EON	50MG	N76302 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76302 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76302 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76302 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76302 005	SEP 16, 2003	SEP	NEWA
AB	GENEVA PHARMS	50MG	N76072 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76072 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76072 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76072 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76072 005	SEP 16, 2003	SEP	NEWA
AB	IVAX PHARMS	50MG	N75763 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N75763 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N75763 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N75763 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N75763 005	SEP 16, 2003	SEP	NEWA
AB	MYLAN	100MG	N76129 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76129 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76129 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76129 005	SEP 16, 2003	SEP	NEWA
AB	RANBAXY	50MG	N76409 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76409 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76409 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76409 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76409 005	SEP 16, 2003	SEP	NEWA
AB	ROXANE	50MG	N76196 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76196 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76196 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76196 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76196 005	SEP 16, 2003	SEP	NEWA
AB	TEVA	50MG	N76037 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76037 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76037 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76037 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76037 005	SEP 16, 2003	SEP	NEWA
AB	WATSON LABS	100MG	N76073 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76073 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76073 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76073 005	SEP 16, 2003	SEP	NEWA

NEFAZODONE HYDROCHLORIDE
TABLET; ORAL
SERZONE

AB	BRISTOL MYERS SQUIBB	50MG	N20152 001	DEC 22, 1994	SEP	CFTG
AB		100MG	N20152 002	DEC 22, 1994	SEP	CFTG
AB		150MG	N20152 003	DEC 22, 1994	SEP	CFTG
AB		200MG	N20152 004	DEC 22, 1994	SEP	CFTG
AB +		250MG	N20152 005	DEC 22, 1994	SEP	CFTG

NELFINAVIR MESYLATE
TABLET; ORAL
VIRACEPT

+	AGOURON	EQ 625MG BASE	N21503 001	APR 30, 2003	APR	NEWA

NIFEDIPINE
CAPSULE; ORAL
ADALAT

@	BAYER PHARMS	10MG	N19478 001	NOV 27, 1985	JUN	DISC
@		20MG	N19478 002	SEP 17, 1986	JUN	DISC

TABLET, EXTENDED RELEASE; ORAL
PROCARDIA XL

AB2	PFIZER	30MG	N19684 001	SEP 06, 1989	JUL	CRLD
AB2		60MG	N19684 002	SEP 06, 1989	JUL	CRLD

NITROFURANTOIN
TABLET; ORAL
FURADANTIN

@	PROCTER AND GAMBLE	50MG	N08693 001		APR	DISC
@		100MG	N08693 002		APR	DISC

NITROFURANTOIN

@	WATSON LAB	50MG	N80447 001		APR	DISC
@	WHITEWORTH TOWN PLSN	100MG	N84085 002		APR	DISC

NITROFURAZONE
OINTMENT; TOPICAL
FURACIN

@	SHIRE PHARM	0.2%	N05795 001		MAR	DISC

NITROGLYCERIN
FILM, EXTENDED RELEASE; TRANSDERMAL*
NITROGLYCERIN

AB2	MYLAN TECHNOLOGIES	0.1MG/HR	N75033 001	FEB 06, 1998	APR	CAHN
AB2 +		0.1MG/HR	N75033 001	FEB 06, 1998	AUG	CRLD
AB2		0.2MG/HR	N74609 001	AUG 30, 1996	APR	CAHN
AB2 +		0.2MG/HR	N74609 001	AUG 30, 1996	AUG	CRLD
AB2		0.4MG/HR	N74607 001	AUG 30, 1996	APR	CAHN
AB2 +		0.4MG/HR	N74607 001	AUG 30, 1996	AUG	CRLD
AB2		0.6MG/HR	N74559 001	AUG 30, 1996	APR	CAHN
AB2 +		0.6MG/HR	N74559 001	AUG 30, 1996	AUG	CRLD

TRANSDERM-NITRO

@	NOVARTIS	0.1MG/HR	N20144 001	FEB 27, 1996	AUG	DISC

*SEE SECTION 1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE;TRANSDERMAL

	@	0.2MG/HR	N20144 002	FEB 27, 1996	AUG	DISC		>A>
	@	0.4MG/HR	N20144 003	FEB 27, 1996	AUG	DISC		>D>
	@	0.6MG/HR	N20144 004	FEB 27, 1996	AUG	DISC		>D>
	@	0.8MG/HR	N20144 005	FEB 27, 1996	AUG	DISC		>A>
	INJECTABLE; INJECTION							>D>
	TRIDIL							>D>
	@ FAULDING	0.5MG/ML	N18537 002	JUN 16, 1983	MAY	DISC		>A>
	@	5MG/ML	N18537 001		MAY	DISC		
	OINTMENT; TRANSDERMAL							>D>
	NITROGLYCERIN							>A>
+	FOUGERA	2%	N87355 001	JUL 08, 1988	APR	CAHN		
	NIZATIDINE							
	CAPSULE; ORAL							
	NIZATIDINE							
AB	TORPHARM	150MG	N76383 001	JAN 23, 2003	JAN	NEWA		
AB		300MG	N76383 002	JAN 23, 2003	JAN	NEWA		
	NOREPINEPHRINE BITARTRATE							
	INJECTABLE; INJECTION							
	LEVOPHED							
AP +	ABBOTT	EQ 1MG BASE/ML	N07513 001		MAR	CFTG		
	NOREPINEPHRINE BITARTRATE							
AP	BEDFORD	EQ 1MG BASE/ML	N40462 001	OCT 31, 2003	OCT	NEWA		
AP	GENSIA SICOR PHARMS	EQ 1MG BASE/ML	N40455 001	MAR 03, 2003	MAR	NEWA		
	NORETHINDRONE ACETATE							
	TABLET; ORAL							
	AYGESTIN							
AB +	DURAMED PHARMS BARR	5MG	N18405 001	APR 21, 1982	JUN	CAHN		
AB +	WYETH PHARMS INC	5MG	N18405 001	APR 21, 1982	MAR	CAHN		
	NORFLOXACIN							
	SOLUTION/DROPS; OPHTHALMIC							
	CHIBROXIN							
	@ MERCK	0.3%	N19757 001	JUN 17, 1991	MAY	DISC		
	NORGESTREL							
	TABLET; ORAL							
	OVRETTE							
+	WYETH PHARMS INC	0.075MG	N17031 001		MAR	CAHN		
	NYSTATIN							
	POWDER; ORAL							
	NILSTAT							
	@ CLONMEL HLTHCARE	100%	N50576 001	DEC 22, 1983	JUL	DISC		
	NYSTATIN							
+	PADDOCK	100%	N62613 001	NOV 26, 1985	JUL	CRLD		
	OFLOXACIN							
	INJECTABLE; INJECTION							
>D>	FLOXIN							
>D> AP +	ORTHO MCNEIL PHARM	40MG/ML	N20087 003	MAR 31, 1992	NOV	DISC		

>A>		@	40MG/ML	N20087 003	MAR 31, 1992	NOV	DISC	
>D>		FLOXIN IN DEXTROSE 5%						
>D>	+	ORTHO MCNEIL PHARM	400MG/100ML	N20087 001	MAR 31, 1992	NOV	DISC	
>A>		@	400MG/100ML	N20087 001	MAR 31, 1992	NOV	DISC	
>D>		FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	+	ORTHO MCNEIL PHARM	400MG/100ML	N20087 005	MAR 31, 1992	NOV	DISC	
>A>		@	400MG/100ML	N20087 005	MAR 31, 1992	NOV	DISC	
		OFLOXACIN						
>D>	AP	BEDFORD	40MG/ML	N75762 001	JAN 16, 2002	NOV	CRLD	
>A>	+		40MG/ML	N75762 001	JAN 16, 2002	NOV	CRLD	
		TABLET; ORAL						
		FLOXIN						
	AB	ORTHO MCNEIL PHARM	200MG	N19735 001	DEC 28, 1990	SEP	CFTG	
	AB		300MG	N19735 002	DEC 28, 1990	SEP	CFTG	
	AB	+	400MG	N19735 003	DEC 28, 1990	SEP	CFTG	
		OFLOXACIN						
	AB	PAR PHARM	200MG	N76093 001	SEP 02, 2003	SEP	NEWA	
	AB		300MG	N76093 002	SEP 02, 2003	SEP	NEWA	
	AB		400MG	N76093 003	SEP 02, 2003	SEP	NEWA	
	AB	RANBAXY	200MG	N76220 001	SEP 02, 2003	SEP	NEWA	
	AB		300MG	N76220 002	SEP 02, 2003	SEP	NEWA	
	AB		400MG	N76220 003	SEP 02, 2003	SEP	NEWA	
	AB	TEVA	200MG	N76182 001	SEP 02, 2003	SEP	NEWA	
	AB		300MG	N76182 002	SEP 02, 2003	SEP	NEWA	
	AB		400MG	N76182 003	SEP 02, 2003	SEP	NEWA	
		OLANZAPINE						
		TABLET; ORAL						
		ZYPREXA						
	+	LILLY	5MG	N20592 002	SEP 30, 1996	MAY	CRLD	
			20MG	N20592 006	SEP 09, 1997	MAY	CRLD	
		TABLET, ORALLY DISINTEGRATING; ORAL						
		ZYPREXA ZYDIS						
	+	LILLY	5MG	N21086 001	APR 06, 2000	AUG	CRLD	
			20MG	N21086 004	APR 06, 2000	AUG	CRLD	
		OMEPRAZOLE						
		CAPSULE, DELAYED REL PELLETS; ORAL						
		OMEPRAZOLE						
	AB	LEK SVCS	10MG	N75757 001	JAN 28, 2003	JAN	NEWA	
	AB		20MG	N75757 002	JAN 28, 2003	JAN	NEWA	
	AB	MYLAN	10MG	N75876 001	MAY 29, 2003	MAY	NEWA	
	AB		20MG	N75876 002	MAY 29, 2003	MAY	NEWA	
	AB	TORPHARM	10MG	N76048 001	OCT 06, 2003	OCT	NEWA	
	AB		20MG	N76048 002	OCT 06, 2003	OCT	NEWA	
		ORPHENADRINE CITRATE						
		INJECTABLE; INJECTION						
		ORPHENADRINE CITRATE						
	AP	BEDFORD LABS	30MG/ML	N40463 001	MAR 04, 2003	MAR	NEWA	

OXYBUTYNIN
FILM, EXTENDED RELEASE; TRANSDERMAL
OXYTROL
\+ WATSON LABS (UTAH) 3.9MG/24HR N21351 002 FEB 26, 2003 FEB NEWA

OXYBUTYNIN CHLORIDE
TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
ALZA 5MG N20897 001 DEC 16, 1998 MAY CRLD
10MG N20897 002 DEC 16, 1998 MAY CRLD

OXYCODONE HYDROCHLORIDE
TABLET; ORAL
ROXICODONE
\+ ELAN PHARMS 15MG N21011 001 AUG 31, 2000 OCT CRLD
30MG N21011 002 AUG 31, 2000 OCT CRLD

OXYTOCIN
INJECTABLE; INJECTION
OXYTOCIN
@ BAXTER HLTHCARE CORP 10USP UNITS/ML N18243 001 MAY CAHN

PALONOSETRON HYDROCHLORIDE
INJECTABLE; INTRAVENOUS
ALOXI
\+ HELSINN HLTHCARE EQ 0.25MG BASE/5ML(EQ 0.05MG BASE/ML) N21372 001 JUL 25, 2003 JUL NEWA

PANCURONIUM BROMIDE
INJECTABLE; INJECTION
PANCURONIUM BROMIDE
AP + GENSIA SICOR PHARMS 1MG/ML N72759 001 JUL 31, 1990 MAY CRLD
AP + 2MG/ML N72760 001 JUL 31, 1990 MAY CRLD
PAVULON
@ ORGANON 1MG/ML N17015 002 MAY DISC
@ 2MG/ML N17015 001 MAY DISC

PANTOPRAZOLE SODIUM
INJECTABLE; IV (INFUSION)
PROTONIX IV
\+ WYETH PHARMS INC EQ 40MG BASE/VIAL N20988 001 MAR 22, 2001 MAR CAHN
TABLET, DELAYED RELEASE; ORAL
PROTONIX
\+ WYETH PHARMS INC EQ 20MG BASE N20987 002 JUN 12, 2001 MAR CAHN
EQ 20MG BASE N20987 002 JUN 12, 2001 APR CRLD
\+ EQ 40MG BASE N20987 001 FEB 02, 2000 MAR CAHN

PAROMOMYCIN SULFATE
CAPSULE; ORAL
HUMATIN
AA + KING PHARMS EQ 250MG BASE N62310 001 MAY CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HCL

AB		TORPHARM	EQ 10MG BASE	N75356 001	JUL 30, 2003	JUL	NEWA
AB			EQ 20MG BASE	N75356 002	JUL 30, 2003	JUL	NEWA
AB			EQ 30MG BASE	N75356 003	JUL 30, 2003	JUL	NEWA
AB			EQ 40MG BASE	N75356 004	JUL 30, 2003	JUL	NEWA

PAXIL

AB		GLAXOSMITHKLINE	EQ 10MG BASE	N20031 001	DEC 29, 1992	JUL	CFTG
AB			EQ 20MG BASE	N20031 002	DEC 29, 1992	JUL	CFTG
AB			EQ 30MG BASE	N20031 003	DEC 29, 1992	JUL	CFTG
AB	+		EQ 40MG BASE	N20031 005	DEC 29, 1992	JUL	CFTG

PAROXETINE MESYLATE

TABLET; ORAL

PAROXETINE MESYLATE

		SYNTHON PHARMS	EQ 10MG BASE	N21299 001	JUL 03, 2003	JUL	NEWA
			EQ 20MG BASE	N21299 002	JUL 03, 2003	JUL	NEWA
			EQ 30MG BASE	N21299 003	JUL 03, 2003	JUL	NEWA
	+		EQ 40MG BASE	N21299 004	JUL 03, 2003	JUL	NEWA

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

	+	PHARMACIA AND UPJOHN	10MG/VIAL	N21106 001	MAR 25, 2003	MAR	NEWA
	+		15MG/VIAL	N21106 002	MAR 25, 2003	MAR	NEWA
	+		20MG/VIAL	N21106 003	MAR 25, 2003	MAR	NEWA

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

	@	MARSAM PHARMS LLC	1,000,000 UNITS/VIAL	N62991 001	SEP 13, 1988	JUL	DISC
	@		5,000,000 UNITS/VIAL	N62991 002	SEP 13, 1988	JUL	DISC
	@		10,000,000 UNITS/VIAL	N62991 003	SEP 13, 1988	JUL	DISC
	@		20,000,000 UNITS/VIAL	N62991 004	SEP 13, 1988	JUL	DISC

TABLET; ORAL

	@	WYETH AYERST	200,000 UNITS	N60413 001		JUN	DISC
	@		250,000 UNITS	N60413 002		JUN	DISC
	@		400,000 UNITS	N60413 003		JUN	DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

LEDERCILLIN VK

	@	LEDERLE	EQ 125MG BASE/5ML	N60136 001		JUN	DISC
	@		EQ 250MG BASE/5ML	N60136 002		JUN	DISC

TABLET; ORAL

	@	LEDERLE	EQ 250MG BASE	N60134 001		JUN	DISC
	@		EQ 500MG BASE	N60134 002		JUN	DISC

PEN-VEE K

	@	WYETH AYERST	EQ 250MG BASE	N60006 002		JUN	DISC
	@		EQ 500MG BASE	N60006 003		JUN	DISC

PENTAMIDINE ISETHIONATE							
INJECTABLE; INJECTION							
PENTAMIDINE ISETHIONATE							
@ BAXTER HLTHCARE	300MG/VIAL	N73617 001	DEC 18, 1995	AUG	CAHN		
@ ELKINS SINN	300MG/VIAL	N73617 001	DEC 18, 1995	JUN	DISC		
PENTOBARBITAL SODIUM							
INJECTABLE; INJECTION							
NEMBUTAL SODIUM							
+ ABBOTT	50MG/ML	N83246 001		JUN	CTEC		
SODIUM PENTOBARBITAL							
@ WYETH AYERST	50MG/ML	N83261 001		JUN	DISC		
PERGOLIDE MESYLATE							
TABLET; ORAL							
PERGOLIDE MESYLATE							
AB IVAX PHARMS	EQ 0.05MG BASE	N76094 001	SEP 04, 2003	SEP	NEWA		
AB	EQ 0.25MG BASE	N76094 002	SEP 04, 2003	SEP	NEWA		
AB	EQ 1MG BASE	N76094 003	SEP 04, 2003	SEP	NEWA		
PERMETHRIN							
CREAM; TOPICAL							
PERMETHRIN							
AB CLAY PARK	5%	N76369 001	APR 21, 2003	APR	NEWA		
PERPHENAZINE							
TABLET; ORAL							
PERPHENAZINE							
AB + IVAX PHARMS	16MG	N89457 001	SEP 10, 1987	FEB	CRLD		
TRILAFON							
@ SCHERING	2MG	N10775 001		FEB	DISC		
@	4MG	N10775 002		FEB	DISC		
@	8MG	N10775 003		FEB	DISC		
@	16MG	N10775 004		FEB	DISC		
PHENTERMINE HYDROCHLORIDE							>A>
CAPSULE; ORAL							>A>
PHENTERMINE HCL							>A>
AA ABLE	15MG	N40497 001	MAR 13, 2003	MAR	NEWA		>A>
AA AMBI PHARMS	30MG	N40083 001	MAR 07, 1997	MAY	CAHN		>A>
AA AMIDE PHARM	15MG	N40460 001	JAN 14, 2003	JAN	NEWA		>A>
AA	30MG	N40448 001	JAN 22, 2003	JAN	NEWA		
AA MUTUAL PHARM	30MG	N40525 001	OCT 23, 2003	OCT	NEWA		
AA	37.5MG	N40527 001	OCT 23, 2003	OCT	NEWA		
TABLET; ORAL							
AA + EON	30MG	N88605 001	SEP 28, 1987	JAN	CFTG		
AA MUTUAL PHARM	37.5MG	N40526 001	OCT 23, 2003	OCT	NEWA		
PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE							
SYRUP; ORAL							
PHENERGAN VC							
@ WYETH AYERST	5MG/5ML;6.25MG/5ML	N08604 003	APR 02, 1984	APR	DISC		

	PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE						
	SYRUP; ORAL						
	PROMETH VC PLAIN						
AA	+ ALPHARMA	5MG/5ML;6.25MG/5ML	N88761 001	NOV 08, 1984	APR	CRLD	
	PHENYTOIN						
	SUSPENSION; ORAL						
	PHENYTOIN						
AB	VISTAPHARM	125MG/5ML	N40342 001	JAN 31, 2001	MAR	CAHN	
	PHENYTOIN SODIUM						
	INJECTABLE; INJECTION						
	DILANTIN						
	@ PARKE DAVIS	50MG/ML	N10151 001		MAR	DISC	
	PHENYTOIN						
	+ ELKINS SINN	50MG/ML	N84307 001		MAR	CRLD	
	PHENYTOIN SODIUM						
	@ ABBOTT	50MG/ML	N89521 001	MAR 17, 1987	MAR	DISC	
	@	50MG/ML	N89744 001	DEC 18, 1987	MAR	DISC	
	PHENYTOIN SODIUM, EXTENDED						
	CAPSULE; ORAL						
	DILANTIN						
	PARKE DAVIS	30MG	N84349 001		FEB	CRLD	
	+	30MG	N84349 001		JUN	CRLD	
	EXTENDED PHENYTOIN SODIUM						
AB	BARR	100MG	N40435 001	JUN 20, 2003	JUN	NEWA	
	PILOCARPINE HYDROCHLORIDE						
	TABLET; ORAL						
	SALAGEN						
	MGI PHARMA INC	5MG	N20237 001	MAR 22, 1994	APR	CRLD	
	+	7.5MG	N20237 002	APR 18, 2003	APR	NEWA	
>A>	PIPERACILLIN SODIUM						
>A>	INJECTABLE; INJECTION						
>A>	PIPERACILLIN						
>A>	+ AM PHARM	EQ 2GM BASE/VIAL	N65114 001	NOV 14, 2003	NOV	NEWA	
>A>	+	EQ 3GM BASE/VIAL	N65114 002	NOV 14, 2003	NOV	NEWA	
>A>	+	EQ 4GM BASE/VIAL	N65114 003	NOV 14, 2003	NOV	NEWA	
	PIPRACIL						
	+ WYETH PHARMS INC	EQ 2GM BASE/VIAL	N50545 002		MAR	CAHN	
	@	EQ 2GM BASE/VIAL	N50545 002		JUN	DISC	
		EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	MAR	CAHN	
	@	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	JUN	DISC	
	+	EQ 3GM BASE/VIAL	N50545 003		MAR	CAHN	
	@	EQ 3GM BASE/VIAL	N50545 003		JUN	DISC	
		EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	MAR	CAHN	
	@	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	JUN	DISC	
	+	EQ 4GM BASE/VIAL	N50545 004		MAR	CAHN	
	@	EQ 4GM BASE/VIAL	N50545 004		JUN	DISC	

		EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	MAR	CAHN
	@	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	JUN	DISC
	@	EQ 40GM BASE/VIAL	N50545 006	SEP 30, 1985	MAR	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

ZOSYN

+	WYETH PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993	MAR	CAHN
+		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993	MAR	CAHN
+		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993	MAR	CAHN
+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993	MAR	CAHN

ZOSYN IN PLASTIC CONTAINER

+	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N50750 001	FEB 24, 1998	MAR	CAHN
+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998	MAR	CAHN
+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998	MAR	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

	@ 3M	EQ 0.2MG BASE/INH	N19009 001	DEC 30, 1986	MAY	DISC

PIROXICAM

CAPSULE; ORAL

PIROXICAM

	@ SCS	10MG	N74036 001	MAY 29, 1992	OCT	WDAG
	@	20MG	N74036 002	MAY 29, 1992	OCT	WDAG

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	@ BAXTER HLTHCARE	2MEQ/ML	N80203 001		AUG	CAHN

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M15

	UPSHER SMITH	15MEQ	N74726 003	JUN 06, 2003	JUN	NEWA

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

	@ BAXTER HLTHCARE CORP	300MG/ML	N18799 001	DEC 13, 1982	MAR	CAHN

PROTOPAM CHLORIDE

+	BAXTER HLTHCARE CORP	1GM/VIAL	N14134 001		JUL	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

>D>	+	PHARMACIA AND UPJOHN	0.125MG	N20667 001	JUL 01, 1997	NOV	CRLD
>A>			0.125MG	N20667 001	JUL 01, 1997	NOV	CRLD
	+		0.25MG	N20667 002	JUL 01, 1997	OCT	CRLD
			1.5MG	N20667 005	JUL 01, 1997	OCT	CRLD

PRAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
PRAZOSIN HCL

	@ CLONMEL HLTHCARE	EQ 2MG BASE	N72706 001	MAY 16, 1989	JUL	DISC

PREDNICARBATE
CREAM; TOPICAL
DERMATOP E EMOLLIENT

+	DERMIK LABS	0.1%	N20279 001	OCT 29, 1993	APR	CTNA

PREDNISOLONE
SYRUP; ORAL
PREDNISOLONE

AA	AXIOM PHARM	15MG/5ML	N40287 001	MAY 28, 1999	MAY	CAHN
AA	HI TECH PHARMA	15MG/5ML	N40401 001	FEB 27, 2003	FEB	NEWA
+	KV PHARM	5MG/5ML	N40423 001	OCT 22, 2001	JUL	CRLD
AA +		15MG/5ML	N40364 001	APR 10, 2002	JUL	CRLD
AA	MORTON GROVE	15MG/5ML	N40313 001	SEP 10, 2003	SEP	NEWA
AA	PHARM ASSOC	15MG/5ML	N40399 001	MAR 05, 2003	MAR	NEWA

PRELONE

	@ MURO	5MG/5ML	N89654 001	JAN 17, 1989	JUL	DISC
AA +	TEVA	15MG/5ML	N89081 001	FEB 04, 1986	MAY	CAHN
AA		15MG/5ML	N89081 001	FEB 04, 1986	JUL	CRLD

PREDNISOLONE ACETATE
SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED

	@ ALCON	0.125%	N17468 001		JUN	DISC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
CETAPRED

	@ ALCON	0.25%;10%	N87771 001	AUG 06, 1993	JUN	DISC

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE

AA	HI TECH PHARMA	EQ 5MG BASE/5ML	N75183 001	MAR 26, 2003	MAR	NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM
SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON	EQ 0.23% PHOSPHATE;10%	N73630 001	MAY 27, 1993	APR	CAHN

PREDNISONE
TABLET; ORAL
PREDNISONE

AB	VINTAGE PHARMS	20MG	N40392 001	FEB 12, 2003	FEB	NEWA

PRIMIDONE
TABLET; ORAL
MYSOLINE

AB	+	XCEL PHARMS	50MG	N09170 003		JUL	CRLD
AB			250MG	N09170 002		JUL	CRLD

PROCAINAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
PROCAINAMIDE HCL

	@	BAXTER HLTHCARE	100MG/ML	N89029 001	APR 17, 1986	AUG	CAHN
	@		500MG/ML	N89030 001	APR 17, 1986	AUG	CAHN
	@	ELKINS SINN	100MG/ML	N89029 001	APR 17, 1986	JUN	DISC
	@		500MG/ML	N89030 001	APR 17, 1986	JUN	DISC

PROCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
PROCAINE HCL

	@	AM PHARM PARTNERS	1%	N80421 001		OCT	DISC
	@		2%	N80421 002		OCT	DISC
	@	ELKINS SINN	1%	N83315 001		OCT	DISC
	@		2%	N83315 002		OCT	DISC
	@	STERIS	2%	N80658 002		OCT	DISC

PROCHLORPERAZINE EDISYLATE
INJECTABLE; INJECTION
PROCHLORPERAZINE

AP		BAXTER HLTHCARE	EQ 5MG BASE/ML	N87759 001	OCT 01, 1982	AUG	CAHN

PROCHLORPERAZINE EDISYLATE

	@	BAXTER HLTHCARE	EQ 5MG BASE/ML	N89523 001	MAY 03, 1988	AUG	CAHN
AP		GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N40505 001	MAY 30, 2003	MAY	NEWA

PROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
SPARINE

	@	BAXTER HLTHCARE CORP	25MG/ML	N10349 008		AUG	CAHN
	@		50MG/ML	N10349 006		AUG	CAHN

PROMETHAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
PHENERGAN

	@	WYETH AYERST	25MG/ML	N08857 002		JUN	DISC
	@		50MG/ML	N08857 003		APR	DISC

PROMETHAZINE HCL

AP		BAXTER HLTHCARE	25MG/ML	N83312 001		JUN	CAHN
AP			50MG/ML	N83312 002		JUN	CAHN
AP	+	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	APR	CRLD
AP	+		50MG/ML	N40454 002	AUG 22, 2002	APR	CRLD
AP		PHARMAFORCE	25MG/ML	N40515 001	MAR 19, 2003	MAR	NEWA

SUPPOSITORY; RECTAL
PHENERGAN

AB	+	WYETH AYERST	50MG	N11689 001		FEB	CTEC
AB		WYETH PHARMS INC	12.5MG	N10926 002		MAR	CAHN

	AB	+		25MG	N10926 001		MAR	CAHN
	AB	+		50MG	N11689 001		MAR	CAHN
			PROMETHAZINE HCL					
	AB		ABLE	12.5MG	N40504 001	APR 11, 2003	APR	NEWA
	AB			25MG	N40504 002	APR 11, 2003	APR	NEWA
	AB			50MG	N40449 001	FEB 27, 2003	FEB	NEWA
	AB		CLAY PARK	12.5MG	N40500 001	JUN 30, 2003	JUN	NEWA
	AB			25MG	N40500 002	JUN 30, 2003	JUN	NEWA
	AB		G AND W LABS	12.5MG	N40428 002	MAR 31, 2003	MAR	NEWA
	AB		PADDOCK	12.5MG	N40479 001	JUN 24, 2003	JUN	NEWA
	AB			25MG	N40479 002	JUN 24, 2003	JUN	NEWA
			SYRUP; ORAL					
			PHENERGAN PLAIN					
			@ WYETH AYERST	6.25MG/5ML	N08381 004	APR 18, 1984	JUN	DISC
			PROMETH PLAIN					
	AA	+	ALPHARMA	6.25MG/5ML	N85953 001		JUN	CRLD
			TABLET; ORAL					
			PHENERGAN					
			WYETH PHARMS INC	12.5MG	N07935 002		MAR	CAHN
	BP			25MG	N07935 003		MAR	CAHN
	BP	+		50MG	N07935 004		MAR	CAHN
			PROPAFENONE HYDROCHLORIDE					
			CAPSULE, EXTENDED RELEASE; ORAL					
			RYTHMOL SR					
>D>			ABBOTT	225MG	N21416 001	SEP 04, 2003	NOV	CAHN
				225MG	N21416 001	SEP 04, 2003	SEP	NEWA
>D>				325MG	N21416 002	SEP 04, 2003	NOV	CAHN
				325MG	N21416 002	SEP 04, 2003	SEP	NEWA
>D>		+		425MG	N21416 003	SEP 04, 2003	NOV	CAHN
		+		425MG	N21416 003	SEP 04, 2003	SEP	NEWA
>A>			RELIANT PHARMS	225MG	N21416 001	SEP 04, 2003	NOV	CAHN
>A>				325MG	N21416 002	SEP 04, 2003	NOV	CAHN
>A>		+		425MG	N21416 003	SEP 04, 2003	NOV	CAHN
			TABLET; ORAL					
			RYTHMOL					
>D>	AB		ABBOTT	150MG	N19151 001	NOV 27, 1989	NOV	CAHN
>D>	AB			225MG	N19151 003	NOV 20, 1992	NOV	CAHN
>D>	AB	+		300MG	N19151 002	NOV 27, 1989	NOV	CAHN
>A>	AB		RELIANT PHARMS	150MG	N19151 001	NOV 27, 1989	NOV	CAHN
>A>	AB			225MG	N19151 003	NOV 20, 1992	NOV	CAHN
>A>	AB	+		300MG	N19151 002	NOV 27, 1989	NOV	CAHN
			PROPIOMAZINE HYDROCHLORIDE					
			INJECTABLE; INJECTION					
			LARGON					
			@ BAXTER HLTHCARE CORP	20MG/ML	N12382 002		MAY	CAHN
			PROPOXYPHENE HYDROCHLORIDE					
			CAPSULE; ORAL					
			DARVON					
>D>	AA	+	AAIPHARMA LLC	32MG	N10997 001		NOV	CTEC
>A>		+		32MG	N10997 001		NOV	CTEC

PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL

		DOLENE						
		@ CLONMEL HLTHCARE	65MG	N80530 001			AUG	DISC
		PROPOXYPHENE HCL						
>D>	AA	MYLAN	32MG	N83528 001			NOV	DISC
>A>		@	32MG	N83528 001			NOV	DISC

PROPOXYPHENE NAPSYLATE
SUSPENSION; ORAL

		DARVON-N						
		@ AAIPHARMA LLC	50MG/5ML	N16861 001			JUL	DISC

PROPRANOLOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL

		INDERAL LA						
		WYETH PHARMS INC	60MG	N18553 004	MAR 18, 1987		MAR	CAHN
	BX		80MG	N18553 002	APR 19, 1983		MAR	CTEC
	BX		120MG	N18553 003	APR 19, 1983		MAR	CTEC
	+		160MG	N18553 001	APR 19, 1983		MAR	CAHN
		INNOPRAN XL						
	BX	RELIANT PHARMS	80MG	N21438 001	MAR 12, 2003		MAR	NEWA
	BX		120MG	N21438 002	MAR 12, 2003		MAR	NEWA

INJECTABLE; INJECTION

		INDERAL						
AP	+	BAXTER HLTHCARE CORP	1MG/ML	N16419 001			MAY	CAHN
		PROPRANOLOL HCL						
AP	+	BAXTER HLTHCARE CORP	1MG/ML	N16419 001			AUG	CTNA
AP		SABEX 2002	1MG/ML	N76400 001	FEB 26, 2003		FEB	NEWA

TABLET; ORAL

		INDERAL						
AB	+	WYETH PHARMS INC	10MG	N16418 001			MAR	CAHN
AB			20MG	N16418 003			MAR	CAHN
AB			40MG	N16418 002			MAR	CAHN
AB			60MG	N16418 009	OCT 18, 1982		MAR	CAHN
AB	+		80MG	N16418 004			MAR	CAHN
		@	90MG	N16418 010	OCT 18, 1982		MAR	CAHN

PROTAMINE SULFATE
INJECTABLE; INJECTION

		PROTAMINE SULFATE						
		@ BAXTER HLTHCARE	10MG/ML	N89474 001	NOV 05, 1986		AUG	CAHN
		@	10MG/ML	N89475 001	NOV 05, 1986		AUG	CAHN
		@ ELKINS SINN	10MG/ML	N89474 001	NOV 05, 1986		JUN	DISC
		@	10MG/ML	N89475 001	NOV 05, 1986		JUN	DISC

PROTIRELIN
INJECTABLE; INJECTION

		THYREL TRH						
		@ FERRING	0.5MG/ML	N18087 001			JUL	DISC

PYRIDOSTIGMINE BROMIDE
INJECTABLE; INJECTION
REGONOL

	@ ORGANON	5MG/ML	N17398 001		MAY	DISC
	@ SABEX 2002	5MG/ML	N17398 001		JUN	CAHN
AP		5MG/ML	N17398 001		OCT	CMFD

TABLET; ORAL
PYRIDOSTIGMINE BROMIDE

AB	BARR	60MG	N40512 001	OCT 08, 2003	OCT	NEWA
AB	IMPAX LABS	60MG	N40502 001	APR 24, 2003	APR	NEWA
	@ US ARMY	30MG	N20414 001	FEB 05, 2003	FEB	NEWA

QUETIAPINE FUMARATE
TABLET; ORAL
SEROQUEL

+	ASTRAZENECA	EQ 25MG BASE	N20639 001	SEP 26, 1997	MAR	CRLD

QUINAPRIL HYDROCHLORIDE
TABLET; ORAL
ACCUPRIL

AB	PFIZER PHARMS	EQ 5MG BASE	N19885 001	NOV 19, 1991	MAY	CFTG
AB		EQ 10MG BASE	N19885 002	NOV 19, 1991	MAY	CFTG
AB		EQ 20MG BASE	N19885 003	NOV 19, 1991	MAY	CFTG
AB +		EQ 40MG BASE	N19885 004	NOV 19, 1991	MAY	CFTG

QUINAPRIL HCL

AB	TEVA	EQ 5MG BASE	N75504 001	MAY 30, 2003	MAY	NEWA
AB		EQ 10MG BASE	N75504 002	MAY 30, 2003	MAY	NEWA
AB		EQ 20MG BASE	N75504 003	MAY 30, 2003	MAY	NEWA
AB		EQ 40MG BASE	N75504 004	NOV 20, 1998	MAY	NEWA

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE; ORAL
QUINAGLUTE

	@ BERLEX LABS	324MG	N16647 001		MAR	DISC

QUINIDINE GLUCONATE

BX +	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	APR	CRLD
+		324MG	N89338 001	FEB 11, 1987	MAY	CTEC
+	WATSON LABS	324MG	N87810 001	SEP 29, 1982	MAR	CRLD
BX		324MG	N87810 001	SEP 29, 1982	APR	CRLD
	@	324MG	N87810 001	SEP 29, 1982	MAY	DISC

QUINIDINE SULFATE
TABLET; ORAL
QUINIDINE SULFATE

AB	CLONMEL HLTHCARE	200MG	N87011 001		JUL	CAHN

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

AB +	WYETH PHARMS INC	300MG	N12796 002		MAR	CAHN
	@	300MG	N12796 002		JUN	DISC

QUINIDINE SULFATE

+	COPLEY PHARM	300MG	N40045 001	JUN 30, 1994	JUN	CTEC

RANITIDINE HYDROCHLORIDE
CAPSULE; ORAL
RANITIDINE HCL

AB		TEVA	EQ 150MG BASE	N75557 001	OCT 31, 2003	OCT	NEWA
AB			EQ 300MG BASE	N75557 002	OCT 31, 2003	OCT	NEWA

RESERPINE; TRICHLORMETHIAZIDE
TABLET; ORAL

		METATENSIN #2					
		@ AVENTIS PHARMS	0.1MG;2MG	N12972 001		MAY	DISC
		METATENSIN #4					
		@ AVENTIS PHARMS	0.1MG;4MG	N12972 002		MAY	DISC

RIBAVIRIN
SOLUTION; ORAL
REBETOL

	+	SCHERING	40MG/ML	N21546 001	JUL 29, 2003	JUL	NEWA

RILUZOLE
TABLET; ORAL
RILUTEK

AB	+	AVENTIS	50MG	N20599 001	DEC 12, 1995	JAN	CFTG
		RILUZOLE					
AB		IMPAX LABS	50MG	N76173 001	JAN 29, 2003	JAN	NEWA

RIMANTADINE HYDROCHLORIDE
TABLET; ORAL
RIMANTADINE HCL

AB		AMIDE PHARM	100MG	N76375 001	JAN 14, 2003	JAN	NEWA

RISPERIDONE
INJECTABLE; INTRAMUSCULAR
RISPERDAL CONSTA

		JOHNSON AND JOHNSON	25MG/VIAL	N21346 001	OCT 29, 2003	OCT	NEWA
			37.5MG/VIAL	N21346 002	OCT 29, 2003	OCT	NEWA
	+		50MG/VIAL	N21346 003	OCT 29, 2003	OCT	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

		JOHNSON AND JOHNSON	0.5MG	N21444 001	APR 02, 2003	APR	NEWA
	+		1MG	N21444 002	APR 02, 2003	APR	NEWA
			2MG	N21444 003	APR 02, 2003	APR	NEWA

ROSIGLITAZONE MALEATE
TABLET; ORAL
AVANDIA

		SB PHARMCO	EQ 2MG BASE	N21071 002	MAY 25, 1999	APR	CAHN
			EQ 4MG BASE	N21071 003	MAY 25, 1999	APR	CAHN
	+		EQ 8MG BASE	N21071 004	MAY 25, 1999	APR	CAHN

ROSUVASTATIN CALCIUM
TABLET; ORAL
CRESTOR
ASTRAZENECA 5MG N21366 002 AUG 12, 2003 AUG NEWA
10MG N21366 003 AUG 12, 2003 AUG NEWA
20MG N21366 004 AUG 12, 2003 AUG NEWA
\+ 40MG N21366 005 AUG 12, 2003 AUG NEWA

SACROSIDASE
SOLUTION; ORAL
SUCRAID
\+ QOL MEDCL 8,500 IU/ML N20772 001 APR 09, 1998 MAY CAHN

SECOBARBITAL SODIUM
INJECTABLE; INJECTION
SODIUM SECOBARBITAL
@ WYETH AYERST 50MG/ML N83262 001 JUN DISC

SECRETIN
FOR SOLUTION; INTRAVENOUS
SECREFLO
>A> \+ CHIRHOCLIN 16UGM/VIAL N21136 001 APR 04, 2002 NOV NEWA

SELEGILINE HYDROCHLORIDE
CAPSULE; ORAL
SELEGELINE HCL
AB AAIPHARMA LLC 5MG N75145 001 SEP 15, 2003 SEP NEWA

SERMORELIN ACETATE
INJECTABLE; INJECTION
GEREF
@ SERONO EQ 0.5MG BASE/VIAL N20443 001 SEP 26, 1997 JUN DISC
@ EQ 1MG BASE/VIAL N20443 002 SEP 26, 1997 JUN DISC

SEVELAMER HYDROCHLORIDE
CAPSULE; ORAL
RENAGEL
\+ GENZYME 403MG N20926 001 OCT 30, 1998 APR CAHN
TABLET; ORAL
GENZYME 400MG N21179 001 JUL 12, 2000 APR CAHN
\+ 800MG N21179 002 JUL 12, 2000 APR CAHN

SILDENAFIL CITRATE
TABLET; ORAL
VIAGRA
PFIZER IRELAND 25MG N20895 001 MAR 27, 1998 OCT CAHN
50MG N20895 002 MAR 27, 1998 OCT CAHN
\+ 100MG N20895 003 MAR 27, 1998 OCT CAHN

									AB2
	SIROLIMUS								
	SOLUTION; ORAL								
	RAPAMUNE								AB2
	+ WYETH PHARMS INC	1MG/ML	N21083 001	SEP 15, 1999	MAR	CAHN			AB2 +
	TABLET; ORAL								
	WYETH PHARMS INC	1MG	N21110 001	AUG 25, 2000	MAR	CRLD			AB1
	+	2MG	N21110 002	AUG 22, 2002	MAR	NEWA			AB1
									AB1
									AB1
	SODIUM IODIDE, I-131								
	CAPSULE; ORAL								AB1
	SODIUM IODIDE I 131								
	+ DRAXIMAGE	1-250mCi	N21305 002	JAN 24, 2003	JAN	NEWA			AB1
	+	1-500mCi	N21305 003	JAN 24, 2003	JAN	NEWA			AB1
	SOLUTION; ORAL								AB1
	SODIUM IODIDE I 131, KIT								AB1
	+ DRAXIMAGE	1-250mCi/0.25ML	N21305 002	JAN 24, 2003	FEB	CDFR			AB1
	+	1-500mCi/0.5ML	N21305 003	JAN 24, 2003	FEB	CDFR			AB1
									AB1
									AB1
	SODIUM NITROPRUSSIDE								AB1
	INJECTABLE; INJECTION								AB1
	NITROPRESS								
AP	+ ABBOTT	50MG/VIAL	N70566 001	JUN 09, 1986	JUN	CRLD			AB1
	+	50MG/VIAL	N70566 001	JUN 09, 1986	AUG	CTEC			AB1
	SODIUM NITROPRUSSIDE								AB1
	@ BAXTER HLTHCARE	50MG/VIAL	N18581 001	JUL 28, 1982	AUG	CAHN			AB1
	@ ELKINS SINN	50MG/VIAL	N18581 001	JUL 28, 1982	JUN	DISC			AB1
									AB1
									AB1
	SOMATROPIN RECOMBINANT								AB1
	INJECTABLE; INJECTION								AB1
	BIO-TROPIN								
	@ BIO TECH GEN	4.8MG/VIAL	N19774 001	MAY 25, 1995	MAR	DISC			AB1
	NORDITROPIN								AB1
BX	NOVO NORDISK	4MG/VIAL	N19721 001	MAY 08, 1995	JUL	CMFD			AB1
		8MG/VIAL	N19721 002	MAY 08, 1995	JUL	CMFD			AB1
	SEROSTIM								AB1
>D> BX	+ SERONO	4MG/VIAL	N20604 003	JUL 25, 1997	NOV	CRLD			AB1
>A>		4MG/VIAL	N20604 003	JUL 25, 1997	NOV	CRLD			AB1
	TEV-TROPIN								AB1
BX	+ BIO TECH GEN	5MG/ML	N19774 002	JAN 04, 2002	FEB	CTNA			AB2
									AB2
									AB2
	SOTALOL HYDROCHLORIDE							>A>	AB1
	TABLET; ORAL							>A>	AB1
	BETAPACE							>A>	AB1
AB1	BERLEX LABS	80MG	N19865 001	OCT 30, 1992	AUG	CTEC		>A>	AB1
AB1		120MG	N19865 005	APR 20, 1994	AUG	CTEC			AB1
AB1	+	160MG	N19865 002	OCT 30, 1992	AUG	CTEC			AB1
AB1		240MG	N19865 003	OCT 30, 1992	AUG	CTEC			AB1
	BETAPACE AF								AB1
	@ BERLEX LABS	40MG	N21151 006	APR 02, 2003	MAY	DISC			AB1
		40MG	N21151 006	APR 02, 2003	APR	NEWA			
	@	60MG	N21151 007	APR 02, 2003	MAY	DISC			
		60MG	N21151 007	APR 02, 2003	APR	NEWA			

	AB2		80MG	N21151	001	FEB 22, 2000	AUG	CFTG
		@	100MG	N21151	005	MAR 14, 2003	MAY	DISC
			100MG	N21151	005	MAR 14, 2003	MAR	NEWA
	AB2		120MG	N21151	002	FEB 22, 2000	AUG	CFTG
	AB2 +		160MG	N21151	003	FEB 22, 2000	AUG	CFTG
		SORINE						
	AB1	UPSHER SMITH	80MG	N75500	001	APR 27, 2001	AUG	CTEC
	AB1		120MG	N75500	004	APR 27, 2001	AUG	CTEC
	AB1		160MG	N75500	002	APR 27, 2001	AUG	CTEC
	AB1		240MG	N75500	003	APR 27, 2001	AUG	CTEC
		SOTALOL HCL						
	AB1	APOTEX	80MG	N76140	001	SEP 26, 2002	AUG	CTEC
	AB1		120MG	N76140	002	SEP 26, 2002	AUG	CTEC
	AB1		160MG	N76140	003	SEP 26, 2002	AUG	CTEC
	AB1		240MG	N76140	004	SEP 26, 2002	AUG	CTEC
	AB1	EON	80MG	N75366	001	MAY 01, 2000	AUG	CTEC
	AB1		120MG	N75366	002	MAY 01, 2000	AUG	CTEC
	AB1		160MG	N75366	003	MAY 01, 2000	AUG	CTEC
	AB1		240MG	N75366	004	MAY 01, 2000	AUG	CTEC
	AB1	GENPHARM	80MG	N75237	001	MAY 01, 2000	AUG	CTEC
	AB1		120MG	N75237	002	MAY 01, 2000	AUG	CTEC
	AB1		160MG	N75237	003	MAY 01, 2000	AUG	CTEC
	AB1		240MG	N75237	004	MAY 01, 2000	AUG	CTEC
	AB1	IMPAX PHARMS	80MG	N75663	001	NOV 07, 2000	AUG	CTEC
	AB1		120MG	N75663	002	NOV 07, 2000	AUG	CTEC
	AB1		160MG	N75663	003	NOV 07, 2000	AUG	CTEC
	AB1		240MG	N75663	004	NOV 07, 2000	AUG	CTEC
	AB1	MUTUAL PHARM	80MG	N75515	001	OCT 15, 2001	AUG	CTEC
	AB1		120MG	N75515	004	OCT 15, 2001	AUG	CTEC
	AB1		160MG	N75515	002	OCT 15, 2001	AUG	CTEC
	AB1		240MG	N75515	003	OCT 15, 2001	AUG	CTEC
	AB1	MYLAN	80MG	N75725	001	DEC 19, 2000	AUG	CTEC
	AB1		120MG	N75725	002	DEC 19, 2000	AUG	CTEC
	AB1		160MG	N75725	003	DEC 19, 2000	AUG	CTEC
	AB1		240MG	N75725	004	DEC 19, 2000	AUG	CTEC
	AB1	TEVA	80MG	N75429	001	MAY 01, 2000	AUG	CTEC
	AB1		120MG	N75429	002	MAY 01, 2000	AUG	CTEC
	AB1		160MG	N75429	003	MAY 01, 2000	AUG	CTEC
	AB1		240MG	N75429	004	MAY 01, 2000	AUG	CTEC
	AB2	TORPHARM	80MG	N76214	001	AUG 27, 2003	AUG	NEWA
	AB2		120MG	N76214	002	AUG 27, 2003	AUG	NEWA
	AB2		160MG	N76214	003	AUG 27, 2003	AUG	NEWA
>A>	AB1	VINTAGE PHARMS	80MG	N75563	001	NOV 07, 2003	NOV	NEWA
>A>	AB1		120MG	N75563	002	NOV 07, 2003	NOV	NEWA
>A>	AB1		160MG	N75563	003	NOV 07, 2003	NOV	NEWA
>A>	AB1		240MG	N75563	004	NOV 07, 2003	NOV	NEWA
	AB1	WATSON LABS	80MG	N75238	001	JUL 13, 2000	AUG	CTEC
	AB1		120MG	N75238	002	JUL 13, 2000	AUG	CTEC
	AB1		160MG	N75238	003	JUL 13, 2000	AUG	CTEC
	AB1		240MG	N75238	004	JUL 13, 2000	AUG	CTEC

		STANOZOLOL						
		TABLET; ORAL						
		WINSTROL						
	+	OVATION PHARMS	2MG	N12885 001	MAY 14, 1984	JUL	CAHN
	@	WINSTROL	2MG	N12885 001	MAY 14, 1984	AUG	DISC
		STREPTOZOCIN						
		INJECTABLE; INJECTION						
		ZANOSAR						
	+	GENSIA SICOR PHARMS	1GM/VIAL	N50577 001	MAY 07, 1982	JUN	CAHN
		STRONTIUM CHLORIDE, SR-89						
		INJECTABLE; INJECTION						
		METASTRON						
AP	+	AMERSHAM HLTH	1mCi/ML	N20134 001	JUN 18, 1993	JAN	CFTG
		STRONTIUM CHLORIDE SR-89						
AP		BIO NUCLEONICS	1mCi/ML	N75941 001	JAN 06, 2003	JAN	NEWA
		SUCCIMER						
		CAPSULE; ORAL						
		CHEMET						
	+	OVATION PHARMS	100MG	N19998 002	JAN 30, 1991	JUL	CAHN
		SUCRALFATE						
		SUSPENSION; ORAL						
		CARAFATE						
>D>	+	AVENTIS PHARMS	1GM/10ML	N19183 001	DEC 16, 1993	NOV	CAHN
>A>	+	AXCAN SCANDIPHARM	1GM/10ML	N19183 001	DEC 16, 1993	NOV	CAHN
		SULFAMETHOXAZOLE; TRIMETHOPRIM						
		INJECTABLE; INJECTION						
		SEPTRA						
	@	MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001		MAY	DISC
		SULFANILAMIDE						
		SUPPOSITORY; VAGINAL						
		AVC						
	@	NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	SEP	DISC
		SULINDAC						
		TABLET; ORAL						
		SULINDAC						
	@	CLONMEL HLTHCARE	150MG	N73261 001	SEP 06, 1991	JUN	DISC
	@		200MG	N73262 001	SEP 06, 1991	JUN	DISC
>A>		TADALAFIL						
>A>		TABLET; ORAL						
>A>		CIALIS						
>A>		LILLY ICOS	5MG	N21368 001	NOV 21, 2003	NOV	NEWA
>A>			10MG	N21368 002	NOV 21, 2003	NOV	NEWA
>A>	+		20MG	N21368 003	NOV 21, 2003	NOV	NEWA

			TAMOXIFEN CITRATE						
			TABLET; ORAL						
			NOLVADEX						
JUL	CAHN	AB	ASTRAZENECA	EQ 10MG BASE	N17970 001			FEB	CTEC
AUG	DISC	AB +		EQ 20MG BASE	N17970 002	MAR 21, 1994		FEB	CTEC
			TAMOXIFEN CITRATE						
		AB	AEGIS PHARMS	EQ 10MG BASE	N76398 001	MAR 31, 2003		MAR	NEWA
		AB		EQ 20MG BASE	N76398 002	MAR 31, 2003		MAR	NEWA
		AB	ANDRX PHARMS	EQ 10MG BASE	N76179 001	FEB 20, 2003		FEB	NEWA
JUN	CAHN	AB		EQ 20MG BASE	N76179 002	FEB 20, 2003		FEB	NEWA
		AB	BARR	EQ 10MG BASE	N70929 001	FEB 20, 2003		FEB	NEWA
		AB		EQ 20MG BASE	N70929 002	FEB 20, 2003		FEB	NEWA
		AB	IVAX PHARMS	EQ 10MG BASE	N75740 001	FEB 20, 2003		FEB	NEWA
		AB		EQ 20MG BASE	N75740 002	FEB 20, 2003		FEB	NEWA
JAN	CFTG	AB	MYLAN	EQ 10MG BASE	N74732 002	FEB 20, 2003		FEB	NEWA
		AB		EQ 20MG BASE	N74732 001	FEB 20, 2003		FEB	NEWA
JAN	NEWA	AB	PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAR 31, 2003		APR	CAHN
		AB		EQ 20MG BASE	N74858 001	FEB 20, 2003		FEB	NEWA
		AB	ROXANE	EQ 10MG BASE	N76027 001	FEB 20, 2003		FEB	NEWA
		AB		EQ 20MG BASE	N76027 002	FEB 20, 2003		FEB	NEWA
		AB	TEVA	EQ 10MG BASE	N74504 001	APR 28, 2003		APR	NEWA
JUL	CAHN	AB		EQ 10MG BASE	N74539 001	MAR 31, 2003		MAR	NEWA
		AB		EQ 10MG BASE	N75797 001	FEB 20, 2003		FEB	NEWA
		AB		EQ 20MG BASE	N74504 002	APR 28, 2003		APR	NEWA
			TECHNETIUM TC-99M MEDRONATE KIT						
NOV	CAHN		INJECTABLE; INJECTION						
NOV	CAHN		TECHNESCAN MDP KIT						
		AP +	DRAXIMAGE	N/A	N18035 001			MAR	CRLD
			TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT						
			INJECTABLE; INJECTION						
MAY	DISC		PYROLITE						
			@ CIS	N/A	N17684 001			MAY	DISC
			TELMISARTAN						
			TABLET; ORAL						
SEP	DISC		MICARDIS						
			BOEHRINGER INGELHEIM	20MG	N20850 003	APR 04, 2000		JUL	CRLD
			TESTOSTERONE						
			GEL; TOPICAL						
JUN	DISC		ANDROGEL						
JUN	DISC	BX +	UNIMED PHARMS	1%	N21015 001	FEB 28, 2000		APR	CTEC
			TESTIM						
		BX +	AUXILIUM A2	1%	N21454 001	OCT 31, 2002		APR	CTEC
			TABLET, EXTENDED RELEASE; BUCCAL						
			STRIANT						
NOV	NEWA	+	COLUMBIA LABS	30MG	N21543 001	JUN 19, 2003		JUN	NEWA
NOV	NEWA								
NOV	NEWA								

TESTOSTERONE ENANTHATE
INJECTABLE; INJECTION
DELATESTRYL
@ SAVIENT PHARMS 200MG/ML N09165 001 OCT CAHN
AO + 200MG/ML N09165 003 OCT CAHN

TETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
ACHROMYCIN V
@ CLONMEL HLTHCARE 250MG N50278 003 JUN DISC
@ 500MG N50278 001 JUN DISC
SUMYCIN
AB + APOTHECON 500MG N60429 003 JUN CRLD
TETRACYCLINE HCL
AB AXIOM PHARM 250MG N60736 001 MAY CAHN
AB 500MG N60736 002 MAY CAHN
@ ROXANE 500MG N61214 002 OCT DISC
FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE
@ ALZA 12.7MG/FIBER N50653 001 MAR 25, 1994 JUN DISC

THALIDOMIDE
CAPSULE; ORAL
THALOMID
CELGENE 50MG N20785 001 JUL 16, 1998 AUG CRLD
100MG N20785 002 JAN 17, 2003 JAN NEWA
+ 200MG N20785 003 JAN 17, 2003 JAN NEWA

THALLOUS CHLORIDE, TL-201
INJECTABLE; INTRAVENOUS
THALLOUS CHLORIDE TL 201
+ BRISTOL MYERS SQUIBB 2mCi/ML N17806 002 OCT 09, 1998 OCT NEWA

THEOPHYLLINE
SYRUP; ORAL
SLO-PHYLLIN
@ AVENTIS 80MG/15ML N85187 001 AUG DISC >D>
>A>
TABLET; ORAL
@ AVENTIS 100MG N85202 001 AUG DISC >D>
@ 200MG N85204 001 AUG DISC >A>
TABLET, EXTENDED RELEASE; ORAL
THEO-DUR
@ SCHERING 100MG N85328 001 SEP DISC
@ 200MG N86998 001 SEP DISC
@ 300MG N85328 002 SEP DISC
@ 450MG N89131 001 JUN 25, 1986 SEP DISC
THEOPHYLLINE
AB PLIVA 300MG N89763 001 APR 30, 1990 AUG CRLD
UNI-DUR
@ SCHERING 600MG N89823 001 JAN 04, 1995 SEP DISC

	THIAMINE HYDROCHLORIDE					
	INJECTABLE; INJECTION					
	THIAMINE HCL					
	@ WYETH AYERST	100MG/ML	N80553 001		JUN	DISC
	THIETHYLPERAZINE MALEATE					
	SUPPOSITORY; RECTAL					
	TORECAN					
	@ NOVARTIS	10MG	N13247 001		JUN	DISC
	THIOTEPA					
	INJECTABLE; INJECTION					
	THIOPLEX					
	@ IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	JUL	DISC
	THIOTEPA					
AP +	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	JUL	CRLD
	THIOTHIXENE					
	CAPSULE; ORAL					
	NAVANE					
AB	PFIZER	1MG	N16584 001		FEB	CAHN
AB		2MG	N16584 002		FEB	CAHN
AB +		5MG	N16584 003		FEB	CAHN
AB		10MG	N16584 004		FEB	CAHN
		20MG	N16584 005		FEB	CAHN
	THIOTHIXENE HYDROCHLORIDE					
	CONCENTRATE; ORAL					
AA +	PFIZER	EQ 5MG BASE/ML	N16758 001		FEB	CAHN
	INJECTABLE; INJECTION					
	@ PFIZER	EQ 2MG BASE/ML	N16904 001		FEB	CAHN
	+	EQ 10MG BASE/VIAL	N16904 002		FEB	CAHN
	TIMOLOL MALEATE					
	SOLUTION/DROPS; OPHTHALMIC					
	TIMOLOL MALEATE					
>D>	@ FALCON PHARMS	EQ 0.25% BASE	N74261 001	APR 28, 1995	NOV	CMFD
>A> AT		EQ 0.25% BASE	N74261 001	APR 28, 1995	NOV	CMFD
>D>	@	EQ 0.5% BASE	N74262 001	APR 28, 1995	NOV	CMFD
>A> AT		EQ 0.5% BASE	N74262 001	APR 28, 1995	NOV	CMFD
	TIROFIBAN HYDROCHLORIDE					
	INJECTABLE; INJECTION					
	AGGRASTAT					
	+ GUILFORD PHARMS	EQ 0.05MG BASE/ML	N20913 001	MAY 14, 1998	OCT	CAHN
	+	EQ 0.25MG BASE/ML	N20912 001	MAY 14, 1998	OCT	CAHN
	TIZANIDINE HYDROCHLORIDE					
	TABLET; ORAL					
	TIZANIDINE HCL					
AB	AMIDE PHARM	EQ 2MG BASE	N76281 001	OCT 20, 2003	OCT	NEWA
AB		EQ 4MG BASE	N76281 002	OCT 20, 2003	OCT	NEWA

AB	BARR	EQ 2MG BASE	N76371 001	APR 09, 2003	APR	NEWA
AB		EQ 4MG BASE	N76371 002	APR 09, 2003	APR	NEWA
AB	CARACO	EQ 2MG BASE	N76416 001	SEP 29, 2003	SEP	NEWA
AB		EQ 4MG BASE	N76416 002	SEP 29, 2003	SEP	NEWA
AB	MYLAN	EQ 2MG BASE	N76354 001	MAR 28, 2003	MAR	NEWA
AB		EQ 4MG BASE	N76354 002	MAR 28, 2003	MAR	NEWA

TOBRAMYCIN SULFATE
INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

	@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	AUG	CAHN
	@	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	AUG	CAHN
AP		EQ 40MG BASE/ML	N63117 001	APR 26, 1991	AUG	CAHN
AP		EQ 40MG BASE/ML	N63118 001	JUL 29, 1991	AUG	CAHN
	@	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	AUG	CAHN

TOLBUTAMIDE
TABLET; ORAL
TOLBUTAMIDE

	@ CLONMEL HLTHCARE	500MG	N86926 001		JUL	DISC

TOLBUTAMIDE SODIUM
INJECTABLE; INJECTION
ORINASE DIAGNOSTIC

	@ PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N12095 001		JUN	DISC

TORSEMIDE
TABLET; ORAL
TORSEMIDE

AB	PAR PHARM	5MG	N76226 001	MAY 27, 2003	MAY	NEWA
AB		10MG	N76226 002	MAY 27, 2003	MAY	NEWA
AB		20MG	N76226 003	MAY 27, 2003	MAY	NEWA
AB		100MG	N76226 004	MAY 27, 2003	MAY	NEWA
AB	PLIVA PHARM IND	5MG	N76346 001	MAY 30, 2003	MAY	NEWA
AB		10MG	N76346 002	MAY 30, 2003	MAY	NEWA
AB		20MG	N76346 003	MAY 30, 2003	MAY	NEWA

TRAMADOL HYDROCHLORIDE
TABLET; ORAL
TRAMADOL HCL

AB	IVAX PHARMS	50MG	N75963 001	JUL 03, 2002	MAR	CAHN

TRIAMCINOLONE ACETONIDE
AEROSOL, METERED; NASAL
NASACORT

	@ AVENTIS	0.055MG/INH	N19798 001	JUL 11, 1991	JUL	DISC

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	ALTANA	0.025%	N40467 001	APR 21, 2003	APR	NEWA
AT		0.1%	N40467 002	APR 21, 2003	APR	NEWA

SPRAY, METERED; NASAL
TRI-NASAL

	@ COLLEGIUM	0.05MG/SPRAY	N20120 001	FEB 04, 2000	JUL	CAHN

APR	NEWA								
APR	NEWA			TRICHLORMETHIAZIDE					
SEP	NEWA			TABLET; ORAL					
SEP	NEWA			METAHYDRIN					
MAR	NEWA			@ AVENTIS PHARMS	2MG	N12594 001	JUN 16, 1988	MAY	DISC
MAR	NEWA			@	4MG	N12594 002	JUN 16, 1988	MAY	DISC
				TRIHEXYPHENIDYL HYDROCHLORIDE					
				ELIXIR; ORAL					
				ARTANE					
AUG	CAHN			@ LEDERLE	2MG/5ML	N06773 009		JUN	DISC
AUG	CAHN			TRIHEXYPHENIDYL HCL					
AUG	CAHN		AA	+ PHARM VENTURES	2MG/5ML	N89514 001	APR 07, 1989	JUN	CRLD
AUG	CAHN			TABLET; ORAL					
AUG	CAHN			ARTANE					
				@ LEDERLE	2MG	N06773 005		JUN	DISC
				@	5MG	N06773 003		JUN	DISC
		>D>		TRIHEXYPHENIDYL HCL					
		>D>	AA	NYLOS	5MG	N85622 001		NOV	DISC
JUL	DISC	>A>		@	5MG	N85622 001		NOV	DISC
			AA	+ WATSON LABS	2MG	N84363 001		JUN	CRLD
			AA	+	5MG	N84364 001		JUN	CRLD
				TRIMETHOBENZAMIDE HYDROCHLORIDE					
JUN	DISC			CAPSULE; ORAL					
				TIGAN					
			AB	+ KING PHARMS	300MG	N17531 006	DEC 13, 2001	AUG	CFTG
				TRIMETHOBENZAMIDE HCL					
			AB	AMIDE PHARM	300MG	N76546 001	AUG 20, 2003	AUG	NEWA
MAY	NEWA		AB	MUTUAL PHARMA	300MG	N76570 001	AUG 28, 2003	AUG	NEWA
MAY	NEWA								
MAY	NEWA			TRIMETHOPRIM					
MAY	NEWA			TABLET; ORAL					
MAY	NEWA			PROLOPRIM					
MAY	NEWA			@ MONARCH PHARMS	200MG	N17943 003	JUL 14, 1982	MAY	DISC
MAY	NEWA			TRIMETHOPRIM					
				+ TEVA	200MG	N71259 001	JUN 18, 1987	MAY	CRLD
				TRIPELENNAMINE HYDROCHLORIDE					
				TABLET; ORAL					
MAR	CAHN			PBZ					
		>D>		+ NOVARTIS	25MG	N83149 001		NOV	DISC
		>A>		@	25MG	N83149 001		NOV	DISC
		>D>		TRIPELENNAMINE HCL					
		>D>	AA	LANNETT	50MG	N83557 001		NOV	DISC
JUL	DISC	>A>		@	50MG	N83557 001		NOV	DISC
		>D>	AA	NYLOS	50MG	N85412 001		NOV	DISC
		>A>		@	50MG	N85412 001		NOV	DISC
APR	NEWA	>D>	AA	WATSON LABS	50MG	N80713 001		NOV	DISC
APR	NEWA	>A>		@	50MG	N80713 001		NOV	DISC
JUL	CAHN								

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)							
CREAM; VAGINAL							
GYNE-SULF							
@ G AND W LABS		3.7%;2.86%;3.42%	N88607 001	JUN 09, 1986	OCT	DISC
SULTRIN							
@ ORTHO MCNEIL PHARM		3.7%;2.86%;3.42%	N05794 001		AUG	DISC
TRIPLE SULFA							
@ ALPHARMA		3.7%;2.86%;3.42%	N87864 001	SEP 01, 1982	OCT	WDAG
@ CLAY PARK		3.7%;2.86%;3.42%	N87285 001	NOV 15, 1982	OCT	DISC
TRYSUL							
@ SAVAGE LABS		3.7%;2.86%;3.42%	N87887 001	JUL 23, 1982	OCT	DISC
UREA, C-13							
FOR SOLUTION; ORAL							
HELICOSOL							
@ METABOLIC SOLUTIONS		125MG/VIAL	N21092 001	DEC 17, 1999	MAY	DISC
PYLORI-CHEK BREATH TEST							
@ DXS DEVICES		100MG/VIAL	N20900 001	FEB 04, 1999	MAR	CAHN
VALPROATE SODIUM							
INJECTABLE; INJECTION							
VALPROATE SODIUM							
AP	AM PHARM	EQ 100MG BASE/ML	N76539 001	JUN 26, 2003	JUN	NEWA
VALSARTAN							
TABLET; ORAL							
DIOVAN							
	NOVARTIS	40MG	N21283 004	AUG 14, 2002	JUL	NEWA
VANCOMYCIN HYDROCHLORIDE							
FOR SOLUTION; ORAL							
VANCOCIN HCL							
+	LILLY	EQ 250MG BASE/5ML	N61667 002	JUL 13, 1983	JUN	CTEC
VANCOLED							
@ LEDERLE		EQ 250MG BASE/5ML	N63321 002	OCT 15, 1993	JUN	DISC
INJECTABLE; INJECTION							
AP +	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62682 001	JUL 22, 1986	AUG	CAHN
AP +		EQ 1GM BASE/VIAL	N62682 002	MAR 30, 1988	AUG	CAHN
+		EQ 2GM BASE/VIAL	N62682 003	MAY 11, 1988	AUG	CAHN
AP +		EQ 5GM BASE/VIAL	N62682 004	MAY 11, 1988	AUG	CAHN
AP +		EQ 10GM BASE/VIAL	N62682 005	MAY 11, 1988	AUG	CAHN
VANCOMYCIN HCL							
@ BAXTER HLTHCARE		EQ 500MG BASE/VIAL	N62879 001	AUG 02, 1988	AUG	CAHN
@		EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988	AUG	CAHN
VARDENAFIL HYDROCHLORIDE							
TABLET; ORAL							
LEVITRA							
	BAYER PHARMS	2.5MG	N21400 003	AUG 19, 2003	AUG	NEWA
		5MG	N21400 001	AUG 19, 2003	AUG	NEWA
		10MG	N21400 002	AUG 19, 2003	AUG	NEWA
+		20MG	N21400 004	AUG 19, 2003	AUG	NEWA

VECURONIUM BROMIDE
INJECTABLE; INJECTION
NORCURON
@ ORGANON 10MG/VIAL N18776 002 APR 30, 1984 MAY DISC
VECURONIUM BROMIDE
AP BAXTER HLTHCARE 10MG/VIAL N75218 001 AUG 23, 1999 AUG CAHN
AP 20MG/VIAL N75218 002 AUG 23, 1999 AUG CAHN
AP + BEDFORD 10MG/VIAL N75549 001 JUN 13, 2000 MAY CRLD

VENLAFAXINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR
WYETH PHARMS INC EQ 37.5MG BASE N20699 001 OCT 20, 1997 MAR CAHN
EQ 75MG BASE N20699 002 OCT 20, 1997 MAR CRLD
@ EQ 100MG BASE N20699 003 OCT 20, 1997 MAR CAHN
+ EQ 150MG BASE N20699 004 OCT 20, 1997 MAR CRLD
TABLET; ORAL
EFFEXOR
@ WYETH PHARMS INC EQ 12.5MG BASE N20151 001 DEC 28, 1993 MAR CAHN
EQ 25MG BASE N20151 002 DEC 28, 1993 MAR CRLD
EQ 37.5MG BASE N20151 006 DEC 28, 1993 MAR CAHN
EQ 50MG BASE N20151 003 DEC 28, 1993 MAR CAHN
EQ 75MG BASE N20151 004 DEC 28, 1993 MAR CAHN
+ EQ 100MG BASE N20151 005 DEC 28, 1993 MAR CAHN

VERAPAMIL HYDROCHLORIDE
TABLET; ORAL
VERAPAMIL HCL
@ CLONMEL HLTHCARE 80MG N71880 001 APR 05, 1988 JUL DISC
@ 120MG N71881 001 APR 05, 1988 JUL DISC

VIDARABINE
OINTMENT; OPHTHALMIC
VIRA-A
@ PARKEDALE 3% N50486 001 MAY DISC

VINCRISTINE SULFATE
INJECTABLE; INJECTION
VINCASAR PFS
AP GENSIA SICOR PHARMS 1MG/ML N71426 001 JUL 17, 1987 JUL CAHN
VINCRISTINE SULFATE
AP AM PHARM 1MG/ML N76401 001 OCT 28, 2003 OCT NEWA
AP + AM PHARM PARTNERS 1MG/ML N76296 001 DEC 20, 2002 OCT CTEC
VINCRISTINE SULFATE PFS
AP SICOR PHARMS 1MG/ML N75493 001 SEP 01, 1999 JUL CAHN

VINORELBINE TARTRATE
INJECTABLE; INJECTION
NAVELBINE
AP + GLAXOSMITHKLINE EQ 10MG BASE/ML N20388 001 DEC 23, 1994 FEB CFTG
VINORELBINE TARTRATE
AP ESI LEDERLE EQ 10MG BASE/ML N75992 001 JUN 10, 2003 JUN NEWA

AP	GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N76028 001	FEB 03, 2003	FEB	NEWA
	WARFARIN SODIUM					
	TABLET; ORAL					
	JANTOVEN					
AB	USL PHARMA	1MG	N40416 001	OCT 02, 2003	OCT	NEWA
AB		2MG	N40416 002	OCT 02, 2003	OCT	NEWA
AB		2.5MG	N40416 003	OCT 02, 2003	OCT	NEWA
AB		3MG	N40416 004	OCT 02, 2003	OCT	NEWA
AB		4MG	N40416 005	OCT 02, 2003	OCT	NEWA
AB		5MG	N40416 006	OCT 02, 2003	OCT	NEWA
AB		6MG	N40416 007	OCT 02, 2003	OCT	NEWA
AB		7.5MG	N40416 008	OCT 02, 2003	OCT	NEWA
AB		10MG	N40416 009	OCT 02, 2003	OCT	NEWA
	XENON, XE-133					
	GAS; INHALATION					
	XENON XE 133					
	GEN ELECTRIC	5-100 CI/CYLINDER	N17550 001		JUL	CPOT
		0.25-5 CI/AMP	N17550 003		JUL	CPOT
	ZALEPLON					
	CAPSULE; ORAL					
	SONATA					
	JONES PHARMA	5MG	N20859 001	AUG 13, 1999	JUN	CAHN
+		10MG	N20859 002	AUG 13, 1999	JUN	CAHN
	ZOLEDRONIC ACID					
	INJECTABLE; IV (INFUSION)					
	ZOMETA					
+	NOVARTIS	EQ 4MG BASE/5ML	N21223 002	MAR 07, 2003	MAR	NEWA
	ZOLMITRIPTAN					
	SPRAY; NASAL					
	ZOMIG					
+	ASTRAZENECA	5MG/SPRAY	N21450 004	SEP 30, 2003	SEP	NEWA
	ZONISAMIDE					
	CAPSULE; ORAL					
	ZONEGRAN					
	DAINIPPON	25MG	N20789 003	AUG 22, 2003	AUG	NEWA
		50MG	N20789 002	AUG 22, 2003	AUG	NEWA

>A>

FEB	NEWA							
		ACETAMINOPHEN						
		TABLET, EXTENDED RELEASE; ORAL						
		TYLENOL (CAPLET)						
		+ MCNEIL CONS SPECLT	650MG	N19872 001	JUN 08, 1994	JUN	CTNA	
OCT	NEWA	TYLENOL (GELTAB)						
OCT	NEWA	+ MCNEIL CONS SPECLT	650MG	N19872 002	JAN 11, 2001	JUN	NEWA	
OCT	NEWA							
OCT	NEWA	ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE						
OCT	NEWA	TABLET, CHEWABLE; ORAL						
OCT	NEWA	FOAMICON						
OCT	NEWA	NOVARTIS	80MG;20MG	N72687 001	JUN 28, 1989	MAR	CAHN	
OCT	NEWA	@	80MG;20MG	N72687 001	JUN 28, 1989	OCT	WDAG	
OCT	NEWA							
		CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE						
		@ CENT PHARMS	8MG;120MG	N19428 001	AUG 02, 1988	MAR	DISC	
JUL	CPOT							
JUL	CPOT	CIMETIDINE						
		TABLET; ORAL						
		CIMETIDINE						
		@ LEK PHARMS	100MG	N75122 001	JUN 19, 1998	MAR	CAHN	
			200MG	N75122 002	JUN 19, 1998	MAR	CAHN	
JUN	CAHN							
JUN	CAHN	EPINEPHRINE						
		AEROSOL, METERED; INHALATION						
		BRONKAID MIST						
		@ STERLING	0.25MG/INH	N16803 001		MAY	DISC	
MAR	NEWA	FAMOTIDINE						
		TABLET; ORAL						
		PEPCID AC						
		MERCK	10MG	N20325 001	APR 28, 1995	SEP	CRLD	
		+	20MG	N20325 002	SEP 23, 2003	SEP	NEWA	
SEP	NEWA	PEPCID AC (GELTAB)						
		MERCK	10MG	N20902 001	AUG 05, 1999	AUG	CTNA	
		TABLET, CHEWABLE; ORAL						
		FAMOTIDINE						
		PERRIGO	10MG	N75715 001	AUG 22, 2003	AUG	NEWA	
AUG	NEWA							
AUG	NEWA	GUAIFENESIN						
		TABLET, EXTENDED RELEASE; ORAL						
		MUCINEX						
		ADAMS LABS	600MG	N21282 001	JUL 12, 2002	JAN	CRLD	
		+	1.2GM	N21282 002	DEC 18, 2002	JAN	NEWA	
		IBUPROFEN						
		TABLET; ORAL						
		IBUPROFEN						
>A>		NEIL	200MG	N76460 001	NOV 26, 2003	NOV	NEWA	
		JUNIOR STRENGTH MOTRIN						
		MCNEIL	100MG	N20602 001	JUN 10, 1996	JUN	CRLD	

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HCL

>A>		PERRIGO	100MG/5ML;15MG/5ML	N76478	001	NOV 05, 2003	NOV	NEWA

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HCL

		LNK	2MG	N76497	001	JUN 10, 2003	JUN	NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM ADVANCED

	+	MCNEIL CONS SPECLT	2MG;125MG	N21140	001	NOV 30, 2000	JAN	CRLD

LORATADINE

SYRUP; ORAL

CLARITIN

	+	SCHERING	1MG/ML	N20641	002	NOV 27, 2002	APR	CRLD
			1MG/ML	N20641	002	NOV 27, 2002	MAR	NEWA

CLARITIN HIVES RELIEF

>A>	+	SCHERING	1MG/ML	N20641	003	NOV 19, 2003	NOV	NEWA	>A>

LORATADINE

>A>		TEVA	1MG/ML	N75505	001	NOV 07, 2003	NOV	NEWA

TABLET; ORAL

CLARITIN

	+	SCHERING	10MG	N19658	002	NOV 27, 2002	APR	CRLD
			10MG	N19658	002	NOV 27, 2002	MAR	NEWA

CLARITIN HIVES RELIEF

>A>	+	SCHERING	10MG	N19658	003	NOV 19, 2003	NOV	NEWA

LORATADINE

		GENEVA PHARMS	10MG	N75209	001	JAN 21, 2003	JAN	NEWA
		GENPHARM	10MG	N76154	001	AUG 20, 2003	AUG	NEWA
		RANBAXY	10MG	N76134	001	AUG 18, 2003	AUG	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

		WYETH CONS	10MG	N21375	001	DEC 19, 2002	APR	CRLD

CLARITIN HIVES RELIEF REDITAB

>A>	+	SCHERING	10MG	N20704	003	NOV 19, 2003	NOV	NEWA

CLARITIN REDITABS

	+	SCHERING	10MG	N20704	002	NOV 27, 2002	APR	CRLD	
			10MG	N20704	002	NOV 27, 2002	MAR	NEWA	>D>

LORATADINE

>A>		ANDRX PHARMS	10MG	N75990	001	NOV 03, 2003	NOV	NEWA	>D>
		IMPAX LABS	10MG	N76011	001	SEP 29, 2003	SEP	NEWA	>A>
		WYETH CONS	10MG	N75822	001	FEB 10, 2003	FEB	NEWA	>A>

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

	+	SCHERING	5MG;120MG	N19670	002	NOV 27, 2002	APR	CRLD
			5MG;120MG	N19670	002	NOV 27, 2002	MAR	NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE
TABLET, EXTENDED RELEASE; ORAL
CLARITIN-D 24 HOUR
+ SCHERING 10MG;240MG N20470 002 NOV 27, 2002 APR CRLD
10MG;240MG N20470 002 NOV 27, 2002 MAR NEWA
LORATADINE AND PSEUDOEPHEDRINE HCL
ANDRX PHARMS 10MG;240MG N75706 001 FEB 21, 2003 FEB NEWA
LORATADINE AND PSEUDOEPHEDRINE SULFATE
ANDRX PHARMS 10MG;240MG N75706 001 FEB 21, 2003 OCT CTNA
IMPAX LABS 5MG;120MG N76050 001 JAN 30, 2003 JAN NEWA

MICONAZOLE NITRATE
CREAM; TOPICAL, VAGINAL
MONISTAT 3 COMBINATION PACK
+ PERSONAL PRODS 2%,4% N21261 003 JUN 17, 2003 JUN NEWA
MONISTAT 3 COMBINATION PACK (PREFILLED)
+ PERSONAL PRODS 2%,4% N21261 001 FEB 02, 2001 JUN CTNA
CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT 1 COMBINATION PACK
>A> + PERSONAL PRODS 1.2GM,2% N21308 001 JUN 29, 2001 NOV NEWA

MINOXIDIL
SOLUTION; TOPICAL
MINOXIDIL EXTRA STRENGTH (FOR MEN)
MORTON GROVE 5% N75438 001 FEB 27, 2003 FEB NEWA

NICOTINE
FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP
+ AVEVA 11MG/24HR N19983 003 DEC 23, 1998 OCT CAHN
+ 22MG/24HR N19983 004 DEC 23, 1998 OCT CAHN

NICOTINE POLACRILEX
TROCHE/LOZENGE; ORAL
COMMIT
GLAXOSMITHKLINE CONS EQ 2MG BASE N21330 001 OCT 31, 2002 SEP CPOT
+ EQ 4MG BASE N21330 002 OCT 31, 2002 SEP CPOT

OMEPRAZOLE MAGNESIUM
TABLET, DELAYED RELEASE; ORAL
>D> PRILOSEC
>D> + ASTRAZENECA EQ 20MG BASE N21229 001 JUN 20, 2003 NOV CTNA
+ EQ 20MG BASE N21229 001 JUN 20, 2003 JUN NEWA
>A> PRILOSEC OTC
>A> + ASTRAZENECA EQ 20MG BASE N21229 001 JUN 20, 2003 NOV CTNA

PERMETHRIN
LOTION; TOPICAL
NIX
+ INSIGHT PHARMS 1% N19918 001 MAY 02, 1990 MAR CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER '03

NO NOVEMBER 2003 APPROVALS

This data is provided to the Office of Generic Drugs from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
November 2003

Generic Name/ Trade Name (if present):	Date Designated = DD Date Approved= MA	Indication Designated:	Sponsor and Address
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	BioMedicines, Inc. 2000 Powell Street
	MA:		Suite 1640 Emeryville CA 94608
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	DD: 7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc. 3130 Highland Ave.
	MA:		Third Floor Cincinnati OH 45219
1,1'-[1,4-phenylenebis(methylene)-bis-1,4,8,11-tetraazacyclotetradecan	DD: 7/10/2003	For combination use with filgrastim to improve the yield of progentor cells in the apheresis product for subsequest stem cell	AnorMED Inc. 200-20353 64th Avenue
	MA:	transplantation following myelosuppressive or myeloablative chemotherapy	Langley, BC, V2Y IN5
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003	Treatment of mitochondrial disease	Repligen Corporation 41 Seyon Street Building 1, Suite 100
	MA:		Waltham MA 02453
2-(3-diethylaminopropyl)-8,8-dipro Inc. pyl-2-azaspiro [4,5] decan dimaleate	DD: 12/2/2003	Treatment of mulitple myeloma and	Callisto Pharmaceuticals,
Atiprimod	MA:	associated bone resorption	2 Executive Drive
	MA:		Suite 450 Somerset NJ 08873
2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	DD: 8/15/2003	Treatment of cystic fibrosis	Inologic, Inc. 101 Elliott Ave., West
	MA:		Seattle WA 98119
4,5-dibromorhodamine 123 Theralux Irradiation Device	DD: 4/10/2003	Treatment of chronic myelogenous leukemia	Celmed BioSciences Inc. 2310 boul Alfred-Nobel
	MA:		Saint-Laurent, Quebec
5,5',5"-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	DD: 8/20/2003	Treatment of pancreatic cancer	Now Pharm AG 241, route d'Arlon
	MA:		L-1150

Orphan Products Designations and Approvals List
November 2003

a-(3-aminophthalimido) Actimid	DD: 1/15/2003 MA: MA:	Treatment of multiple myeloma	Celgene Corporation 7 Powder Horn Drive Warren NJ 07059
a-Galactosidase A Corporation Plant-Produced Human a-Glactosidase	DD: 1/21/2003 MA:	Treatment of Fabry's disease	Large Scale Biology 3333 Vacaville Parkway Suite 1000 Vacaville CA 95688
ACA125 Laboratories	DD: MA:	Treatment of epithelial ovarian cancer	CellControl Biomedical AG Am Klopferspitz 19 D-82152
alendronate Fosamax	DD: 3/31/2003 MA:	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
alteplase University Activase University Jefferson 1-109	DD: 1/27/2003 MA:	Treatment of intraventricular hemmorage associated with intracerebral hemmorrhage	Daniel F. Hanley, MD Johns Hopkins Johns Hopkins 600 N. Wolfe St., Baltimore MD 21287
AMG 531 Drive 91320-1799	DD: 3/27/2003 MA:	Treatment of immune thrombocytopenic purpura.	Amgen, Inc. One Amgen Center Thousand Oaks CA
anti-CD23 IgG1, kappa monoclonal Inc. antibody	DD: 2/12/2003 MA:	Treatment of chronic lymphocytic leukemia	IDEC Pharmaceuticals, 3030 Callan Road San Diego CA 92121
Anti-CEA Sheep-human chimeric monoclonal antibody labeled Court w/iodine-131 (KAb201)	DD: 5/21/2003 MA:	Treatment of pancreatic cancer	KS Biomedix Ltd Ground Floor, 1 Occam Surrey Research Park
anti-interferon-gamma Fab from Inc. goats Blvd. 91367	DD: MA:	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, 6355 Topanga Canyon Suite 510 Woodland Hills CA

Orphan Products Designations and Approvals List
November 2003

antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] GTI-2040	DD: 3/12/2003 MA: MA:	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc 2 Meridan Road Toronto, Ontario
arsenic trioxide Trisenox	DD: 5/13/2003 MA:	Treatment of chronic lymphocytic leukemia	Cell Therapeutics, Inc. 501 Elliott avenue West Suite 400 Seattle WA 98119
arsenic trioxide Trisenox	DD: 6/13/2003 MA:	Treatment of liver cancer	Cell Therapeutics, Inc. 501 Elliott Avenue West Suite 400 Seattle WA 98119
Atomoxetine hydrochloride STRATTERA	DD: 8/26/2003 MA:	Treatment of Tourette's Syndrome	ELI LILLY & Company Lilly Corporate Center Indianapolis IN 46285
baclofen NE 55432-5604	DD: 12/2/2003 MA:	Treatment of dystonia	Medtronic Neurological 710 Medtronic Parkway Minneapolis MN
bifidobacterium longum infantis Limited 35624	DD: 1/16/2003 MA:	Treatment of pediatric Crohn's disease	Alimentary Health Guardwell, Kinsale
bortezomib Pharmaceuticals, Inc. VELCADE	DD: 1/15/2003 MA:	To treat multiple myeloma	Millennium 75 Sidney Street Cambridge MA 02139
Capsaicin Park 4117	DD: 5/2/2003 MA:	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc. San Carlos Business 981F Industrial Road San Carols CA 94070-
Carboxypeptidase G2 Suite 405	DD: 8/19/2003 MA:	Treatment of patients at risk of methotrexate toxicity	Protherics, Inc. 5214 Maryland Way, Brentwood TN 37027
cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanolic acid)	DD: 7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Dr. Falk Pharma GmbH Leinenweberstrasse 5

Orphan Products Designations and Approvals List
November 2003

Falkochol	MA: MA:		Postfach 6529
cinacalcet Drive 91320-1799	DD: 5/12/2003 MA:	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc. One Amgen Center Thousand Oaks CA
Combretastatin A4 Phosphate	DD: 7/23/2003 MA: MA:	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc 321 Arsenal Street Watertown MA 02472
conjugated bile acids COBARTin 4317	DD: 7/18/2003 MA:	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc. 1824 S. Robertson Blvd. 1824 S. Robertson Blvd. Los Angeles CA 90035-
cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	DD: 8/15/2003 MA:	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center Division of Pediatric Allergy & Immunology Erwin Road Durham NC 27710
cyclosporin	DD: MA:	Prophylaxis of acute rejection in patients requiring allogenic lung transplant	Chiron Corporation 4560 Horton Street Emeryville CA 94608
cyclosporine	DD: MA: MA:	For the treatment of refractory acute rejection in patients requiring allogenic lung transplants.	Chiron Corporation 4560 Horton Street Emeryville CA 94608
debrase Debridase Floor	DD: 8/20/2003 MA:	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd. 3, Azrieli Center 3, Azrieli Center Triangular Tower 45th
Defibrotide (CO)	DD: 5/21/2003 MA:	For the treatment of hepatic veno-occlusive disease	Gentium SpA Piazza XX Settembre, 2 22079 Villa Guardia
Dehydroepiandrosterone (DHEA) Avenue Suite Fidelin Avenue Suite	DD: 8/19/2003 MA:	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc. 6111 Royalmount 6111 Royalmount Montreal, Quebec

Orphan Products Designations and Approvals List
November 2003

dextran 1	DD: 3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600
	MA:		
DHA-paclitaxel Boulevard Taxoprexin Boulevard	DD: 5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance 2200 Renaissance Suite 450 King of Prussia PA
	MA:		
19406 diferuloylmethane LLC	DD: 6/13/2003	Treatment of cystic fibrosis	Seer Pharmarceuticals, P. O. Box 138 Southport CT 06890
	MA:		
diphenylcyclopenone	DD: 6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis	Lloyd E. King, Jr. 1900 Patterson Street Suite 104
	MA:		
	MA:	[AT]/Alopecia Universalis [AU])	Nashville TN 37203
eculizumab Pharmaceuticals, Inc.	DD: 8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion 352 Knotter Drive Cheshire CT 06410
	MA:		
Erlotinib Hydrochloride Tarceva 94080-4990	DD: 7/18/2003	Treatment of malignant gliomas	Genentech, Inc 1 DNA Way South San Francisco CA
	MA:		
Factor XIII [A2] homodimer, recombinant DNA origin East	DD: 5/21/2003	Treatment of congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue
	MA:		Seattle WA 98102
Factor XIII {A2} homodimer, recombinant DNA origin East	DD: 11/6/2003	For the prophylaxis of bleeding associated with congential FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue
	MA:		Seattle WA 98102
ferric hexacyanoferrate (II) "Prussian Blue"	DD: 6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG Weissfrauenstr.9 D-60287 Frankfurt
	MA:		

Orphan Products Designations and Approvals List
November 2003

HepeX-B Biopharmaceuticals, Ltd.	DD: 7/15/2003	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	XTL Kiryat Weizmann Science Park Bldg 3
	MA: MA:		
Human Anti-tumor Necrosis factor alpha monoclonal antibody Parkway 1307	DD: 1/16/2003 MA:	Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Centocor, Inc. 200 Great Valley Malvern PA 19355-
human gammaglobulin Inc. Road	DD: MA:	Treatment of idiopathic inflammatory myopathies	Protein Therapeutics, 2761 N. Country Club Suite 202 Tucson AZ 85716
hydroxocobalamin Inc. Cyanokit Suite 500	DD: MA:	Treatment of acute cyanide poisoning	EMD Pharmaceuticals, P. O. Box 13319 2311 Shannon Road, Durham NC 27707
Icatbant	DD: MA:	Treatment of angioedema	Jerini AG Invalidenstr. 130 10115 Berlin
IDN 6556 Inc.	DD: 8/19/2003 MA:	Treatment of patients undergoing solid organ transplantation.	Idun Pharmaceuticals, 9380 Judicial drive San Diego CA 92121
imexon CorporationAmpliMed,	DD: 11/1/2003 MA:	Treatment of pancreatic adenocarcinoma	AmpliMed, Corporation 2321 Camino La Zorrela Tucson AZ 85718
infliximab Remicade Parkway 1307	DD: 5/6/2003 MA:	Treatment of giant cell arteritis	Centocor, Inc. 200 Great Valley Malvern PA 19355-
infliximab Remicade Parkway 1307	DD: 5/21/2003 MA:	Treatment of chronic sarcoidosis	Centocor, Inc. 200 Great Valley Malvern PA 19355-

Orphan Products Designations and Approvals List
November 2003

infliximab Parkway REMICADE Parkway 1307	DD: MA:	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc. 200 Great Valley 200 Great Valley Malvern PA 19355-
infliximab Parkway REMICADE Parkway 1307	DD: MA:	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Centocor, Inc. 200 Great Valley 200 Great Valley Malvern PA 19355-
INGN 201 Inc. ADVEXIN	DD: 1/27/2003 MA: MA:	Treatment of head and neck cancer	Introgen Therapeutics, 2250 Holcombe Blvd Houston TX 77030
iron(III)-hexacyanoferrate(II) Pharmzeutische KG Radiogardase Republic of	DD: 5/1/2003 MA: MA:	Treatment of patients with known or susupected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch- Fabrik GMBH & Co, Goerzallee 253 Goerzallee 253 D-14167 Berlin, Federal Germany
Lactoferrin alpha	DD: 8/20/2003 MA:	For the treatment of graft versus host disease	Agennix, Inc. Greenway Plaza Suite 910 Houston TX 77046
Lactoferrin alpha	DD: 8/20/2003 MA:	For the prevention of graft-versus-host disease	Agennix, Inc. 8 Greenway Plaza Suite 910 Houston TX 77046
liposomal p-ethoxy growth Pharmaceuticals, INc. receptor bound protein-2	DD: 12/5/2003 MA:	Treatment of chronic myelogenous leukemia	Interpath 2615 Hollymist Houston TX 77084
Mafosfamide (formerly Oncology)	DD: 1/21/2003 MA:	Treatment of neoplastic meningitis	Baxter Oncology GmbH ASTA Medica Daimlerstrasse 40 60314 franfurt/Main

Orphan Products Designations and Approvals List
November 2003

MaxAdFVIII Corporation	DD: 3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics 10865 Altman Row Suite 200 San Diego CA 92121-
1113	MA:		
monarsen B, 10th Floor	DD:	Treatment of Myasthenia Gravis	Medica Venture Partners Ackerstein Towers, Bldg ISRAEL
	MA:		
motexafin gadolinium Xcytrin 4521	DD: 1/27/2003 MA: MA:	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc. 999 East Arques Avenue 999 East Arques Avenue Sunnyvale CA 94085-
Mx-dnG1 or Rexin-G retroviral Corporation REXIN-G 1803W	DD: 8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies 345 Pioneer Drive, Glendale CA 91203
	MA:		
myristoylated recombinant SCR1-3 of human complement reseptor Pk, type I APT070 Saffron Walden,	DD: 5/21/2003 MA: MA:	Prevention of delayed graft function in solid organ transplant	Adprotech, Ltd. Chesterford Research Little Chesterford,
N-acetyl-sarcosyl-glycyl-L-valyl-D-a lloisoleucyl-L-threonyl-L-norvalyl- L-isoleucyl-L-arginyl_L-prolylethyl aminde acetate	DD: 12/9/2003 MA:	For the treatment of soft tissue sarcoma	Abbott Laboratories Pharmaceutical Products Division 200 Abbott Park Road Abbott Park IL 60064
niprisan Inc. Hemoxin Technology Center Building B, Suite 08901	DD: 8/15/2003 MA:	Treatment of sickle cell disease	Xechem International, New Brunswick 100 Jersey Avenue, 310 New Brunswick NJ

Orphan Products Designations and Approvals List
November 2003

polyinosinic-polycytidilic acid NW Poly-ICLC NW 3450	DD: 3/3/2003 MA: MA:	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Ribopharm, Inc. 3203 Cleveland Ave., 3203 Cleveland Ave., Washington DC 20008-
Protaxel Court	DD: 5/21/2003 MA:	Treatment of ovarian cancer	Biophysica, Inc. 3333 North Torrey Pines Suite 100 La Jolla CA 92037
recombinant adeno-associated Technologies Corp. virus alpha 1-antitrypsin vector rAAV-AAT	DD: 1/27/2003 MA: MA:	Treatment of alpha1-antitrypsin deficiency	Applied Genetic 12085 Research Drive Suite 110 Alachua FL 32615
recombinant human neutrophil inhibitor (hNE)	DD: 12/9/2003 MA:	Treatment of cystic fibrosis	Dyax Corporation 300 Technology Square Cambridge MA 02139
recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003 MA:	Treatment of angioedema	Dyax Corp 300 Technology Square Cambridge MA 02139
Recombinant T-cell receptor Square Road	DD: 5/2/2003 MA: MA:	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive residues 35-55 to myelin oligodendrocyte glycoprotein	Virogenomics, Inc. 9020 SW Washington Suite 380 Tigard, OR 97223-4332
repertaxin	DD: 1/27/2003 MA:	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila
repository corticotropin or Pharmaceuticals, Inc. adrenocorticotropic hormone H.P. Acthar Gel 1217	DD: 5/21/2003 MA: MA:	Treatment of infantile spasms	Questcor 3260 Whipple Road Union City CA 94587-

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 2003 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020977 001	ABACAVIR SULFATE;ZIAGEN	#5034394	DEC 18, 2011			
			#5034394*PED	JUN 18, 2012			
	020978 001	ABACAVIR SULFATE;ZIAGEN	#5034394	DEC 18, 2011			
			#5034394*PED	JUN 18, 2012			
	020213 001	ACETYLCHOLINE CHLORIDE;MIOCHOL-E	#6261546	APR 29, 2019	U-506		
	021478 001	ACYCLOVIR;ZOVIRAX	#4963555	OCT 16, 2007			
>ADD>	020338 001	ADAPALENE;DIFFERIN	#RE34440	MAY 31, 2010	U-275		
	020899 001	ALBUMIN HUMAN;OPTISON	#5573751	APR 25, 2012			
			#5529766	JUN 25, 2013	U-505		
			#5558094	FEB 28, 2012	U-505		
	020950 001	ALBUTEROL SULFATE;DUONEB	6632842	DEC 28, 2021	U-532		
	020560 001	ALENDRONATE SODIUM;FOSAMAX	#5358941	DEC 02, 2012		I-309	SEP 29, 2003
			#4621077	AUG 06, 2007	U-114	PED	MAR 29, 2004
			#5681590	DEC 02, 2012			
			#5849726	JUN 06, 2015			
			#6008207	JUN 06, 2015	U-303		
			#6090410	DEC 02, 2012			
			#6194004	DEC 02, 2012			
			#4621077*PED	FEB 06, 2008	U-114		
			#5358941*PED	JUN 02, 2013			
			#5681590*PED	JUN 02, 2013			
			#5849726*PED	DEC 06, 2015			
			#6008207*PED	DEC 06, 2015	U-303		
			#6090410*PED	JUN 02, 2013			
			#6194004*PED	JUN 02, 2013			
	020560 002	ALENDRONATE SODIUM;FOSAMAX	#5358941	DEC 02, 2012			
			#4621077	AUG 06, 2007	U-114		
			#5681590	DEC 02, 2012			
			#5849726	JUN 06, 2015			
			#6008207	JUN 06, 2015	U-303		
			#6090410	DEC 02, 2012			
			#4621077*PED	FEB 06, 2008	U-114		
			#5358941*PED	JUN 02, 2013			
			#5681590*PED	JUN 02, 2013			
			#5849726*PED	DEC 06, 2015			
			#6008207*PED	JUN 06, 2015	U-303		
			#6090410*PED	JUN 02, 2013			
	020560 003	ALENDRONATE SODIUM;FOSAMAX	#5358941	DEC 02, 2012			
			#4621077	AUG 06, 2007	U-114		
			#5681590	DEC 02, 2012			
			#5849726	JUN 06, 2015			
			#6008207	JUN 06, 2015	U-303		
			#6090410	DEC 02, 2012			
			#4621077*PED	FEB 06, 2008	U-114		
			#5358941*PED	JUN 02, 2013			
			#5681590*PED	JUN 02, 2013			
			#5849726*PED	DEC 06, 2015			
			#6008207*PED	DEC 06, 2015	U-303		
			#6090410*PED	JUN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020560 004	ALENDRONATE SODIUM;FOSAMAX	#6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		#4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		#5358941	DEC 02, 2012		D-62	OCT 20, 2003
		#5681590	DEC 02, 2012		PED	APR 20, 2004
		#5849726	JUN 06, 2015		PED	APR 20, 2004
		#6008207	JUN 06, 2015		PED	APR 20, 2004
		#6090410	DEC 02, 2012			
		#5994329	JUL 17, 2018			
		#6225294	JUL 17, 2018			
		#4621077*PED	FEB 06, 2008	U-114		
		#5358941*PED	JUN 02, 2013			
		#5681590*PED	JUN 02, 2013			
		#5849726*PED	DEC 16, 2015			
		#5994329*PED	JAN 17, 2019			
		#6008207*PED	DEC 06, 2015			
		#6015801*PED	JAN 17, 2019	U-353		
		#6090410*PED	JUN 02, 2013			
		#6225294*PED	JAN 17, 2019			
020560 005	ALENDRONATE SODIUM;FOSAMAX	#6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		#4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		#5358941	DEC 02, 2012		D-62	OCT 20, 2003
		#5681590	DEC 02, 2012		PED	APR 20, 2004
		#5849726	JUN 06, 2015		PED	APR 20, 2004
		#5994329	JUL 17, 2018		PED	APR 20, 2004
		#6008207	JUN 06, 2015			
		#6090410	DEC 02, 2012			
		#6225294	JUL 17, 2018			
		#4621077*PED	FEB 06, 2008	U-114		
		#5358941*PED	JUN 02, 2013			
		#5681590*PED	JUN 02, 2013			
		#5849726*PED	DEC 06, 2015			
		#5994329*PED	JAN 17, 2019			
		#6008207*PED	DEC 06, 2015			
		#6015801*PED	JAN 17, 2019	U-353		
		#6090410*PED	JUN 02, 2013			
		#6225294*PED	JAN 17, 2019			
021575 001	ALENDRONATE SODIUM;FOSAMAX	#4621077	AUG 06, 2007		I-309	SEP 29, 2003
		4621077*PED	FEB 06, 2008		PED	MAR 29, 2004
		#5462932	MAY 17, 2014		D-61	OCT 20, 2003
		#5994329	JUL 17, 2018		PED	APR 20, 2004
		5994329*PED	JAN 17, 2019			
		#6015801	JUL 17, 2018			
		6015801*PED	JAN 17, 2019			
		#6225294	JUL 17, 2018			
		6225294*PED	JAN 17, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021287 001	ALFUZOSIN HYDROCHLORIDE;UROXATRAL	#4661491	MAY 27, 2006		NCE	JUN 12, 2008
		#6149940	AUG 22, 2017			
021001 001	ALMOTRIPTAN MALATE;AXERT	#5565447	MAY 07, 2015			
021001 002	ALMOTRIPTAN MALATE;AXERT	#5565447	MAY 07, 2015			
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	#5360800	JAN 13, 2013			
021434 001	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 002	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 003	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 004	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
020221 002	AMIFOSTINE;ETHYOL	#5424471	JUL 31, 2012			
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	#5954703	OCT 31, 2017	U-289		
020364 002	AMLODIPINE BESYLATE;LOTREL	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			
020364 003	AMLODIPINE BESYLATE;LOTREL	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			
020364 004	AMLODIPINE BESYLATE;LOTREL	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			
020364 005	AMLODIPINE BESYLATE;LOTREL	#4410520	AUG 11, 2003		NS	JUN 20, 2005
		#4410520*PED	FEB 11, 2004		PED	DEC 20, 2005
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
040422 005	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
040422 006	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
040422 007	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
021007 001	AMPRENAVIR;AGENERASE	#5723490	MAR 03, 2015	U-257		
021549 001	APREPITANT;EMEND	#5719147	JUN 29, 2012		NCE	MAR 26, 2008
		#5538982	JUL 23, 2013			
		#6048859	JUN 29, 2012			
		#6096742	JUL 01, 2018			
		#6235735	JUN 29, 2012			
021549 002	APREPITANT;EMEND	#5719147	JUN 29, 2012		NCE	MAR 26, 2008
		#5538982	JUL 23, 2013			
		#6048859	JUN 29, 2012			
		#6096742	JUL 01, 2018			
		#6235735	JUN 29, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021436 001	ARIPIPRAZOLE;ABILIFY	#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009			
021436 002	ARIPIPRAZOLE;ABILIFY	#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009			
021436 003	ARIPIPRAZOLE;ABILIFY	#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009			
021436 004	ARIPIPRAZOLE;ABILIFY	#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009			
021436 005	ARIPIPRAZOLE;ABILIFY	#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009			
021436 006	ARIPIPRAZOLE;ABILIFY	#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009			
021387 001	ASPIRIN;PRAVIGARD PAC (COPAC	#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009			
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2208			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
		#5622985*PED	OCT 22, 2014	U-335		
021387 002	ASPIRIN;PRAVIGARD PAC (COPAC	#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
		#5622985*PED	OCT 22, 2014	U-335		
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
021387 003	ASPIRIN;PRAVIGARD PAC (COPAC	#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
		#5622985*PED	OCT 22, 2014	U-335		
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
021387 004	ASPIRIN;PRAVIGARD PAC (COPAC	#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
		#5622985*PED	OCT 22, 2014	U-335		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021387 005	ASPIRIN;PRAVIGARD PAC (COPAC	#4346227	OCT 20, 2005			
			#4346227*PED	APR 20, 2006			
			#5030447	JUL 09, 2008			
			#5030447*PED	JAN 09, 2009			
			#5180589	JUL 09, 2008			
			#5180589*PED	JAN 09, 2009			
			#5622985	APR 22, 2014	U-335		
			#5622985*PED	OCT 22, 2014	U-335		
	021387 006	ASPIRIN;PRAVIGARD PAC (COPAC	#4346227	OCT 20, 2005			
			#4346227*PED	APR 20, 2006			
			#5030447	JUL 09, 2008			
			#5030447*PED	JAN 09, 2009			
			#5180589	JUL 09, 2008			
			#5180589*PED	JAN 09, 2009			
			#5622985	APR 22, 2014	U-335		
			#5622985*PED	OCT 22, 2014	U-335		
	021567 001	ATAZANAVIR SULFATE;REYATAZ	#5849911	APR 09, 2017		NCE	JUN 20, 2008
			#6087383	DEC 21, 2018			
	021567 002	ATAZANAVIR SULFATE;REYATAZ	#5849911	APR 09, 2017		NCE	JUN 20, 2008
			#6087383	DEC 21, 2018			
	021567 003	ATAZANAVIR SULFATE;REYATAZ	#5849911	APR 09, 2017		NCE	JUN 20, 2008
			#6087383	DEC 21, 2018			
	021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
>ADD>	020702 002	ATORVASTATIN CALCIUM;LIPITOR	#5969156*PED	JAN 08, 2017			
	021078 001	ATOVAQUONE;MALARONE	#6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
			#5053432	OCT 01, 2008		PED	JAN 14, 2004
			#6291488	NOV 25, 2013			
			#5053432*PED	APR 01, 2009			
			#6166046*PED	MAY 25, 2014			
			#6291488*PED	MAY 25, 2014			
	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	#6166046	NOV 25, 2013		NC	JUL 14, 2003
			#5053432	OCT 01, 2008		PED	JAN 14, 2004
			#6291488	NOV 25, 2013	U-406		
			#5053432*PED	APR 01, 2009			
			#6166046*PED	MAY 25, 2014			
			#6291488*PED	MAY 25, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020259 001	ATOVAQUONE;MEPRON	#4981874	AUG 15, 2009	U-69		
			#5053432	OCT 01, 2008			
			#5053432*PED	APR 01, 2009			
	020500 001	ATOVAQUONE;MEPRON	4981874*PED	FEB 15, 2010	U-69		
			#4981874	AUG 15, 2009	U-69	ODE	JAN 05, 2006
			#5053432	OCT 01, 2008		PED	JUL 05, 2006
			#5053432*PED	APR 01, 2009			
			4981874*PED	FEB 15, 2010	U-69		
	021470 001	AZELAIC ACID;FINACEA	#6534070	NOV 18, 2018			
>ADD>	021589 001	BACLOFEN;KEMSTRO	6024981	APR 09, 2018			
>ADD>			6221392	APR 09, 2018			
>ADD>	021589 002	BACLOFEN;KEMSTRO	6024981	APR 09, 2018			
>ADD>			6221392	APR 09, 2018			
	019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	#4410520	AUG 11, 2003			
			#4410520*PED	FEB 11, 2004			
	019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	#4410520	AUG 11, 2003			
			#4410520*PED	FEB 11, 2004			
	019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	#4410520	AUG 11, 2003			
			#4410520*PED	FEB 11, 2004			
	019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	#4410520	AUG 11, 2003			
			#4410520*PED	FEB 11, 2004			
	020033 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	#4410520	AUG 11, 2003			
			#4410520*PED	FEB 11, 2004			
	020033 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	#4410520	AUG 11, 2003			
			#4410520*PED	FEB 11, 2004			
	020033 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	#4410520	AUG 11, 2003			
			#4410520*PED	FEB 11, 2004			
	020033 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	#4410520	AUG 11, 2003			
			#4410520*PED	FEB 11, 2004			
	021055 001	BEXAROTENE;TARGRETIN	#5780676	JUL 14, 2015	U-509		
	021056 001	BEXAROTENE;TARGRETIN	#5780676	JUL 14, 2015	U-510		
	021602 001	BORTEZOMIB;VELCADE	#5780454	OCT 28, 2014		NCE	MAY 13, 2008
			#6083903	OCT 28, 2014	U-515	ODE	MAY 13, 2010
	021290 001	BOSENTAN;TRACLEER	#6297217	OCT 28, 2014	U-515		
	021290 002	BOSENTAN;TRACLEER	6617317	OCT 28, 2014			
	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	#5292740	NOV 20, 2015			
			#5292740	NOV 20, 2015			
			#6562873	JUL 10, 2021			
			#6562873*PED	JAN 10, 2022			
	076260 001	BRIMONIDINE TARTRATE;BRIMONIDINE TARTRATE	6627210	JUL 18, 2021			
			6627210*PED	JAN 18, 2022			
			6641834	JUL 28, 2021			
			6641834*PED	JAN 28, 2022			
						PC	SEP 16, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020929 001	BUDESONIDE;PULMICORT RESPULES	#6598603	DEC 23, 2018	U-529		
		6598603*PED	JUN 23, 2019			
020929 002	BUDESONIDE;PULMICORT RESPULES	#6598603	DEC 23, 2018	U-529		
		6598603*PED	JUN 23, 2019			
020929 003	BUDESONIDE;PULMICORT RESPULES	#6598603	DEC 23, 2018	U-529		
		6598603*PED	JUN 23, 2019			
021515 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN XL	#6096341	OCT 30, 2018		M-10	JUN 11, 2004
		#6143327	OCT 30, 2018			
021515 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN XL	#6096341	OCT 30, 2018		M-10	JUN 11, 2004
		#6143327	OCT 30, 2018			
075766 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075766 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075823 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075823 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075836 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075836 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
021160 002	CALCIUM ACETATE;PHOSLO	#6576665	APR 03, 2021			
021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	#6576665	APR 03, 2021			
021485 002	CARBIDOPA;STALEVO 100	#5446194	AUG 29, 2012		NCE	OCT 19, 2004
		#5135950	OCT 31, 2010			
		#4963590	NOV 27, 2007			
		#6500867	JUN 29, 2020			
		#5112861	MAY 12, 2009			
021485 003	CARBIDOPA;STALEVO 150	#5446194	AUG 29, 2012		NCE	OCT 19, 2004
		#5135950	OCT 31, 2010			
		#4963590	NOV 27, 2007			
		#6500867	JUN 29, 2020			
		#5112861	MAY 12, 2009			
021485 001	CARBIDOPA;STALEVO 50	#5446194	AUG 29, 2012		NCE	OCT 19, 2004
		#5135950	OCT 31, 2010			
		#4963590	NOV 27, 2007			
		#6500867	JUN 29, 2020			
		#5112861	MAY 12, 2009			
020452 001	CARBOPLATIN;PARAPLATIN	#4657927	APR 14, 2004	U-175		
020452 002	CARBOPLATIN;PARAPLATIN	#4657927	APR 14, 2004	U-175		
020452 003	CARBOPLATIN;PARAPLATIN	#4657927	APR 14, 2004	U-175		
020637 001	CARMUSTINE;GLIADEL	#4789724	AUG 01, 2006		I-382	FEB 25, 2006
		#4757128	AUG 01, 2006			
020297 001	CARVEDILOL;COREG				I-388	MAR 27, 2006
020297 002	CARVEDILOL;COREG				I-388	MAR 27, 2006
020297 003	CARVEDILOL;COREG				I-388	MAR 27, 2006
020297 004	CARVEDILOL;COREG				I-388	MAR 27, 2006
021227 001	CASPOFUNGIN ACETATE;CANCIDAS				I-399	JAN 07, 2006
021227 002	CASPOFUNGIN ACETATE;CANCIDAS				I-399	JAN 07, 2006

represents patent information submitted prior to 08/18/03

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	#4525358	JUN 25, 2007	U-295		
		#4525358*PED	DEC 25, 2007	U-295		
		#6469009	JUL 13, 2019	U-295		
		#6489329	APR 08, 2016			
		#5002769	MAR 16, 2006			
		#5023082	MAR 30, 2005			
020774 001	CHLORHEXIDINE GLUCONATE;PERIOCHIP	#4670444	DEC 09, 2003		NDF	FEB 28, 2006
					NDF	DEC 13, 2005
021159 001	CICLOPIROX;LOPROX				NDF	DEC 13, 2005
021473 001	CIPROFLOXACIN;CIPRO XR	#4844902	FEB 11, 2008		NC	JUL 18, 2006
021473 002	CIPROFLOXACIN;CIPRO XR	#6284804	AUG 10, 2020			
021537 001	CIPROFLOXACIN;CIPRODEX	#6359016	AUG 10, 2020			
020822 004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
021535 001	CLOBETASOL PROPIONATE;CLOBEX	#6106848	SEP 22, 2017		NDF	JUL 24, 2006
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	#6504030	JUN 10, 2019			
019758 001	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
019758 002	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	#6066678	JUN 10, 2014	U-323		
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	#6066678	JUN 10, 2014	U-323		
017821 001	CYCLOBENZAPRINE HYDROCHLORIDE;FLEXERIL					
021572 001	DAPTOMYCIN;CUBICIN	#5912226	JUN 15, 2016		D-78	FEB 03, 2006
		#6468967	SEP 24, 2019		NCE	SEP 12, 2008
021572 002	DAPTOMYCIN;CUBICIN	#5912226	JUN 15, 2016			
		#6468967	SEP 24, 2019		NCE	SEP 12, 2008
020705 002	DELAVIRDINE MESYLATE;RESCRIPTOR	#5563142	OCT 08, 2013			
		#6177101	JUN 11, 2018			
021271 001	DESIRUDIN;IPRIVASK	#4745177	MAY 17, 2005			
		#4801576	JAN 31, 2006			
		#5733874	MAR 31, 2015			
021165 001	DESLORATADINE;CLARINEX	#4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
		#4863931	SEP 15, 2008		PED	JUN 21, 2007
		#4804666	FEB 14, 2006	U-428		
		#5595997	DEC 30, 2014	U-429		
		#6100274	JUL 07, 2019			
		#4659716*PED	OCT 21, 2004	U-427		
		#4804666*PED	AUG 14, 2006	U-428		
		#4863931*PED	MAR 15, 2009			
		#5595997*PED	JUN 30, 2015	U-429		
		#6100274*PED	JAN 07, 2020			
021312 001	DESLORATADINE;CLARINEX	#4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
		#4659716*PED	OCT 21, 2004	U-427	PED	JUN 21, 2007
		#4863931	SEP 15, 2008			
		#4863931*PED	MAR 15, 2009			
		#4804666	FEB 14, 2006	U-428		
		#4804666*PED	AUG 14, 2006	U-428		
		#5595997	DEC 30, 2014	U-429		
		#5595997*PED	JUN 30, 2015	U-429		
		#6100274	JUL 07, 2019			
		#6100274*PED	JAN 07, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020648 001	DIAZEPAM;DIASTAT	#5462740	SEP 17, 2013			
	020648 002	DIAZEPAM;DIASTAT	#5462740	SEP 17, 2013			
	020648 003	DIAZEPAM;DIASTAT	#5462740	SEP 17, 2013			
	020648 004	DIAZEPAM;DIASTAT	#5462740	SEP 17, 2013			
	020648 005	DIAZEPAM;DIASTAT	#5462740	SEP 17, 2013			
	021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	#5288505	JUN 26, 2011		NDF	FEB 06, 2006
			#5529791	JUN 25, 2013			
	021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	#5288505	JUN 26, 2011		NDF	FEB 06, 2006
			#5529791	JUN 25, 2013			
	021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	#5288505	JUN 26, 2011		NDF	FEB 06, 2006
			#5529791	JUN 25, 2013			
	021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	#5288505	JUN 26, 2011		NDF	FEB 06, 2006
			#5529791	JUN 25, 2013			
	021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	#5288505	JUN 26, 2011		NDF	FEB 06, 2006
			#5529791	JUN 25, 2013			
	021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	#5288505	JUN 26, 2011		NDF	FEB 06, 2006
			#5529791	JUN 25, 2013			
	020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	#5529791	JUN 25, 2013			
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	#6511678	DEC 18, 2018			
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	#6511678	DEC 18, 2018			
	020941 001	DOCOSANOL;ABREVA	#4874794	APR 28, 2014			
	020624 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	#4906755	JUL 02, 2011			
	020624 003	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	#4906755	JUL 02, 2011			
>ADD>	020972 001	EFAVIRENZ;SUSTIVA	6639071	FEB 14, 2018			
			#6555133	APR 06, 2019	U-248		
>ADD>	020972 002	EFAVIRENZ;SUSTIVA	6639071	FEB 14, 2018			
			#6555133	APR 06, 2019	U-248		
>ADD>	020972 003	EFAVIRENZ;SUSTIVA	6639071	FEB 14, 2018			
			#6555133	APR 06, 2019	U-248		
>ADD>	021360 001	EFAVIRENZ;SUSTIVA	6639071	FEB 14, 2018			
			#5663169	SEP 02, 2014			
>ADD>	021360 002	EFAVIRENZ;SUSTIVA	6639071	FEB 14, 2018			
	021500 001	EMTRICITABINE;EMTRIVA	#5210085	MAY 11, 2010		NCE	JUL 02, 2008
			#5814639	SEP 29, 2015			
			#5914331	SEP 29, 2015			
	021481 001	ENFUVIRTIDE;FUZEON	#5464933	JUN 07, 2013		NCE	MAR 13, 2008
			#6133418	JUN 07, 2013			
			#6475491	JUN 07, 2015	U-248		
	020164 007	ENOXAPARIN SODIUM;LOVENOX				I-315	NOV 17, 2003
	020164 008	ENOXAPARIN SODIUM;LOVENOX				I-315	NOV 17, 2003
	020164 009	ENOXAPARIN SODIUM;LOVENOX	#4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
			#5389618	FEB 14, 2012			
	020796 001	ENTACAPONE;COMTAN	6599530	SEP 14, 2018			
	021565 001	EPINASTINE HYDROCHLORIDE;ELESTAT				NCE	OCT 15, 2008

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021437 001	EPLERENONE;INSPRA	#4559332	APR 09, 2004	U-537	I-407	OCT 07, 2006
		6558707	DEC 08, 2009	U-537		
		#6534093	DEC 08, 2019	U-537		
		#6495165	DEC 08, 2019	U-537		
		#6534093	DEC 08, 2019	U-3		
		#6410054	DEC 08, 2019	U-537		
021437 002	EPLERENONE;INSPRA	#4559332	APR 09, 2004	U-537	I-407	OCT 07, 2006
		#6534093	DEC 08, 2019	U-3		
		6558707	DEC 08, 2009	U-537		
		#6495165	DEC 08, 2019	U-537		
		#6534093	DEC 08, 2019	U-537		
		#6410054	DEC 08, 2019	U-537		
021437 003	EPLERENONE;INSPRA	#4559332	APR 09, 2004	U-537	I-407	OCT 07, 2006
		6558707	DEC 08, 2009	U-537		
		#6410054	DEC 08, 2019	U-537		
		#6495165	DEC 08, 2019	U-537		
		#6534093	DEC 08, 2019	U-3		
021365 001	ESCITALOPRAM OXALATE;LEXAPRO	#6534093	DEC 08, 2019	U-537		
		#RE34712	JUN 08, 2009			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	#RE34712*PED	DEC 08, 2009			
		#4593119	JUN 03, 2003			
		#5017609	MAY 21, 2008			
		5017609*PED	NOV 21, 2008			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119*PED	DEC 03, 2003			
		#5017609	MAY 21, 2008			
		#4593119	JUN 03, 2003			
		5017609*PED	NOV 21, 2008			
019386 004	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119*PED	DEC 03, 2003			
		#6528540	JAN 12, 2021			
		#4593119	JUN 03, 2003			
		#6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
019386 006	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119*PED	DEC 03, 2003			
		#6528540	JAN 12, 2021			
		#4593119	JUN 03, 2003			
		#6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
019386 007	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119*PED	DEC 03, 2003			
		#4593119	JUN 03, 2003			
		#6310094	JAN 12, 2021			
		#6528540	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019386 005	ESMOLOL HYDROCHLORIDE;BREVIBLOC DOUBLE STR	#6528540	JAN 12, 2021			
			#4593119	JUN 03, 2003			
			#6310094	JAN 12, 2021			
			6528540*PED	JUL 12, 2021			
			6310094*PED	JUL 12, 2021			
			4593119*PED	DEC 03, 2003			
	021367 001	ESTRADIOL ACETATE;FEMRING	#5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
	021367 002	ESTRADIOL ACETATE;FEMRING	#5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
	020375 005	ESTRADIOL;CLIMARA	#5223261	JUN 29, 2010			
	020375 006	ESTRADIOL;CLIMARA	#5223261	JUN 29, 2010			
>ADD>	021258 001	ESTRADIOL;CLIMARA PRO	5252334	OCT 12, 2010			
>ADD>			5770219	OCT 12, 2010			
>ADD>			5393529	FEB 28, 2012			
>ADD>			5676968	OCT 14, 2014			
	004782 003	ESTROGENS, CONJUGATED;PREMARIN				D-82	JUL 16, 2006
	004782 006	ESTROGENS, CONJUGATED;PREMARIN				D-82	JUL 16, 2006
	020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	#RE36247	MAY 02, 2006			
	020527 001	ESTROGENS, CONJUGATED;PREMPRO				D-79	MAR 12, 2006
	020527 003	ESTROGENS, CONJUGATED;PREMPRO				D-79	MAR 12, 2006
	020527 004	ESTROGENS, CONJUGATED;PREMPRO	#RE36247	MAY 02, 2006		NP	MAR 12, 2006
			#5547948	JAN 17, 2015		D-79	MAR 12, 2006
			#5210081	FEB 26, 2012		D-81	JUN 04, 2006
	020527 005	ESTROGENS, CONJUGATED;PREMPRO	#5210081	FEB 26, 2012		NS	JUN 04, 2006
			#RE36247	MAY 02, 2006		D-81	JUN 04, 2006
			#5547948	JAN 17, 2015			
	021180 001	ETHINYL ESTRADIOL;ORTHO EVRA	#5876746	JUN 07, 2015	U-514		
			#5972377	JUN 07, 2015	U-514		
	021544 001	ETHINYL ESTRADIOL;SEASONALE	#5898032	JUN 23, 2017	U-1	NP	SEP 05, 2006
	020325 002	FAMOTIDINE;PEPCID AC				NP	SEP 23, 2006
>ADD>	021203 001	FENOFIBRATE;TRICOR	6652881	JAN 09, 2018			
			#6589552	JAN 09, 2018			
>ADD>	021203 003	FENOFIBRATE;TRICOR	6652881	JAN 09, 2018			
			#6589552	JAN 09, 2018			
	020747 001	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
			#5785989	SEP 05, 2006			
	020747 002	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
			#5785989	SEP 05, 2006			
	020747 003	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
			#5785989	SEP 05, 2006			
	020747 004	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
			#5785989	SEP 05, 2006			
	020747 005	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
			#5785989	SEP 05, 2006			
	020747 006	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
			#5785989	SEP 05, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019813 001	FENTANYL;DURAGESIC	#4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
		#4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
019813 002	FENTANYL;DURAGESIC	#4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
		#4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
019813 003	FENTANYL;DURAGESIC	#4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
		#4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
019813 004	FENTANYL;DURAGESIC	#4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
		#4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
021626 001	FERRIC HEXACYANOFERRATE(II);RADIOGARDASE (PRUSSI				ODE	OCT 02, 2010
					NCE	OCT 02, 2008
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	#5578610	NOV 26, 2013	U-192	M-25	MAY 12, 2006
		#5855912	FEB 28, 2015		PED	NOV 12, 2006
		#5738872	FEB 28, 2015			
		#5932247	FEB 28, 2015			
		#6037353	MAR 14, 2017	U-138		
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012	U-138		
		#6399632	MAY 11, 2012	U-468		
		#5578610*PED	MAY 26, 2014	U-192		
		#5738872*PED	AUG 28, 2015			
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017	U-138		
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012	U-138		
		#6399632*PED	NOV 11, 2012	U-468		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	#5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		#5932247	FEB 28, 2015		PED	AUG 25, 2003
		#5855912	FEB 28, 2015		M-25	MAY 12, 2006
		#6037353	MAR 14, 2017	U-138	PED	NOV 12, 2006
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012	U-138		
		#6399632	MAY 11, 2012	U-468		
		#5578610*PED	MAY 26, 2014	U-139		
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017	U-138		
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012	U-138		
		#6399632*PED	NOV 11, 2012	U-468		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	#5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		#5932247	FEB 28, 2015		PED	AUG 25, 2003
		#5855912	FEB 28, 2015		M-25	MAY 12, 2006
		#6037353	MAR 14, 2017	U-138	PED	NOV 12, 2006
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012	U-138		
		#6399632	MAY 11, 2012	U-468		
		#5578610*PED	MAY 26, 2014	U-139		
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017	U-138		
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012	U-138		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		#6399632*PED	NOV 11, 2012	U-468		
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	#5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		#5932247	FEB 28, 2015		PED	AUG 25, 2003
		#5855912	FEB 28, 2015		M-25	MAY 12, 2006
		#6037353	MAR 14, 2017	U-138	PED	NOV 12, 2006
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012	U-138		
		#6399632	MAY 11, 2012	U-468		
		#5578610*PED	MAY 26, 2014	U-139		
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017	U-138		
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012	U-138		
		#6399632*PED	NOV 11, 2012	U-468		
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	#5578610	NOV 26, 2013		M-25	MAY 12, 2006
		#5855912	FEB 28, 2015		PED	NOV 12, 2006
		#6037353	MAR 14, 2017	U-138		
		#6039974	JUL 31, 2018			
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012	U-138		
		#6399632	MAY 11, 2012	U-468		
		#5578610*PED	MAY 26, 2014			
		#5855912*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017	U-138		
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012	U-138		
		#6399632*PED	NOV 11, 2012	U-468		
020180 001	FINASTERIDE;PROSCAR	#6046183	MAR 20, 2011			
020038 001	FLUDARABINE PHOSPHATE;FLUDARA	#4357324	FEB 24, 2003			
		#4357324*PED	AUG 24, 2003			
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	#4335121	NOV 14, 2003		NC	AUG 24, 2003
		#5270305	SEP 07, 2010	U-387		
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	#4335121	NOV 14, 2003		NC	AUG 24, 2003
			#5270305	SEP 07, 2010	U-387	I-410	NOV 17, 2006
			#4992474	FEB 12, 2008	U-211		
			#5225445	FEB 12, 2008	U-211		
			#5126375	FEB 12, 2008			
			#5290815	MAR 01, 2011	U-386		
			#4335121*PED	MAY 14, 2004			
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	#4335121	NOV 14, 2003		NC	AUG 24, 2003
			#5270305	SEP 07, 2010	U-387		
			#4992474	FEB 12, 2008	U-211		
			#5225445	FEB 12, 2008	U-211		
			#5126375	FEB 12, 2008			
			#5290815	MAR 01, 2011	U-386		
			#4335121*PED	MAY 14, 2004			
	019957 001	FLUTICASONE PROPIONATE;CUTIVATE	#4335121	NOV 14, 2003			
			#4335121*PED	MAY 14, 2004			
	019958 001	FLUTICASONE PROPIONATE;CUTIVATE	#4335121	NOV 14, 2003			
			#4335121*PED	MAY 14, 2004			
	020121 001	FLUTICASONE PROPIONATE;FLONASE	#4335121	NOV 14, 2003		D-76	MAY 23, 2005
			#4335121*PED	MAY 14, 2004		PED	NOV 23, 2005
						M-24	MAY 01, 2006
						PED	NOV 01, 2006
	020548 001	FLUTICASONE PROPIONATE;FLOVENT	#4335121	NOV 14, 2003			
			#4335121*PED	MAY 14, 2004			
	020548 002	FLUTICASONE PROPIONATE;FLOVENT	#4335121	NOV 14, 2003			
			#4335121*PED	MAY 14, 2004			
	020548 003	FLUTICASONE PROPIONATE;FLOVENT	#4335121	NOV 14, 2003			
			#4335121*PED	MAY 14, 2004			
	020549 001	FLUTICASONE PROPIONATE;FLOVENT	#4335121	NOV 14, 2003	U-409		
			#4335121*PED	MAY 14, 2004	U-409		
	020549 002	FLUTICASONE PROPIONATE;FLOVENT	#4335121	NOV 14, 2003	U-409		
			#4335121*PED	MAY 14, 2004	U-409		
	020549 003	FLUTICASONE PROPIONATE;FLOVENT	#4335121	NOV 14, 2003	U-409		
			#4335121*PED	MAY 14, 2004	U-409		
	020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	#4335121	NOV 14, 2003	U-409		
			#4335121*PED	MAY 14, 2004	U-409		
	020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	#4335121	NOV 14, 2003	U-409		
			#4335121*PED	MAY 14, 2004	U-409		
	020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	#4335121	NOV 14, 2003	U-409		
			#4335121*PED	MAY 14, 2004	U-409		
	020261 001	FLUVASTATIN SODIUM;LESCOL	#5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
			#5354772	OCT 11, 2011	U-413		
	020261 002	FLUVASTATIN SODIUM;LESCOL	#5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
			#5354772	OCT 11, 2011	U-413		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021192 001	FLUVASTATIN SODIUM;LESCOL XL	#5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
			#5354772	OCT 11, 2011	U-109		
	020961 001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATI	#5442049	AUG 15, 2012			
			#5595978	AUG 15, 2012	U-522		
			#4689320	OCT 15, 2004	U-522		
			#5264423	NOV 23, 2010	U-522		
			#5276019	JAN 04, 2011	U-522		
	021345 001	FONDAPARINUX SODIUM;ARIXTRA				I-397	JUN 17, 2006
	020831 001	FORMOTEROL FUMARATE;FORADIL	#6488027	MAR 08, 2019		I-342	SEP 25, 2004
						NPP	JUN 27, 2006
>ADD>	021548 001	FOSAMPRENAVIR CALCIUM;LEXIVA	#6436989	DEC 24, 2017	U-257	NE	OCT 20, 2006
			#6514953	JUL 15, 2019	U-257		
	019915 002	FOSINOPRIL SODIUM;MONOPRIL	#4337201	DEC 04, 2002		NPP	MAY 27, 2006
			#5006344	JUL 10, 2009		PED	NOV 27, 2006
			#5006344*PED	JAN 10, 2010			
			#4337201*PED	JUN 04, 2003			
	019915 003	FOSINOPRIL SODIUM;MONOPRIL	#4337201	DEC 04, 2002		NPP	MAY 27, 2006
			#5006344	JUL 10, 2009		PED	NOV 27, 2006
			#5006344*PED	JAN 10, 2010			
			#4337201*PED	JUN 04, 2003			
	019915 004	FOSINOPRIL SODIUM;MONOPRIL	#4337201	DEC 04, 2002		NPP	MAY 27, 2006
			#5006344	JUL 10, 2009		PED	NOV 27, 2006
			#5006344*PED	JAN 10, 2010			
			#4337201*PED	JUN 04, 2003			
	020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	#4337201	DEC 04, 2002			
			#5006344	JUL 10, 2009			
			#5006344*PED	JAN 10, 2010			
			#4337201*PED	JUN 04, 2003			
	020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	#4337201	DEC 04, 2002			
			#5006344	JUL 10, 2009			
			#5006344*PED	JAN 10, 2010			
			#4337201*PED	JUN 04, 2003			
	021489 001	GADOTERIDOL;PROHANCE MULTIPACK	#5474756	DEC 12, 2012	U-536		
			#6143274	DEC 12, 2012	U-536		
			#4885363	DEC 05, 2006			
			#5846519	DEC 08, 2015			
	076457 001	GANCICLOVIR;GANCICLOVIR				PC	FEB 16, 2004
	076457 002	GANCICLOVIR;GANCICLOVIR				PC	FEB 16, 2004
	021061 001	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
	021061 002	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
	021062 001	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
	021062 002	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
	021062 003	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
	021062 004	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005

represents patent information submitted prior to 08/18/03

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021493 001	GATIFLOXACIN;ZYMAR					
021399 001	GEFITINIB;IRESSA	#5880283	DEC 05, 2015		NDF	MAR 28, 2006
		#4980470	DEC 15, 2009		NCE	DEC 17, 2004
		#5457105	JAN 19, 2013		NCE	MAY 05, 2008
021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	#5616582	JAN 19, 2013			
		#5770599	APR 26, 2016			
		#6262071	SEP 21, 2019	U-513	NCE	APR 04, 2008
		#6331550	SEP 21, 2019	U-511		
		#6340689	SEP 14, 2019	U-512		
		#6455540	SEP 21, 2019	U-511		
		#5633262	JUN 15, 2015			
		#5776944	JUN 15, 2015			
020622 001	GLATIRAMER ACETATE;COPAXONE	#5962468	JUN 15, 2015	U-282		
020622 002	GLATIRAMER ACETATE;COPAXONE	6620847	MAY 24, 2014			
		#5981589	MAY 24, 2014		ODE	DEC 20, 2003
		#6054430	MAY 24, 2014			
		#6342476	MAY 24, 2014	U-441		
		#6362161	MAY 24, 2014	U-441		
		6620847	MAY 24, 2014			
076467 001	GLIPIZIDE;GLIPIZIDE	#5091190	SEP 05, 2009	U-111	PC	OCT 19, 2003
020329 001	GLIPIZIDE;GLUCOTROL XL	#5545413	JUL 21, 2008	U-111		
		#5091190	SEP 05, 2009	U-111		
020329 002	GLIPIZIDE;GLUCOTROL XL	#5545413	JUL 21, 2008	U-111		
		#4612008	SEP 16, 2003			
020329 003	GLIPIZIDE;GLUCOTROL XL	#5024843	SEP 05, 2009			
		#5082668	SEP 16, 2003			
		#5091190	SEP 05, 2009	U-111		
		#5545413	JUL 21, 2008	U-111		
021178 001	GLYBURIDE;GLUCOVANCE	#5591454	JAN 07, 2014	U-111		
		#6303146	JUL 14, 2019	U-412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U-412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
021178 002	GLYBURIDE;GLUCOVANCE	#6303146	JUL 14, 2019	U-412	PED	MAR 30, 2006
		6303146*PED	JAN 14, 2020	U-412	NC	JUL 31, 2003
					I-368	SEP 30, 2005
021178 003	GLYBURIDE;GLUCOVANCE	#6303146	JUL 14, 2019	U-412	PED	JAN 31, 2004
		6303146*PED	JAN 14, 2020	U-412	PED	MAR 30, 2006
					NC	JUL 31, 2003
					I-368	SEP 30, 2005
020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	#5952340	SEP 14, 2016	U-519	PED	JAN 31, 2004
020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	#5952340	SEP 14, 2016	U-519	PED	MAR 30, 2006
021282 002	GUAIFENESIN;MUCINEX	#6372252	APR 28, 2020	U-489		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019968 001	HALOBETASOL PROPIONATE;ULTRAVATE	#4619921	DEC 16, 2004			
	021532 002	HYDROCHLOROTHIAZIDE;BENICAR HCT	#5616599	APR 01, 2014	U-500	NC	JUN 05, 2006
						NCE	APR 25, 2007
	021532 003	HYDROCHLOROTHIAZIDE;BENICAR HCT	#5616599	APR 01, 2014	U-500	NC	JUN 05, 2006
						NCE	APR 25, 2007
	021532 005	HYDROCHLOROTHIAZIDE;BENICAR HCT	#5616599	APR 01, 2014	U-500	NC	JUN 05, 2006
						NCE	APR 25, 2007
	020818 003	HYDROCHLOROTHIAZIDE;DIOVAN HCT	#5399578	MAR 21, 2012	U-3		
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	#6294197	JUN 18, 2017	U-3		
			#5153197	OCT 06, 2009	U-538		
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	#5153197*PED	APR 06, 2010	U-538		
			#5153197	OCT 06, 2009	U-538		
	021162 001	HYDROCHLOROTHIAZIDE;MICARDIS HCT	#5153197*PED	APR 06, 2010	U-538		
	021162 002	HYDROCHLOROTHIAZIDE;MICARDIS HCT	#6358986	JAN 10, 2020			
	020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	#6358986	JAN 10, 2020			
	020453 001	HYDROCORTISONE PROBUTATE;PANDEL	#6599531	JUN 10, 2017			
	021455 001	IBANDRONATE SODIUM;BONIVA	#4794106	AUG 28, 2006			
			#4927814	JUL 09, 2007	U-520	NCE	MAY 16, 2008
	021472 001	IBUPROFEN;IBUPROFEN	#6143326	APR 21, 2017	U-520		
	021321 001	ICODEXTRIN;EXTRANEAL	#6294196	OCT 07, 2019			
			#6251426	JUN 25, 2018			
			#6248726	JUN 19, 2018	U-495	ODE	DEC 20, 2009
			#4761237	AUG 02, 2005	U-495		
			#4886789	DEC 12, 2006	U-495		
	021335 001	IMATINIB MESYLATE;GLEEVEC	#6077836	JUN 20, 2017	U-495		
	021335 002	IMATINIB MESYLATE;GLEEVEC				I-392	MAY 20, 2006
	021588 001	IMATINIB MESYLATE;GLEEVEC	#5521184	MAY 28, 2013		I-392	MAY 20, 2006
						NCE	MAY 10, 2006
						I-376	DEC 20, 2005
						ODE	FEB 01, 2009
						ODE	MAY 10, 2008
	021588 002	IMATINIB MESYLATE;GLEEVEC	#5521184	MAY 28, 2013		I-392	MAY 20, 2006
						NCE	MAY 10, 2006
						I-376	DEC 20, 2005
						ODE	FEB 01, 2009
						ODE	MAY 10, 2008
						I-392	MAY 20, 2006
	020367 002	IMIGLUCERASE;CEREZYME	#5549982	AUG 27, 2013	U-252		
>ADD>	020685 001	INDINAVIR SULFATE;CRIXIVAN	6645961	MAR 04, 2018			
>ADD>	020685 003	INDINAVIR SULFATE;CRIXIVAN	6645961	MAR 04, 2018			
>ADD>	020685 005	INDINAVIR SULFATE;CRIXIVAN	6645961	MAR 04, 2018			
>ADD>	020685 006	INDINAVIR SULFATE;CRIXIVAN	6645961	MAR 04, 2018			
	021081 001	INSULIN GLARGINE;LANTUS				D-80	MAY 01, 2006
	020563 001	INSULIN LISPRO;HUMALOG	#5474978	JUN 16, 2014	U-534		
			#5514646	MAY 07, 2013	U-534		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020563 002	INSULIN LISPRO;HUMALOG PEN	#5474978	JUN 16, 2014	U-534		
		#5514646	MAY 07, 2013	U-534		
021425 001	IOPROMIDE;ULTRAVIST (PHARMACY	#4364921	MAR 06, 2005	U-498		
021425 002	IOPROMIDE;ULTRAVIST (PHARMACY	#4364921	MAR 06, 2005	U-498		
021528 001	KETOROLAC TROMETHAMINE;ACULAR LS	#5110493	MAY 05, 2009		NP	MAY 30, 2006
		#5110493*PED	NOV 05, 2009			
020857 001	LAMIVUDINE;COMBIVIR	#5047407*PED	MAY 17, 2010			
		#5047407	NOV 17, 2009			
021003 001	LAMIVUDINE;EPIVIR-HBV	#5047407	NOV 17, 2009			
		#5047407*PED	MAY 17, 2010			
021004 001	LAMIVUDINE;EPIVIR-HBV	#5047407	NOV 17, 2009			
		#5047407*PED	MAY 17, 2010			
020241 001	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 002	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 003	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 004	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 005	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 006	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020764 001	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020764 002	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020764 003	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020764 004	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
021281 001	LANSOPRAZOLE;PREVACID	#4628098	MAY 10, 2009			
		#4689333	JUL 29, 2005	U-126		
		#5013743	FEB 12, 2010	U-452		
		#5026560	JUN 25, 2008			
		#5045321	SEP 03, 2008			
		#5093132	SEP 03, 2008			
		#5433959	SEP 03, 2008			
021281 002	LANSOPRAZOLE;PREVACID	#4628098	MAY 10, 2009			
		#4689333	JUL 29, 2005	U-126		
		#5013743	FEB 12, 2010	U-452		
		#5026560	JUN 25, 2008			
		#5045321	SEP 03, 2008			
		#5093132	SEP 03, 2008			
		#5433959	SEP 03, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020905 001	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
>ADD>						I-395	JUN 13, 2006
>ADD>						PED	MAR 10, 2004
>ADD>						PED	DEC 13, 2006
>ADD>	020905 002	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
>ADD>						I-395	JUN 13, 2006
>ADD>						PED	MAR 10, 2004
>ADD>						PED	DEC 13, 2006
>ADD>	020905 003	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
>ADD>						I-395	JUN 13, 2006
>ADD>						PED	MAR 10, 2004
>ADD>						PED	DEC 13, 2006
	021488 001	LEUPROLIDE ACETATE;ELIGARD	#4938763	OCT 03, 2008		NP	FEB 13, 2006
			#5278201	JAN 11, 2011			
			#5324519	OCT 20, 2011			
			#5599552	FEB 04, 2014			
			#5733950	OCT 03, 2008			
			#5739176	OCT 03, 2008			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	#5362755	NOV 08, 2011	U-332		
	021035 001	LEVETIRACETAM;KEPPRA	#4943639	JUN 06, 2006			
	021035 002	LEVETIRACETAM;KEPPRA	#4943639	JUN 06, 2006			
	021035 003	LEVETIRACETAM;KEPPRA	#4943639	JUN 06, 2006			
	021505 001	LEVETIRACETAM;KEPPRA	#4943639	JUN 06, 2006		NCE	NOV 30, 2004
			#4837223	JUN 06, 2006			
>ADD>	020219 001	LEVOCABASTINE HYDROCHLORIDE;LIVOSTIN	#4369184	DEC 07, 2004			
	020634 001	LEVOFLOXACIN;LEVAQUIN				I-393	MAY 23, 2006
						D-83	OCT 23, 2006
	020634 002	LEVOFLOXACIN;LEVAQUIN				I-393	MAY 23, 2006
						D-83	OCT 23, 2006
	020634 003	LEVOFLOXACIN;LEVAQUIN				I-393	MAY 23, 2006
						D-83	OCT 23, 2006
	020635 001	LEVOFLOXACIN;LEVAQUIN				I-393	MAY 23, 2006
						D-83	OCT 23, 2006
>ADD>	020635 004	LEVOFLOXACIN;LEVAQUIN	#5053407	DEC 20, 2010		I-393	MAY 23, 2006
>ADD>						I-372	OCT 30, 2005
	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-393	MAY 23, 2006
						D-83	OCT 23, 2006
	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-393	MAY 23, 2006
						D-83	OCT 23, 2006
>ADD>	020635 005	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE	#5053407	DEC 20, 2010		I-393	MAY 23, 2006
>ADD>						I-372	OCT 30, 2005
	021199 001	LEVOFLOXACIN;QUIXIN	#5053407	DEC 20, 2010			
	021301 001	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 002	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021301 003	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 004	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 005	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 006	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 007	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 008	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 009	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 010	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 011	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	021301 012	LEVOTHYROXINE SODIUM;LEVOXYL	#6555581	FEB 15, 2022			
	020612 001	LIDOCAINE;LIDODERM	#5589180	MAR 17, 2009	U-485		
			#5411738	MAY 02, 2012			
			#5827529	OCT 27, 2015	U-486		
			#5709869	MAR 17, 2009	U-485		
			#5601838	MAY 02, 2012	U-488		
>ADD>	021130 001	LINEZOLID;ZYVOX	6514529	MAR 15, 2021		NPP	DEC 19, 2005
>ADD>	021130 002	LINEZOLID;ZYVOX	#6559305	JAN 29, 2021		I-402	JUL 22, 2006
	021131 001	LINEZOLID;ZYVOX	6514529	MAR 15, 2021		NPP	DEC 19, 2005
			#6559305	JAN 29, 2021		I-402	JUL 22, 2006
	021132 001	LINEZOLID;ZYVOX	#6559305	JAN 29, 2021		NPP	DEC 19, 2005
			#6559305	JAN 29, 2021		I-402	JUL 22, 2006
	019558 001	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
						PED	NOV 29, 2006
	019558 002	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
						PED	NOV 29, 2006
	019558 003	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
						PED	NOV 29, 2006
	019558 004	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
						PED	NOV 29, 2006
	019558 006	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
						PED	NOV 29, 2006
	019777 001	LISINOPRIL;ZESTRIL				NPP	MAY 29, 2006
						PED	NOV 29, 2006
	019777 002	LISINOPRIL;ZESTRIL				PED	NOV 29, 2006
						NPP	MAY 29, 2006
	019777 003	LISINOPRIL;ZESTRIL				PED	NOV 29, 2006
						NPP	MAY 29, 2006
	019777 004	LISINOPRIL;ZESTRIL				PED	NOV 29, 2006
						NPP	MAY 29, 2006
	019777 005	LISINOPRIL;ZESTRIL				PED	NOV 29, 2006
						NPP	MAY 29, 2006
	019777 006	LISINOPRIL;ZESTRIL				PED	NOV 29, 2003
						NPP	MAY 29, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021226 001	LOPINAVIR;KALETRA	#6521651	NOV 01, 2017			
	019658 002	LORATADINE;CLARITIN	#4659716	APR 21, 2004	U-142		
			#4659716*PED	OCT 21, 2004	U-142		
			#4863931	SEP 15, 2008			
			#4863931*PED	MAR 15, 2009			
	020641 002	LORATADINE;CLARITIN	#4659716	APR 21, 2004	U-142		
			#4659716*PED	OCT 21, 2004	U-142		
			#4863931	SEP 15, 2008			
			#4863931*PED	MAR 15, 2009			
			#6132758	JUN 01, 2018			
	020704 002	LORATADINE;CLARITIN REDITABS	#4659716	APR 21, 2004	U-142		
			#4659716*PED	OCT 21, 2004	U-142		
			#4863931	SEP 15, 2008			
			#4863931*PED	MAR 15, 2009			
	019670 002	LORATADINE;CLARITIN-D	#4659716	APR 21, 2004	U-142		
			#4659716*PED	OCT 21, 2004	U-142		
			#4863931	SEP 15, 2008			
			#4863931*PED	MAR 15, 2009			
	020470 002	LORATADINE;CLARITIN-D 24 HOUR	#4659716	APR 21, 2004	U-142		
			#4659716*PED	OCT 21, 2004	U-142		
			#4863931	SEP 15, 2008			
			#4863931*PED	MAR 15, 2009			
			#5314697	OCT 23, 2012			
			#5314697*PED	APR 23, 2013			
	075209 001	LORATADINE;LORATADINE				PC	JUL 21, 2003
	075822 001	LORATADINE;LORATADINE				PC	AUG 09, 2003
	075706 001	LORATADINE;LORATADINE AND PSEUD				PC	NOV 29, 2003
	076050 001	LORATADINE;LORATADINE AND PSEUD				PC	JUL 30, 2003
	020386 001	LOSARTAN POTASSIUM;COZAAR	#5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
			#5210079*PED	NOV 11, 2010	U-496		
	020386 002	LOSARTAN POTASSIUM;COZAAR	#5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
			#5210079*PED	NOV 11, 2010	U-496		
	020386 003	LOSARTAN POTASSIUM;COZAAR	#5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
			#5210079*PED	NOV 11, 2010	U-496		
>ADD>	021487 001	MEMANTINE HYDROCHLORIDE;NAMENDA	#5061703	APR 11, 2010	U-539	NCE	OCT 16, 2008
>ADD>			#5614560	MAR 25, 2014	U-539		
>ADD>	021487 002	MEMANTINE HYDROCHLORIDE;NAMENDA	#5061703	APR 11, 2010	U-539	NCE	OCT 16, 2008
>ADD>			#5614560	MAR 25, 2014	U-539		
>ADD>	021487 003	MEMANTINE HYDROCHLORIDE;NAMENDA	#5061703	APR 11, 2010	U-539	NCE	OCT 16, 2008
>ADD>			#5614560	MAR 25, 2014	U-539		
>ADD>	021487 004	MEMANTINE HYDROCHLORIDE;NAMENDA	#5061703	APR 11, 2010	U-539	NCE	OCT 16, 2008
>ADD>			#5614560	MAR 25, 2014	U-539		
	021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	021410 004	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	021410 005	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	021202 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR				NDF	OCT 13, 2003
>ADD>	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	#6475521	MAR 19, 2018			
>ADD>			#5082668	SEP 16, 2003			
>ADD>			#4783337	SEP 16, 2003	U-372		
>ADD>			#4612008	SEP 16, 2003			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337*PED	MAR 16, 2004			
>ADD>			#5082668	SEP 16, 2003			
>ADD>			#4783337	SEP 16, 2003	U-372		
>ADD>			#4612008	SEP 16, 2003			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337*PED	MAR 16, 2004			
>ADD>			#5082668	SEP 16, 2003			
>ADD>			#4783337	SEP 16, 2003	U-372		
>ADD>			#4612008	SEP 16, 2003			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>	021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337*PED	MAR 16, 2004			
>ADD>			#4612008	SEP 16, 2003			
>ADD>			#4783337	SEP 16, 2003	U-372		
>ADD>			#5082668	SEP 16, 2003			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>			4783337*PED	MAR 16, 2004			
	021259 002	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	#6344215	OCT 27, 2020		NDF	APR 03, 2004
	021259 003	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	#6344215	OCT 27, 2020		NDF	APR 03, 2004
>ADD>	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	#5081154	MAR 19, 2008			
>ADD>	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	#5081154	MAR 19, 2008			
>ADD>	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	#5081154	MAR 19, 2008			
			#4927640	MAY 22, 2007			
>ADD>	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	#5081154	MAR 19, 2008	U-107		
	021348 001	MIGLUSTAT;ZAVESCA	#5472969	MAY 13, 2013		NCE	JUL 31, 2008
			#5525616	JUN 11, 2013		ODE	JUL 31, 2010
	076119 001	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 16, 2003
	076119 002	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 16, 2003
	076204 001	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
	076204 002	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-385	FEB 28, 2006
	021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHL	#4990517	JUN 30, 2009	U-298	I-385	FEB 28, 2006
			#5607942	MAR 04, 2014	U-298		
			#5849752	DEC 05, 2016	U-298		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	#4990517	JUN 30, 2009		NDF	APR 15, 2006
			#5607942	MAR 04, 2014		PED	OCT 15, 2006
			#5849752	DEC 05, 2016			
			#4990517*PED	DEC 30, 2009			
			#5607942*PED	SEP 04, 2014			
			#5849752*PED	JUN 05, 2017			
>ADD>	021204 001	NATEGLINIDE;STARLIX	#6559188	SEP 17, 2019		I-411	OCT 20, 2006
>ADD>	021204 002	NATEGLINIDE;STARLIX	#6559188	SEP 17, 2019		I-411	OCT 20, 2006
	020778 001	NELFINAVIR MESYLATE;VIRACEPT	#5484926	OCT 07, 2013			
			#5952343	OCT 07, 2013	U-257		
			#6162812	OCT 07, 2013	U-248		
			5952343*PED	APR 07, 2014	U-257		
			5484926*PED	APR 07, 2014			
			6162812*PED	APR 07, 2014	U-248		
	020779 001	NELFINAVIR MESYLATE;VIRACEPT	#5484926	OCT 07, 2013			
			#5952343	OCT 07, 2013	U-257		
			#6162812	OCT 07, 2013	U-248		
			5484926*PED	APR 07, 2014			
			5952343*PED	APR 07, 2014	U-257		
			6162812*PED	APR 07, 2014	U-248		
	021503 001	NELFINAVIR MESYLATE;VIRACEPT	#5484926	OCT 07, 2013			
			5484926*PED	APR 07, 2014			
			#5952343	OCT 07, 2013	U-257		
			5952343*PED	APR 07, 2014	U-257		
			6162812	OCT 07, 2013	U-248		
			6162812*PED	APR 07, 2014	U-248		
	020636 001	NEVIRAPINE;VIRAMUNE	#5366972	NOV 22, 2011	U-167		
			#5366972*PED	MAY 22, 2012			
	020933 001	NEVIRAPINE;VIRAMUNE	#5366972	NOV 22, 2011			
			#5366972*PED	MAY 22, 2012			
	021330 001	NICOTINE POLACRILEX;COMMIT	#5110605	AUG 21, 2010			
	021330 002	NICOTINE POLACRILEX;COMMIT	#5110605	AUG 21, 2010			
	020076 004	NICOTINE;HABITROL	#4597961	JAN 23, 2005	U-56		
			#5016652	MAY 21, 2008			
	020076 005	NICOTINE;HABITROL	#4597961	JAN 23, 2005	U-56		
			#5016652	MAY 21, 2008			
	020076 006	NICOTINE;HABITROL	#4597961	JAN 23, 2005	U-56		
			#5016652	MAY 21, 2008			
	019983 003	NICOTINE;PROSTEP	#4946853	AUG 07, 2007	U-56		
	019983 004	NICOTINE;PROSTEP	#4946853	AUG 07, 2007	U-56		
	021498 001	NITAZOXANIDE;ALINIA	#5387598	FEB 07, 2012	U-524		
			#5578621	SEP 08, 2014	U-525		
			#5965590	JUL 03, 2017	U-523		
			#5968961	MAY 07, 2017			
			#6020353	SEP 08, 2014			
			#6117894	MAY 07, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021232 001	NITISINONE;ORFADIN	#5006158	APR 09, 2008			
		#5550165	AUG 27, 2013			
021232 002	NITISINONE;ORFADIN	#5006158	APR 09, 2008			
		#5550165	AUG 27, 2013			
021232 003	NITISINONE;ORFADIN	#5006158	APR 09, 2008			
		#5550165	AUG 27, 2013			
020845 002	NITRIC OXIDE;INOMAX	#5873359	JAN 23, 2013	U-297		
020845 003	NITRIC OXIDE;INOMAX	#5873359	JAN 23, 2013	U-297		
020799 001	OFLOXACIN;FLOXIN				D-84	SEP 30, 2006
019921 001	OFLOXACIN;OCUFLOX	#4382892	SEP 02, 2003		ODE	MAY 22, 2003
		#4551456	NOV 14, 2003	U-80	PED	NOV 22, 2003
		#4382892*PED	MAR 02, 2004			
		#4551456*PED	MAY 14, 2004	U-80		
020592 001	OLANZAPINE;ZYPREXA				I-400	JUL 10, 2006
020592 002	OLANZAPINE;ZYPREXA				I-400	JUL 10, 2006
020592 003	OLANZAPINE;ZYPREXA				I-400	JUL 10, 2006
020592 004	OLANZAPINE;ZYPREXA				I-400	JUL 10, 2006
020592 005	OLANZAPINE;ZYPREXA				I-400	JUL 10, 2006
020592 006	OLANZAPINE;ZYPREXA				I-400	JUL 10, 2006
021286 002	OLMESARTAN MEDOXOMIL;BENEVAS	#5616599	APR 01, 2014	U-500		
021286 001	OLMESARTAN MEDOXOMIL;BENICAR	#5616599	APR 01, 2014	U-500		
021286 003	OLMESARTAN MEDOXOMIL;BENICAR	#5616599	APR 01, 2014	U-500		
021229 001	OMEPRAZOLE MAGNESIUM;PRILOSEC OTC	#4738974	APR 19, 2005		RTO	JUN 20, 2006
		#5900424	MAY 04, 2016			
		#4786505	APR 20, 2007			
		#4853230	APR 20, 2007			
		#5690960	NOV 25, 2014			
		#5817338	OCT 06, 2015			
		#5753265	JUN 07, 2015			
		#6403616	NOV 15, 2019			
		#6428810	NOV 03, 2019			
		#4786505*PED	OCT 20, 2007			
		#4853230*PED	OCT 20, 2007			
020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE	#4695578	JAN 25, 2005			
		#4753789	JUN 24, 2006	U-44		
020766 001	ORLISTAT;XENICAL	#4598089	JUN 18, 2009		NCE	APR 23, 2004
		#6004996	JAN 06, 2018		PED	OCT 23, 2004
		4598089*PED	DEC 18, 2009			
		6004996*PED	JUL 06, 2018			
020776 001	OXAPROZIN POTASSIUM;DAYPRO ALTA	#6030643	MAY 16, 2017	U-497		
017577 001	OXYBUTYNIN CHLORIDE;DITROPAN				NPP	APR 15, 2006
					PED	OCT 15, 2006
018211 001	OXYBUTYNIN CHLORIDE;DITROPAN				NPP	APR 15, 2006
					PED	OCT 15, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL				NPP	APR 15, 2006
						PED	OCT 15, 2006
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL				NPP	APR 15, 2006
						PED	OCT 15, 2006
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL				NPP	APR 15, 2006
						PED	OCT 15, 2006
	021351 002	OXYBUTYNIN;OXYTROL	#5164190	DEC 11, 2010		NDF	FEB 26, 2006
			#5601839	APR 26, 2015			
			#5834010	APR 26, 2015			
	021372 001	PALONOSETRON HYDROCHLORIDE;ALOXI	#5202333	APR 13, 2010	U-528	NCE	JUL 25, 2008
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX	#4758579	JUL 19, 2010			
	020987 002	PANTOPRAZOLE SODIUM;PROTONIX	#4758579	JUL 19, 2010			
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	#4758579	JUL 19, 2010			
>ADD>	020819 001	PARICALCITOL;ZEMPLAR	#5246925	APR 17, 2012	U-314		
>ADD>			#6136799	APR 08, 2018			
>ADD>			6361758	APR 08, 2018			
>ADD>			5587497*PED	JUN 24, 2014			
>ADD>			6361758*PED	OCT 08, 2018			
>ADD>			6136799*PED	OCT 08, 2019			
>ADD>			5246925*PED	OCT 17, 2012			
>ADD>			#5587497	DEC 24, 2013			
	075356 001	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
	075356 002	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
	075356 003	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
	075356 004	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	#6548084	JUL 19, 2016		I-405	AUG 28, 2006
			#6548084*PED	JAN 19, 2017			
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	#6548084	JUL 19, 2016		I-405	AUG 28, 2006
			#6548084*PED	JAN 19, 2017			
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	#6548084	JUL 19, 2016		I-405	AUG 28, 2006
			#6548084*PED	JAN 19, 2017			
	021299 001	PAROXETINE MESYLATE;PAROXETINE MESYLATE	#5874447	JUN 10, 2017	U-286		
			#5874447	JUN 10, 2017	U-518		
			#5874447	JUN 10, 2017	U-46		
	021299 002	PAROXETINE MESYLATE;PAROXETINE MESYLATE	#5874447	JUN 10, 2017	U-286		
			#5874447	JUN 10, 2017	U-518		
			#5874447	JUN 10, 2017	U-46		
	021299 003	PAROXETINE MESYLATE;PAROXETINE MESYLATE	#5874447	JUN 10, 2017	U-286		
			#5874447	JUN 10, 2017	U-518		
			#5874447	JUN 10, 2017	U-46		
	021299 004	PAROXETINE MESYLATE;PAROXETINE MESYLATE	#5874447	JUN 10, 2017	U-286		
			#5874447	JUN 10, 2017	U-518		
			#5874447	JUN 10, 2017	U-46		
	021106 001	PEGVISOMANT;SOMAVERT	#6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
			#5849535	SEP 21, 2015		ODE	MAR 25, 2010
			#5958879	SEP 27, 2011	U-507		
			#5350836	SEP 27, 2011	U-507		
			#5681809	SEP 27, 2011	U-507		
			#6583115	SEP 27, 2011	U-507		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021106 002	PEGVISOMANT;SOMAVERT	#6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
		#5849535	SEP 21, 2015		ODE	MAR 25, 2010
		#5958879	SEP 27, 2011	U-507		
		#5350836	SEP 27, 2011	U-507		
		#5681809	SEP 27, 2011	U-507		
		#6583115	SEP 27, 2011	U-507		
021106 003	PEGVISOMANT;SOMAVERT	#6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
		#5849535	SEP 21, 2015		ODE	MAR 25, 2010
		#5958879	SEP 27, 2011	U-507		
		#5350836	SEP 27, 2011	U-507		
		#5681809	SEP 27, 2011	U-507		
		#6583115	SEP 27, 2011	U-507		
020629 001	PENCICLOVIR SODIUM;DENAVIR	#6469015	OCT 22, 2019	U-501	NPP	OCT 10, 2006
		#6573378	SEP 24, 2010			
		#6579981	JUN 17, 2020	U-501		
076061 001	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
076061 002	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
076061 003	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
020184 001	PERINDOPRIL ERBUMINE;ACEON	5162362	NOV 10, 2009	U-531		
020184 002	PERINDOPRIL ERBUMINE;ACEON	5162362	NOV 10, 2009	U-531		
020184 003	PERINDOPRIL ERBUMINE;ACEON	5162362	NOV 10, 2009	U-531		
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	#4687777	JAN 17, 2011			
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	#4687777	JAN 17, 2011			
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	#4687777	JAN 17, 2011			
020451 001	PORFIMER SODIUM;PHOTOFRIN	#6150384	JUN 19, 2016	U-419		
					I-391	AUG 01, 2006
074726 003	POTASSIUM CHLORIDE;KLOR-CON M15				ODE	AUG 01, 2010
021416 001	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR				PC	DEC 24, 2003
021416 002	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR	#5681588	OCT 28, 2014		NDF	SEP 04, 2006
021416 003	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR	#5681588	OCT 28, 2014		NDF	SEP 04, 2006
021438 001	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	#5681588	OCT 28, 2014		NDF	SEP 04, 2006
021438 002	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	#6500454	DEC 31, 2022		NP	MAR 12, 2006
020973 001	RABEPRAZOLE SODIUM;ACIPHEX	#6500454	DEC 31, 2022		NP	MAR 12, 2006
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	#5045552	MAY 08, 2013	U-385		
019901 001	RAMIPRIL;ALTACE	#5045552	MAY 08, 2013	U-385		
019901 002	RAMIPRIL;ALTACE	#5403856	APR 04, 2012	U-71		
019901 003	RAMIPRIL;ALTACE	#5403856	APR 04, 2012	U-71		
019901 004	RAMIPRIL;ALTACE	#5403856	APR 04, 2012	U-71		
020903 001	RIBAVIRIN;REBETOL	#5403856	APR 04, 2012	U-71		
		#6524570	NOV 01, 2016	U-499	M-26	MAR 06, 2005
020903 002	RIBAVIRIN;REBETOL	#6524570*PED	MAY 01, 2017	U-499	ODE	JUL 29, 2010
					PED	JAN 29, 2011
					M-26	MAR 06, 2005
					ODE	JUL 29, 2010
					PED	JAN 29, 2011

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021546 001	RIBAVIRIN;REBETOL	#6472373	SEP 21, 2017	U-521	NDF	JUL 29, 2006
			#6472373*PED	MAR 21, 2018	U-521	PED	JAN 29, 2007
			#6461605	NOV 01, 2016	U-521	ODE	JUL 29, 2010
			#6461605*PED	MAY 01, 2017	U-521	PED	JAN 29, 2011
			#6172046	SEP 21, 2017	U-521		
			#6172046*PED	MAR 21, 2018	U-521		
			#6063772	JAN 23, 2016	U-521		
			#6063772*PED	JUL 23, 2016	U-521		
			#5767097	JAN 23, 2016	U-521		
			#5767097*PED	JUL 23, 2016	U-521		
	020835 001	RISEDRONATE SODIUM;ACTONEL	#6096342	NOV 22, 2011			
	020835 002	RISEDRONATE SODIUM;ACTONEL	#6096342	NOV 22, 2011			
	020835 003	RISEDRONATE SODIUM;ACTONEL	#5583122	DEC 10, 2013	U-222		
			#6096342	NOV 22, 2011			
			#6165513	JUN 10, 2018			
	021444 001	RISPERIDONE;RISPERDAL	#4804663	DEC 29, 2007	U-516	M-15	MAR 03, 2005
			#5648093	JUL 15, 2014			
			#6224905	JUN 10, 2017	U-516		
	021444 002	RISPERIDONE;RISPERDAL	#4804663	DEC 29, 2007	U-516	M-15	MAR 03, 2005
			#5648093	JUL 15, 2014			
			#6224905	JUN 10, 2017	U-516		
	021444 003	RISPERIDONE;RISPERDAL	#4804663	DEC 29, 2007		M-15	MAR 03, 2005
			#5648093	JUL 15, 2014			
			#6224905	JUN 10, 2017	U-516		
					U-516		
>ADD>	021346 001	RISPERIDONE;RISPERDAL CONSTA	6596316	DEC 30, 2008		NDF	OCT 29, 2006
>ADD>			6379703	DEC 30, 2018			
>ADD>			6534092	MAY 19, 2020			
>ADD>			6379704	MAY 19, 2020			
			#4804663	DEC 29, 2007			
			#5688801	NOV 18, 2014			
			#5770231	NOV 19, 2013			
			#5965168	NOV 19, 2013			
			#6110921	NOV 19, 2013			
			#5792477	MAY 02, 2017			
			#5916598	MAY 02, 2017			
			#6110503	MAY 02, 2017			
			#6194006	DEC 30, 2018			
			#6264987	MAY 19, 2020			
>ADD>	021346 002	RISPERIDONE;RISPERDAL CONSTA	6596316	DEC 30, 2008		NDF	OCT 29, 2006
>ADD>			6379703	DEC 30, 2018			
>ADD>			6534092	MAY 19, 2020			
>ADD>			6379704	MAY 19, 2020			
			#4804663	DEC 29, 2007			
			#5688801	NOV 18, 2014			
			#5770231	NOV 19, 2013			
			#5965168	NOV 19, 2013			
			#6110921	NOV 19, 2013			
			#5792477	MAY 02, 2017			
			#5916598	MAY 02, 2017			
			#6110503	MAY 02, 2017			
			#6194006	DEC 30, 2018			
			#6264987	MAY 19, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021346 003	RISPERIDONE;RISPERDAL CONSTA	6596316	DEC 30, 2008		NDF	OCT 29, 2006
>ADD>			6379703	DEC 30, 2018			
>ADD>			6534092	MAY 19, 2020			
>ADD>			6379704	MAY 19, 2020			
			#4804663	DEC 29, 2007			
			#5688801	NOV 18, 2014			
			#5770231	NOV 19, 2013			
			#5965168	NOV 19, 2013			
			#6110921	NOV 19, 2013			
			#5792477	MAY 02, 2017			
			#5916598	MAY 02, 2017			
			#6110503	MAY 02, 2017			
			#6194006	DEC 30, 2018			
			#6264987	MAY 19, 2020			
	021042 001	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
	021042 002	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
	021042 003	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
	021052 001	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
	021052 002	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
	020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	#4824860	MAY 19, 2008			
	020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	#4824860	MAY 19, 2008			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	021366 002	ROSUVASTATIN CALCIUM;CRESTOR	#RE37314	JUN 12, 2012		NCE	AUG 12, 2008
			#6589959	DEC 23, 2019			
			#6316460	AUG 04, 2020			
	021366 003	ROSUVASTATIN CALCIUM;CRESTOR	#RE37314	JUN 12, 2012		NCE	AUG 12, 2008
			#6589959	DEC 23, 2019			
			#6316460	AUG 04, 2020			
	021366 004	ROSUVASTATIN CALCIUM;CRESTOR	#RE37314	JUN 12, 2012		NCE	AUG 12, 2008
			#6589959	DEC 23, 2019			
			#6316460	AUG 04, 2020			
	021366 005	ROSUVASTATIN CALCIUM;CRESTOR	#RE37314	JUN 12, 2012		NCE	AUG 12, 2008
			#6589959	DEC 23, 2019			
			#6316460	AUG 04, 2020			
	019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	#4562829	MAY 01, 2004	U-503		
	021136 001	SECRETIN;SECREFLO				NP	APR 04, 2005
						ODE	APR 04, 2009
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-408	NOV 01, 2005
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
						I-261	FEB 07, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	#6509013	AUG 13, 2013			
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	#6509013	AUG 13, 2013			
021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	#6509013	AUG 13, 2013			
019766 001	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
019766 002	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
019766 003	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
019766 004	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
019766 005	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
021083 001	SIROLIMUS;RAPAMUNE				I-386	APR 11, 2006
021110 001	SIROLIMUS;RAPAMUNE				I-386	APR 11, 2006
021110 002	SIROLIMUS;RAPAMUNE	#5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
		#5212155	MAY 18, 2010	U-291	I-386	APR 11, 2006
		#5308847	MAY 03, 2011	U-292		
		#5403833	APR 04, 2012	U-293		
		#5989591	MAR 11, 2018			
020231 001	SODIUM FLUORIDE;COLGATE TOTAL	#5288480	JUL 16, 2008			
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN				ODE	OCT 31, 2004
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
019640 001	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
019640 004	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
019640 005	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
019640 006	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
019640 007	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
021148 001	SOMATROPIN RECOMBINANT;NORDITROPIN	#5633352	MAY 27, 2014			
		#5849700	DEC 15, 2015	U-340		
		#5849704	DEC 15, 2015			
021148 002	SOMATROPIN RECOMBINANT;NORDITROPIN	#5633352	MAY 27, 2014			
		#5849700	DEC 15, 2015	U-340		
		#5849704	DEC 15, 2015			
021148 003	SOMATROPIN RECOMBINANT;NORDITROPIN	#5633352	MAY 27, 2014			
		#5849700	DEC 15, 2015	U-340		
		#5849704	DEC 15, 2015			
021151 005	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021151 006	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 007	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
020413 001	STAVUDINE;ZERIT	#4978655	JUN 24, 2008			
		#4978655*PED	DEC 24, 2008			
021453 001	STAVUDINE;ZERIT XR	#4978655	JUN 24, 2008	U-248	NDF	DEC 31, 2005
		#4978655*PED	DEC 24, 2008	U-248	PED	JUL 01, 2006
021453 002	STAVUDINE;ZERIT XR	#4978655	JUN 24, 2008	U-248	NDF	DEC 31, 2005
		#4978655*PED	DEC 24, 2008	U-248	PED	JUL 01, 2006
021453 003	STAVUDINE;ZERIT XR	#4978655	JUN 24, 2008	U-248	NDF	DEC 31, 2005
		#4978655*PED	DEC 24, 2008	U-248	PED	JUL 01, 2006
021453 004	STAVUDINE;ZERIT XR	#4978655	JUN 24, 2008	U-248	NDF	DEC 31, 2005
		#4978655*PED	DEC 24, 2008	U-248	PED	JUL 01, 2006
020600 001	TAZAROTENE;TAZORAC	#5914334	JUN 07, 2014	U-517		
		#6258830	JUN 07, 2014	U-517		
020600 002	TAZAROTENE;TAZORAC	#5914334	JUN 07, 2014	U-517		
		#6258830	JUN 07, 2014	U-517		
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW				I-396	FEB 28, 2006
020850 001	TELMISARTAN;MICARDIS	#6358986	JAN 10, 2020			
020850 002	TELMISARTAN;MICARDIS	#6358986	JAN 10, 2020			
020850 003	TELMISARTAN;MICARDIS	#5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
		#6358986	JAN 10, 2020			
021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD				NPP	AUG 15, 2006
020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	#6121314	MAY 18, 2012	U-502		
021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	#6121314	MAY 18, 2012	U-504		
020489 001	TESTOSTERONE;ANDRODERM	#4863970	NOV 14, 2006			
		#4983395	NOV 12, 2007			
		#5152997	DEC 11, 2010	U-490		
		#5164190	DEC 11, 2010			
		#4849224	NOV 12, 2007			
		#4855294	SEP 06, 2008			
020489 002	TESTOSTERONE;ANDRODERM	#4849224	NOV 12, 2007			
		#4855294	SEP 06, 2008			
		#4863970	NOV 14, 2006			
		#4983395	NOV 12, 2007			
		#5152997	DEC 11, 2010	U-490		
		#5164190	DEC 11, 2010			
021543 001	TESTOSTERONE;STRIANT	#4615697	OCT 07, 2003		NP	JUN 19, 2006
		#6248358	AUG 23, 2019	U-527		
021454 001	TESTOSTERONE;TESTIM				NP	OCT 31, 2005
020785 001	THALIDOMIDE;THALOMID	#6561977	OCT 23, 2020	U-371		
		#6561976	AUG 28, 2018	U-371		
020785 002	THALIDOMIDE;THALOMID	#6045501	AUG 28, 2018	U-371	ODE	JUL 16, 2005
		#6315720	OCT 23, 2020	U-442	NCE	JUL 16, 2003
		#6561977	OCT 23, 2020	U-371		
		#6561976	AUG 28, 2018	U-371		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020785 003	THALIDOMIDE;THALOMID	#6045501	AUG 28, 2018	U-371	ODE	JUL 16, 2005
		#6315720	OCT 23, 2020	U-442	NCE	JUL 16, 2003
		#6561977	OCT 23, 2020	U-371		
		#6561976	AUG 28, 2018	U-371		
020771 001	TOLTERODINE TARTRATE;DETROL	#5382600	MAR 25, 2012			
020771 002	TOLTERODINE TARTRATE;DETROL	#5382600	MAR 25, 2012			
021228 001	TOLTERODINE TARTRATE;DETROL LA	#5382600	MAR 25, 2012			
021228 002	TOLTERODINE TARTRATE;DETROL LA	#5382600	MAR 25, 2012			
020505 001	TOPIRAMATE;TOPAMAX	#4513006	SEP 26, 2004			
020505 002	TOPIRAMATE;TOPAMAX	#4513006	SEP 26, 2004			
020505 003	TOPIRAMATE;TOPAMAX	#4513006	SEP 26, 2004			
020505 004	TOPIRAMATE;TOPAMAX	#4513006	SEP 26, 2004			
020505 005	TOPIRAMATE;TOPAMAX	#4513006	SEP 26, 2004			
020505 006	TOPIRAMATE;TOPAMAX	#4513006	SEP 26, 2004			
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	#4513006	SEP 26, 2004			
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	#4513006	SEP 26, 2004			
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	#4513006	SEP 26, 2004			
021257 001	TRAVOPROST;TRAVATAN				M-23	FEB 13, 2006
021108 001	TRETINOIN;RENOVA	#6531141	MAR 07, 2020			
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	#4957924	JUN 23, 2009	U-530		
		#5879706	JAN 19, 2016	U-530		
		#6107302	JAN 19, 2016	U-530		
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	#5879706	JAN 19, 2016	U-530		
		#6107302	JAN 19, 2016	U-530		
		#4957924	JUN 23, 2009	U-530		
020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	#4957924	JUN 23, 2009	U-530	I-381	SEP 09, 2005
		#5879706	JAN 19, 2016	U-530	I-389	APR 01, 2006
		#6107302	JAN 19, 2016	U-530	I-403	AUG 29, 2006
020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	#4957924	JUN 23, 2009	U-530	I-381	SEP 09, 2005
		#5879706	JAN 19, 2016	U-530	I-389	APR 01, 2006
		#6107302	JAN 19, 2016	U-530	I-403	AUG 29, 2006
					I-406	SEP 12, 2006
021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6362178	OCT 31, 2018	U-533	NCE	AUG 19, 2008
021400 001	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	U-533	NCE	AUG 19, 2008
021400 002	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	U-533	NCE	AUG 19, 2008
021400 003	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	U-533	NCE	AUG 19, 2008
021400 004	VARDENAFIL HYDROCHLORIDE;LEVITRA	#6444708	JUN 28, 2013	U-398	I-261	FEB 11, 2006
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	#6444708*PED	DEC 28, 2013	U-398		
		#6419958	MAR 20, 2017	U-535		
		#6419958*PED	SEP 20, 2017	U-535		
		#6403120	MAR 20, 2017	U-535		
		#6403120*PED	SEP 20, 2017	U-535		
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	#6444708	JUN 28, 2013	U-398	I-261	FEB 11, 2006
		#6444708*PED	DEC 28, 2013	U-398		
		#6419958	MAR 20, 2017	U-535		
		#6419958*PED	SEP 20, 2017	U-535		
		#6403120	MAR 20, 2017	U-535		
		#6403120*PED	SEP 20, 2017	U-535		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	#6444708	JUN 28, 2013	U-398	I-261	FEB 11, 2006
			#6444708*PED	DEC 28, 2013	U-398		
			#6419958	MAR 20, 2017	U-535		
			#6419958*PED	SEP 20, 2017	U-535		
			#6403120	MAR 20, 2017	U-535		
			#6403120*PED	SEP 20, 2017	U-535		
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	#6444708	JUN 28, 2013	U-398	I-261	FEB 11, 2006
			#6444708*PED	DEC 28, 2013	U-398		
			#6419958	MAR 20, 2017	U-535		
			#6419958*PED	SEP 20, 2017	U-535		
			#6403120	MAR 20, 2017	U-535		
			#6403120*PED	SEP 20, 2017	U-535		
	020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	#4612008	SEP 16, 2003			
			#6146662	AUG 14, 2007	U-366		
	020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	#4612008	SEP 16, 2003			
			#6146662	AUG 14, 2007	U-366		
>ADD>	021266 001	VORICONAZOLE;VFEND	#5116844	AUG 11, 2009	U-540	I-409	NOV 14, 2006
			#5364938	NOV 15, 2011			
			#5567817	OCT 22, 2013	U-540		
			#5773443	JAN 25, 2011	U-540		
>ADD>	021266 002	VORICONAZOLE;VFEND	#5116844	AUG 11, 2009	U-540	I-409	NOV 14, 2006
			#5364938	NOV 15, 2011			
			#5567817	OCT 22, 2013	U-540		
			#5773443	JAN 25, 2011	U-540		
>ADD>	021267 001	VORICONAZOLE;VFEND	6632803	JUN 02, 2018		I-409	NOV 14, 2006
>ADD>			5376645	JAN 23, 2010			
>ADD>			5134127	JAN 23, 2010			
			#5773443	JAN 25, 2011	U-540		
			#5116844	AUG 11, 2009			
			#5364938	NOV 15, 2011			
			#5567817	OCT 22, 2013	U-540		
	020859 001	ZALEPLON;SONATA	#4626538	JUN 06, 2008			
	020859 002	ZALEPLON;SONATA	#4626538	JUN 06, 2008			
	021223 002	ZOLEDRONIC ACID;ZOMETA	#4777163	JUL 24, 2007		NCE	AUG 20, 2006
			#4939130	NOV 13, 2007	U-53	I-361	FEB 22, 2005
						ODE	AUG 20, 2008
	021450 004	ZOLMITRIPTAN;ZOMIG	#5466699	NOV 14, 2012	U-436	NDF	SEP 26, 2006
	021231 002	ZOLMITRIPTAN;ZOMIG-ZMT	#5466699	NOV 14, 2012		NDF	FEB 13, 2004
	020789 002	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005
	020789 003	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 23RD EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

PATENT & EXCLUSIVITY ABBREVIATIONS

RTO	RX TO OTC SWITCH OR OTC USE

EXCLUSIVITY DOSING SCHEDULE

D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS

EXCLUSIVITY INDICATION

I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
I-387	ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
I-388	TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-389	SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
I-390	USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
I-391	INTENTIONALLY LEFT BLANK
I-392	TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
I-393	CHRONIC BACTERIAL PROSTATITIS

I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
I-395 TO IMPROVE PHYSICAL FUNCTION

I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
I-398 IDIOPATHIC SHORT STATURE
I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409 ESOPHAGEAL CANDIDIASIS
I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS

EXCLUSIVITY MISCELLANEOUS

M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY

PATENT USE

U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495 PERITONEAL DIALYSIS SOLUTION
U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500 USE AS AN ANTIHYPERTENSIVE AGENT

U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEIOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516	METHOD OF TREATING A PSYCHOTIC DISEASE
U-517	STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518	OBSESSIVE COMPULSIVE DISORDER
U-519	POST OPERATIVE NAUSEA AND VOMITING
U-520	PREMENOPAUSAL OSTEOPOROSIS
U-521	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522	TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523	METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED
U-524	METHOD OF TREATING DIARRHEA
U-525	METHOD OF TREATING PARASITIC INFECTIONS
U-526	METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527	METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528	PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529	ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530	TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531	TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532	TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533	ERECTILE DYSFUNCTION
U-534	HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS

United States Government
INFORMATION
PUBLICATIONS ★ PERIODICALS ★ ELECTRONIC PRODUCTS

Approved Drug Products, ADP
SUBSCRIPTION ORDER FORM

Order Processing
Code: **8392**

Easy Secure Internet:
bookstore.gpo.gov

Toll Free: 866 512–1800
Phone: 202 512–1800
Fax: 202 512–2250

Mail: Superintendent of Documents
PO Box 371954
Pittsburgh, PA 15250–7954

❑ **YES,** enter my subscription(s) as follows:

_____subscription(s) of the ***Approved Drug products with Therapeutic Equivalence Evaluations, ADP,*** and the monthly Cumulative Supplements, for $108.00 per year. The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.

Personal name (Please type or print)

Company name

Street address City, State, Zip code

Daytime phone including area code

Purchase Order Number

Check method of payment:

❑ Check payable to Superintendent of Documents

❑ SOD Deposit Account ☐☐☐☐☐☐ — ☐

❑ VISA ❑ MasterCard ❑ Discover/NOVUS ❑ American Express

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

☐☐☐☐ (expiration date)

Thank you for your order!

Authorizing signature

02/03